Compounds as GLP-1R agonists
By providing specific GLP-1 receptor agonist compounds and methods, the problem of inconvenience and insufficient effectiveness of GLP-1 receptor agonist in the prior art in the treatment of cardiovascular metabolism and related diseases has been solved, and the treatment of diabetes and liver disease has been achieved. Effective treatment improves blood sugar control and quality of life.
Patent Information
- Application Number
- CN202380033881.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-23
- Filing Date
- 2023-02-23
- Publication Date
- 2024-12-06
AI Technical Summary
Existing GLP-1 receptor agonists have problems of inconvenience and insufficient effectiveness in the treatment of cardiovascular metabolism and related diseases, especially in the treatment of diabetes and liver disease.
A composition and method comprising a specific compound is provided for treating a GLP-1R-mediated disease, including cardiovascular metabolism, as a GLP-1 receptor agonist Diseases, diabetes and liver disease. These compounds include specific chemical structures such as formula (0) and formula (1), as well as pharmaceutically acceptable salts and carriers thereof to enhance therapeutic effects.
By using these compounds and methods, it can effectively improve blood sugar control, delay disease progression, reduce symptoms, and improve patients' quality of life, especially in the treatment of diabetes and liver disease.
Smart Images

Figure BDA0005081270980000101 
Figure BDA0005081270980000121 
Figure BDA0005081270980000141
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 313,160, filed on February 23, 2022, which is incorporated herein by reference in its entirety for all purposes. Technical Field
[0003] The present invention relates to compositions and methods for modulating the glucagon-like peptide-1 (GLP-1) receptor. Background Art
[0004] Diabetes is a major public health problem due to its increasing prevalence and associated health risks. The disease is characterized by high blood sugar levels caused by defects in insulin production, defects in insulin action, or both. There are two recognized main forms of diabetes: type 1 and type 2. Type 1 diabetes (T1D) occurs when the body's immune system destroys the pancreatic beta cells, the only cells in the body that make insulin, which regulates blood sugar. In order to survive, people with type 1 diabetes must administer insulin via injection or pump. Type 2 diabetes (T2DM) usually begins with insulin resistance or insufficient insulin production to maintain acceptable blood sugar levels.
[0005] Currently, there are a variety of pharmacological approaches available for the treatment of hyperglycemia and subsequent T2DM (Hampp, C. et al. Use of Antidiabetic Drugs in the US, 2003-2012, Diabetes Care 2014, 37, 1367-1374). One of them is the glucagon-like peptide-1 receptor (GLP-1R) agonist (e.g., liraglutide, albiglutide, exenatide, lixisenatide, dulaglutide, semaglutide), which enhances insulin secretion by acting on pancreatic β cells. Commercially available GLP-1R agonists are peptides administered by subcutaneous injection. Liraglutide is also approved for the treatment of obesity.
[0006] GLP-1 is a 30 amino acid long incretin hormone secreted by L cells in the intestine in response to food intake. GLP-1 has been shown to stimulate insulin secretion, reduce glucagon secretion, inhibit gastric emptying, reduce appetite, and stimulate beta cell proliferation in a physiological and glucose-dependent manner. In nonclinical experiments, GLP-1 promotes sustained beta cell competence by stimulating the transcription of genes important for glucose-dependent insulin secretion and by promoting beta cell neogenesis (Meier et al. Biodrugs. 2003; 17(2): 93-102).
[0007] In healthy individuals, GLP-1 plays an important role in regulating postprandial blood glucose levels by stimulating the pancreas to secrete glucose-dependent insulin, resulting in increased peripheral glucose absorption. GLP-1 also inhibits glucagon secretion, resulting in reduced liver glucose output. In addition, GLP-1 delays gastric emptying and slows small intestinal motility, thereby delaying food absorption. In patients with T2DM, the normal postprandial increase of GLP-1 is absent or reduced (Vilsboll T et al. Diabetes. 2001. 50; 609-613).
[0008] Holst (Physiol. Rev. 2007, 87, 1409) and Meier (Nat. Rev. Endocrinol. 2012, 8, 728) described that GLP-1 receptor agonists (such as liraglutide and exendin-4) have three main pharmacological activities to improve glycemic control in patients with T2DM by reducing fasting and postprandial blood glucose (FPG and PPG): (i) increase in glucose-dependent insulin secretion (improvement of first and second phases), (ii) glucagon inhibitory activity under hyperglycemic conditions, and (iii) delayed gastric emptying, which leads to delayed absorption of dietary glucose.
[0009] There remains a need to develop easily administered GLP-1 receptor agonists for preventing and / or treating cardiometabolic and related diseases. Summary of the invention
[0010] Disclosed are compounds useful as glucagon-like peptide-1 receptor (GLP-1R) agonists, compositions containing these compounds, and methods for treating diseases and / or conditions mediated by GLP-1R.
[0011] In one aspect, provided is a compound of formula (0), formula (1) (including compounds of formula (2)-(10), or subformulas of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof, as described in detail herein.
[0012] Also provided is a pharmaceutical composition comprising a compound of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the group consisting of the compounds listed in Table 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
[0013] In another aspect, a method of treating a disease or condition mediated by GLP-1R in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of a compound of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the disease or condition is a cardiovascular metabolic disease. In some embodiments, the disease or condition is diabetes. In some embodiments, the disease or condition is liver disease.
[0014] Also provided is a compound of formula (0), formula (1) (including compounds of formula (2)-(10), or subformulas of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof, for use in treatment as described in detail herein.
[0015] Also provided is the use of a compound of formula (0), formula (1) (including compounds of formula (2)-(10), or subformulas of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment as described in detail herein.
[0016] Also provided is a kit comprising a compound of formula (0), formula (1) (including a compound of formula (2)-(10), or a subformula of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the kit comprises instructions for use according to the methods described herein.
[0017] In yet another aspect, a method for producing a compound of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof is provided. Also provided is a compound intermediate that can be used to synthesize a compound of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the group consisting of compounds listed in Table 1, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION
[0018] definition
[0019] As used herein, the following definitions shall apply unless otherwise stated. In addition, if any term or symbol used herein is not defined as set forth below, it shall have its ordinary meaning in the art.
[0020] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0021] As used herein, and unless otherwise indicated, the terms "about" and "approximately" when used in conjunction with the dose, amount or weight percentage of the ingredients of the composition or dosage form, mean a dose, amount or weight percentage recognized by those of ordinary skill in the art that provides a pharmacological effect equivalent to that obtained from a specified dose, amount or weight percentage. Specifically, when used in conjunction with a value, the terms "about" and "approximately" consider changes within ±15%, ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.5% of the specified value. References herein to "about" a value or parameter include (and describe) embodiments for the value or parameter itself. For example, a description referring to "about X" includes a description of "X".
[0022] "Comprising" is intended to mean that compositions and methods include the recited elements, but not to exclude other elements. When used to define compositions and methods, "consisting essentially of shall mean excluding other elements of any significance to the combination. For example, a composition consisting essentially of the elements as defined herein will not exclude other elements that would not materially affect the basic and novel characteristics of the claimed invention. "Consisting of shall mean excluding more than trace amounts of other ingredients and substantial method steps, such as those recited. Embodiments defined by each of these transitional terms are within the scope of the present invention.
[0023] As used herein, the term "excipient" means an inert or inactive substance that can be used to produce a drug or medicine, such as a tablet containing a compound of the present invention as an active ingredient. The term excipient can include a variety of substances, including but not limited to any substance used as a binder, disintegrant, coating agent, compression / encapsulation aid, cream or lotion, lubricant, solution for parenteral administration, material for chewable tablets, sweetener or flavoring agent, suspending agent / gelling agent or wet granulation agent. Binders include, for example, carbomer, povidone, xanthan gum, etc.; coating agents include, for example, cellulose acetate phthalate, ethyl cellulose, gellan gum, etc. gum), maltodextrin, enteric coating, etc.; compression / encapsulation aids include, for example, calcium carbonate, dextrose, fructose DC (DC = "directly compressible"), honey DC, lactose (anhydrous or monohydrate; optionally in combination with aspartame, cellulose or microcrystalline cellulose), starch DC, sucrose, etc.; disintegrants include, for example, cross-linked sodium carboxymethyl cellulose, gellan gum, sodium starch glycolate, etc.; creams or lotions include, for example, maltodextrin, carrageenan, etc.; Lubricants include, for example, magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; materials for chewable tablets include, for example, dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending agents / gelling agents include, for example, carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, for example, aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulating agents include, for example, calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
[0024] "Pharmaceutically acceptable" means preferably safe and non-toxic for in vivo, more preferably for human administration.
[0025] "Pharmaceutically acceptable salt" refers to a salt that is pharmaceutically acceptable. The compounds described herein can be administered as a pharmaceutically acceptable salt.
[0026] "Salt" refers to an ionic compound formed between an acid and a base. When the compounds provided herein contain an acidic functional group, such salts include, but are not limited to, alkali metal salts, alkaline earth metal salts, and ammonium salts. As used herein, ammonium salts include salts containing protonated nitrogen bases and alkylated nitrogen bases. Exemplary and non-limiting cations that can be used for pharmaceutically acceptable salts include Na, K, Rb, Cs, NH4, Ca, Ba, imidazolium, and ammonium cations based on naturally occurring amino acids. When the compounds used herein contain basic functional groups, such salts include, but are not limited to, organic acids, such as salts of carboxylic acids and sulfonic acids, and inorganic acids, such as salts of hydrogen halides, sulfuric acid, phosphoric acid, etc. Exemplary and non-limiting anions that can be used for pharmaceutically acceptable salts include oxalate, maleate, acetate, propionate, succinate, tartrate, chloride, sulfate, bisulfate, monovalent, divalent and trivalent phosphates, mesylate, toluenesulfonate, etc.
[0027] "Stereoisomer" or "stereoisomers" refers to compounds that differ in the stereoisomerism of the constituent atoms (such as, but not limited to, the chirality of one or more stereocenters) or in the cis or trans configuration with respect to carbon-carbon or carbon-nitrogen double bonds. Stereoisomers include enantiomers and diastereomers.
[0028] As used herein, the term "subject" refers to an animal, including but not limited to a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" are used interchangeably herein, e.g., to refer to a mammalian subject, such as a human.
[0029] As used herein, "treatment" or "treating" is a method of obtaining a beneficial or desired result (including a clinical result). For the purposes of this disclosure, a beneficial or desired result includes, but is not limited to, one or more of the following: reducing one or more symptoms caused by a disease or condition, alleviating the extent of a disease or condition, stabilizing a disease or condition (e.g., preventing or delaying the deterioration of a disease or condition), delaying the occurrence or recurrence of a disease or condition, delaying or slowing the progression of a disease or condition, improving the state of a disease or condition, providing relief of a disease or condition (whether partial or complete), reducing the dose of one or more other drugs required to treat a disease or condition, enhancing the effect of another drug used to treat a disease or condition, delaying the progression of a disease or condition, improving the quality of life, and / or prolonging the survival of a patient. "Treatment" also encompasses reducing the pathological consequences of a disease or condition. The method of this disclosure contemplates any one or more of these treatment aspects.
[0030] A "therapeutically effective amount" or dosage of a compound or composition is an amount of the compound or composition that results in a reduction or suppression of symptoms or a prolongation of survival in a patient. Such results may require multiple doses of the compound or composition.
[0031] "Alkyl" refers to a monovalent saturated aliphatic hydrocarbon group having 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. The term includes, for example, straight and branched hydrocarbon groups such as methyl (CH3-), ethyl (CH3CH2-), n-propyl (CH3CH2CH2-), isopropyl ((CH3)2CH-), n-butyl (CH3CH2CH2CH2-), isobutyl ((CH3)2CHCH2-), sec-butyl ((CH3)(CH3CH2)CH-), tert-butyl ((CH3)3C-), n-pentyl (CH3CH2CH2CH2CH2-) and neopentyl ((CH3)3CCH2-). Cx alkyl refers to an alkyl group having x carbon atoms.
[0032] "Alkylene" refers to a divalent saturated aliphatic hydrocarbon group having 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms, and more preferably 1 to 6 carbon atoms. The term includes, for example, straight and branched hydrocarbon groups such as methylene (-CH2-), ethylene (-CH2CH2- or -CH(Me)-), propylene (-CH2CH2CH2- or -CH(Me)CH2- or -CH(Et)-), and the like.
[0033] "Alkoxy" refers to the group -O-alkyl, wherein alkyl is as defined herein. Alkoxy includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy and n-pentoxy.
[0034] "Aryl" refers to a monovalent aromatic carbocyclic group of 6 to 14 carbon atoms having a single ring (e.g., phenyl (Ph)) or multiple fused rings (e.g., naphthyl or anthracenyl), which may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-on-7-yl, etc.), provided that the point of attachment is on an aromatic carbon atom. Preferred aryl groups include phenyl and naphthyl.
[0035] "Cyano" refers to the radical -CN.
[0036] "Cycloalkyl" refers to a saturated or unsaturated but non-aromatic cyclic alkyl of 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, which has a single or multiple cyclic ring, including condensed rings, bridged rings and spiro ring systems. Cx cycloalkyl refers to a cycloalkyl with x ring carbon atoms. The example of suitable cycloalkyl includes for example adamantyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclooctyl. One or more rings can be aryl, heteroaryl or heterocyclic radical, with the prerequisite that the point of attachment is a saturated carbocyclic ring through a non-aromatic, non-heterocyclic radical ring. "Substituted cycloalkyl" refers to a cycloalkyl group having 1 to 5 or preferably 1 to 3 substituents selected from the group consisting of oxo, thioketone, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl alkyl, substituted ...
[0037] "Halo" or "halogen" refers to fluorine, chlorine, bromine and iodine, and preferably fluorine or chlorine.
[0038] "Hydroxy" or "hydroxyl" refers to the group -OH.
[0039] "Heteroaryl" refers to an aromatic group having 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. Such heteroaryl may have a monocyclic (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizine or benzothienyl), wherein the condensed ring may or may not be aromatic and / or contain heteroatoms, provided that the connection point is through an atom of the aromatic heteroaryl. In one embodiment, the nitrogen and / or sulfur ring atoms of the heteroaryl are optionally oxidized to provide N-oxide (N—>O), sulfinyl or sulfonyl moieties. Preferred heteroaryl includes 5- or 6-yuan heteroaryl, such as pyridyl, pyrrolyl, thienyl and furyl. Other preferred heteroaryl includes 9- or 10-yuan heteroaryl, such as indolyl, quinolyl, quinolone, isoquinolone and isoquinolone.
[0040] "Heterocycle" or "heterocyclic" or "heterocycloalkyl" or "heterocyclyl" refers to a saturated or partially saturated, but non-aromatic group having 1 to 10 ring carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms and 1 to 4 ring heteroatoms, preferably 1 to 3 heteroatoms, more preferably 1 to 2 heteroatoms, selected from the group consisting of nitrogen, sulfur or oxygen. Cx heterocycloalkyl refers to a heterocycloalkyl having x ring atoms (including ring heteroatoms). Heterocycle encompasses monocyclic or multiple fused rings, including fused bridged rings and spirocyclic systems. In a fused ring system, one or more rings may be cycloalkyl, aryl or heteroaryl, provided that the point of attachment is through a non-aromatic ring. In one embodiment, the nitrogen and / or sulfur atoms of the heterocyclyl are optionally oxidized to provide an N-oxide, sulfinyl (S(O)) or sulfonyl (S(O)2) moiety.
[0041] Examples of heterocyclic and heteroaryl groups include, but are not limited to, azetidinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizyl, isoindolyl, indolyl, dihydroindolinyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthylpyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, isothiazolyl, , phenazinyl, isoxazolyl, phenoxazinyl, phenothiazinyl, imidazolidinyl, imidazolinyl, piperidinyl, piperazinyl, indolinyl, phthalimidyl, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrobenzo[b]thienyl, thiazolyl, thiazolidinyl, thienyl, benzo[b]thienyl, morpholinyl, thiomorpholinyl (also known as thiomorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidinyl, and tetrahydrofuranyl.
[0042] "Oxo" refers to the atom (=O) or (O).
[0043] As used throughout the specification, the term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, "the nitrogen atom is optionally oxidized to provide an N-oxide (N—>O) moiety" means that the nitrogen atom may but need not be oxidized, and the description includes instances where the nitrogen atom is not oxidized and instances where the nitrogen atom is oxidized.
[0044] Unless otherwise indicated, "optionally substituted" means that the group can be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituents listed for the group, wherein the substituents can be the same or different. In one embodiment, the optionally substituted group has one substituent. In another embodiment, the optionally substituted group has two substituents. In another embodiment, the optionally substituted group has three substituents. In another embodiment, the optionally substituted group has four substituents. In some embodiments, the optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, the optionally substituted group is unsubstituted.
[0045] It should be understood that if the valence available for substitution on the optionally substituted part allows, the part can be substituted with more than five substituents. For example, a propyl group can be substituted with seven halogen atoms to provide a perhalopropyl group. The substituents can be the same or different.
[0046] Compound
[0047] In one aspect, provided is a compound of formula (0):
[0048]
[0049] or a pharmaceutically acceptable salt thereof, wherein:
[0050] R 13 -C(O)OH or
[0051] X is N or CR x , where R x is hydrogen, OH or C1-C6 alkyl;
[0052] Y is N or CR y , where R y is hydrogen, OH or C1-C6 alkyl;
[0053] n is 0 or 1;
[0054] Q choose freedom – C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where
[0055] R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl; and
[0056] R 9 is hydrogen or C1-C6 alkyl;
[0057] R 1 is an optionally substituted -C1-C6 alkylene group or -C1-C6 alkylene group-R 5 , where R 5 is C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN;
[0058] R 2 and R 3 Together with the carbon atom to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring; or
[0059] R 2 and R x When present, together with the carbon atom to which they are attached, form an optionally substituted C3-C5 cycloalkyl ring, and R 3 is hydrogen, oxo or C1-C6 alkyl;
[0060] m is 0, 1, 2 or 3;
[0061] R 4 is oxo or C1-C6 alkyl;
[0062] Ring A is C6-C 14 Aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH;
[0063] L is a bond, -O-, C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *–NR 6 -C1-C6 alkylene-**, wherein * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, and wherein:
[0064] When L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR 6 -C1-C6 alkylene-**, L is optionally replaced by one to three R L Substituents, where each R L are independently halogen, OH or C1-C6 alkyl; or two R LTogether with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclic group;
[0065] R 6 When present, hydrogen or C1-C6 alkyl; and
[0066] Ring B is C3-C 10 Cycloalkyl, C6-C 14 Aryl, 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents, the substituents being independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3 and phenyl optionally substituted by halo or CN.
[0067] In one aspect, provided is a compound of formula (1):
[0068]
[0069] or a pharmaceutically acceptable salt thereof, wherein:
[0070] X is N or CR x , where R x is hydrogen, OH or C1-C6 alkyl, and
[0071] Y is N or CR Y , where R Y is hydrogen, OH or C1-C6 alkyl;
[0072] n is 0 or 1;
[0073] Q choose freedom – C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where
[0074] R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl, and
[0075] R 9 is hydrogen or C1-C6 alkyl;
[0076] R 1 -C1-C6 alkylene-R 5 , where R 5is a 3- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN;
[0077] R 2 and R 3 Together with the carbon atom to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring; or
[0078] R 2 and R x When present, together with the carbon atom to which they are attached, form an optionally substituted C3-C5 cycloalkyl ring, and R 3 is hydrogen, oxo or C1-C6 alkyl;
[0079] m is 0, 1, 2 or 3;
[0080] R 4 is oxo or C1-C6 alkyl;
[0081] Ring A is C6-C 14 Aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH;
[0082] L is a bond, -O-, C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *–NR 6 -C1-C6 alkylene-**, wherein * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, and wherein:
[0083] When L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR 6 -C1-C6 alkylene-**, L is optionally replaced by one to three R L Substituents, where each R L are independently halogen, OH or C1-C6 alkyl; or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclyl group; and
[0084] R 6 When present, hydrogen or C1-C6 alkyl; and
[0085] Ring B is C3-C 10 Cycloalkyl, C6-C 14 Aryl, 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents, the substituents being independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3 and phenyl optionally substituted by halo or CN.
[0086] In some embodiments of formula (0) or (1), at least one of X and Y is N. In other embodiments of formula (0) or (1), both X and Y are N.
[0087] In some embodiments of Formula (0) or Formula (1), R 2 and R 3 Together with the carbon atoms to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring. In some embodiments, compounds of formula (2) are provided:
[0088]
[0089] or a pharmaceutically acceptable salt thereof, wherein p is 0, 1 or 2; each R 10 is a halogen group; and X, Y, n, Q, R 1 ,m,R 4 , Ring A, L and Ring B are as described in detail herein for Formula (0) or Formula (1).
[0090] In some embodiments of formula (2), at least one of X and Y is N. In other embodiments of formula (2), X and Y are N.
[0091] In some embodiments of formula (2), L is *—OCH2-** and ring B is phenyl. In some embodiments, compounds of formula (3) are provided:
[0092]
[0093] or a pharmaceutically acceptable salt thereof, wherein q is 0, 1, 2 or 3; R 11 is selected from the group consisting of: halo, CN, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3, and phenyl optionally substituted by halo or CN; p and R 10 As described in detail herein for formula (2); and X, Y, n, Q, R 1 ,m,R 4and Ring A are as described in detail herein for Formula (0) or Formula (1).
[0094] In some such embodiments, each R 11 is independently selected from halo and CN. In some embodiments of formula (3), at least one of X and Y is N. In other embodiments of formula (3), X and Y are N.
[0095] In some embodiments of formula (3), ring A is pyridyl. In some embodiments, a compound of formula (4) is provided:
[0096]
[0097] or a pharmaceutically acceptable salt thereof, wherein q and R 11 As described in detail herein for formula (3), p and R 10 As described in detail herein for formula (2), and X, Y, n, Q, R 1 , m and R 4 As described in detail herein for formula (0) or formula (1).
[0098] In some such embodiments, each R 11 is independently selected from halo and CN. In some embodiments of formula (4), at least one of X and Y is N. In other embodiments of formula (4), X and Y are N.
[0099] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2) and subformulae thereof, if applicable) or a pharmaceutically acceptable salt thereof, R 1 is -C1-C6 alkylene-R 5 , where R 5 is a 3- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN. In some embodiments, R 1 For –CH2-R 5 .
[0100] In some embodiments, a compound of formula (5) is provided:
[0101]
[0102] or a pharmaceutically acceptable salt thereof, wherein p and R 10 As described in detail herein for formula (2), and X, Y, n, Q, R5 ,m,R 4 , Ring A, L and Ring B are as described in detail herein for Formula (0) or Formula (1).
[0103] In some embodiments of formula (5), at least one of X and Y is N. In other embodiments of formula (5), X and Y are N.
[0104] In some embodiments of formula (5), L is *—OCH2-** and ring B is phenyl. In some embodiments, compounds of formula (6) are provided:
[0105]
[0106] Where q is 0, 1, 2 or 3; R 11 is halogen, CN, C1-C6 alkyl optionally substituted by halogen or CN, -OC1-C6 alkyl optionally substituted by halogen or CN, -COCH3, -CONH2, -S(O)2CH3, or phenyl optionally substituted by halogen or CN; p and R 10 As described in detail herein for formula (2); and X, Y, n, Q, R 5 ,m,R 4 and Ring A are as described in detail herein for Formula (0) or Formula (1).
[0107] In some such embodiments, each R 11 is independently selected from halo and CN. In some embodiments of formula (6), at least one of X and Y is N. In other embodiments of formula (6), X and Y are N.
[0108] In some embodiments of formula (6), ring A is pyridyl. In some embodiments, a compound of formula (7) is provided:
[0109]
[0110] where q and R 11 As described in detail herein for formula (6); p and R 10 As described in detail herein for formula (2); and X, Y, n, Q, R 5 , m and R 4 As described in detail herein for formula (0) or formula (1).
[0111] In some such embodiments, each R 11 is independently selected from halo and CN. In some embodiments of formula (7), at least one of X and Y is N. In other embodiments of formula (7), X and Y are N.
[0112] In some embodiments of the compounds of formula (0) or formula (1), X is CR x , and R 2 and R x Together with the carbon atoms to which they are attached, they form an optionally substituted C3-C5 cycloalkyl ring. In some embodiments, the compound has the formula (8):
[0113]
[0114] or a pharmaceutically acceptable salt thereof, wherein p is 0, 1 or 2; each R 10 is a halogen group; and n, Q, R 1 , R 3 ,m,R 4 , Ring A, L and Ring B are as described in detail herein for Formula (0) or Formula (1).
[0115] In some embodiments of formula (8), R 2 and R x Together with the carbon atom to which they are attached, they form an optionally substituted C3 cycloalkyl ring. 2 and R x Together with the carbon atom to which they are attached they form an optionally substituted C3 cycloalkyl ring.
[0116] In some embodiments of compounds of formula (8), L is *—OCH2-** and ring B is phenyl. In some embodiments, the compound has formula (9):
[0117]
[0118] or a pharmaceutically acceptable salt thereof, wherein q is 0, 1, 2 or 3; R 11 is halogen, CN, C1-C6 alkyl optionally substituted by halogen or CN, -OC1-C6 alkyl optionally substituted by halogen or CN, -COCH3, -CONH2, -S(O)2CH3, or phenyl optionally substituted by halogen or CN; p and R 10 As described in detail herein for equation (8); and n, Q, R 1 , R 3 ,m,R 4 and Ring A are as described in detail herein for Formula (0) or Formula (1).
[0119] In some embodiments of compounds of formula (9), Ring A is pyridinyl. In some embodiments, the compound has formula (10):
[0120]
[0121] or a pharmaceutically acceptable salt thereof, wherein p and R10 As described in detail herein for formula (8); q and R 11 As described in detail herein for formula (9); and n, Q, R 1 , R 3 , m and R 4 As described in detail herein for formula (0) or formula (1).
[0122] In some embodiments of compounds of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof), R 5 is an optionally substituted 3- to 6-membered heterocyclyl. 5 yes Each of which is optionally substituted. In some embodiments, R 5 yes Each of which is optionally substituted. In some embodiments of any of the foregoing, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, and -OC1-C6 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br, oxo, CN, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br and C1-C3 alkyl. 5is unsubstituted.
[0123] In some embodiments of compounds of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof), R 5 is an optionally substituted 5- to 6-membered heteroaryl. 5 is an optionally substituted 5-membered heteroaryl. 5 is pyrrolyl, oxazolyl, imidazolyl, triazolyl, thiazolyl or isothiazolyl, each of which is optionally substituted. 5 is oxazolyl, triazolyl or thiazolyl, each of which is optionally substituted. 5 is an optionally substituted triazolyl. 5 is an optionally substituted thiazolyl. 5 for
[0124] Each of which is optionally substituted. In some embodiments, R 5 for Each of which is optionally substituted. In some embodiments, R 5 for Each of which is optionally substituted. In some embodiments, R 5 for Each of which is optionally substituted. In some embodiments, R 5 for It is optionally substituted. In some embodiments, R 5 for Where Ak is an alkyl group (e.g., C 1-4 In some embodiments, R 5 for In some embodiments, R 5 for In some embodiments, R 5 for It is optionally substituted. In some embodiments of any of the foregoing, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN. In some such embodiments, R 5is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, and -OC1-C6 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br, oxo, CN, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br and C1-C3 alkyl, such as methyl, ethyl, propyl or isopropyl. 5 is unsubstituted.
[0125] In some embodiments of compounds of formula (0) or (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable), X is N, Y is N, and R 2 and R 3 Together with the carbon atoms to which they are attached, they form a C3-C4 cycloalkyl ring. In some embodiments, X is CR x , where R x is hydrogen, OH or C1-C6 alkyl, Y is N, and R 2 and R 3 Together with the carbon atoms to which they are attached, they form a C3-C4 cycloalkyl ring. In some embodiments, X is N, Y is CR y , where R y is hydrogen, OH or C1-C6 alkyl, and R 2 and R 3 Together with the carbon atoms to which they are attached, they form a C3-C4 cycloalkyl ring. In some embodiments, X is CR x , R x and R 2 Together with the carbon atoms to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring, Y is N, and R3 is hydrogen, oxo or C1-C6 alkyl. In some embodiments of any of the foregoing, Q is CR 7 R 8 .
[0126] In some embodiments, when Q is -O-, -N(R 9 )- or -S-, X is CR x , where R x is hydrogen, OH or C1-C6 alkyl, Y is N, and R 2 and R 3 Together with the carbon atoms to which they are attached, they form a C3-C4 cycloalkyl ring. 9 )- or -S-, X is CR x , R x and R 2 Together with the carbon atoms to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring, Y is N, and R 3 It is hydrogen, oxo or C1-C6 alkyl.
[0127] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof) or a pharmaceutically acceptable salt thereof, n is 0. In other embodiments, n is 1.
[0128] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable) or a pharmaceutically acceptable salt thereof, the moiety for In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable) or a pharmaceutically acceptable salt thereof, Q is CR 7 R 8 , and the part for In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable) or a pharmaceutically acceptable salt thereof, Q is CR 7 R 8 , and the part is for In some such embodiments, Q is CR 7 R 8 And the part for In some such embodiments, Q is CR 7 R 8 And the part for In some such embodiments, Q is CR 7 R 8 And the part for In other embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable) or a pharmaceutically acceptable salt thereof, Q is -O-, -N(R 9 )- or -S-, and the part for In some such embodiments, Q is -O-, -N(R 9 )- or -S-, and the part for In some such embodiments, Q is -O-, -N(R 9 )- or -S-, and the part for
[0129] In some embodiments of compounds of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof) or pharmaceutically acceptable salts thereof, m is 0, 1, 2 or 3. In other embodiments, m is 0, 1 or 2. In other embodiments, m is 0 or 1. In some embodiments of any of the foregoing, each R 4 is oxo or C1-C6 alkyl. In some such embodiments, each R 4 In some embodiments, m is 0.
[0130] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable), Q is selected from -C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl; and R 9 is hydrogen or C1-C6 alkyl. In some embodiments, Q is selected from -C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where R 7 is hydrogen, halogen or C1-C6 alkyl, and R 8 is halogen or C1-C6 alkyl; and R 9is hydrogen or C1-C6 alkyl. Examples of suitable Q groups include, but are not limited to, -CH2-, -CHF-, -C(H)(CH3)-, -CF2, -C(CH3)2-, -NH-, -N(CH3)-, -O-, -S-, etc. In some embodiments, Q is not -CH2-.
[0131] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof) or a pharmaceutically acceptable salt thereof, ring A is an optionally substituted 5- to 12-membered heterocyclyl. In some embodiments, ring A is
[0132] Each of which is optionally substituted. In some embodiments, Ring A is
[0133] Each of which is optionally substituted. In some embodiments of any of the foregoing, Ring A is optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH. In some such embodiments, Ring A is optionally substituted with halo or OH. In some such embodiments, Ring A is optionally substituted with halo. In some embodiments, Ring A is unsubstituted.
[0134] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof) or a pharmaceutically acceptable salt thereof, Ring A is an optionally substituted 5- to 12-membered heteroaryl. In some embodiments, Ring A is
[0135] Each of which is optionally substituted. In some embodiments, Ring A is Each of which is optionally substituted. In some embodiments, Ring A is Each of which is optionally substituted. In some embodiments, Ring A is It is optionally substituted. In some embodiments of any of the foregoing, Ring A is optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH. In some such embodiments, Ring A is optionally substituted with halo or OH. In some such embodiments, Ring A is optionally substituted with halo. In some embodiments, Ring A is unsubstituted.
[0136] In some embodiments of the compound of formula (0) or formula (1) (including compounds of formula (2)-(10) and subformulae thereof, if applicable) or a pharmaceutically acceptable salt thereof, L is a bond. In some embodiments, L is -O-. In some embodiments, L is C1-C6 alkylene. In some embodiments, L is unsubstituted C1-C6 alkylene. In some embodiments, L is optionally substituted by R L Substituted C1-C6 alkylene, wherein each R L are independently halogen, OH, oxo or C1-C6 alkyl, or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl or a 3- to 6-membered heterocyclyl. In some embodiments, L is an unsubstituted C1-C2 alkylene. In some embodiments, L is optionally substituted by R L Substituted C1-C2 alkylene, wherein each R L is independently halo, OH, oxo or C1-C6 alkyl. In some embodiments, L is unsubstituted C2 alkylene. In some embodiments, L is optionally substituted by R L Substituted C2 alkylene, wherein each R L is independently halo, OH, oxo or C1-C6 alkyl. In some such embodiments, L is In some embodiments, L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *-NR 6 -C1-C6 alkylene-**, where * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, where R 6 is hydrogen or C1-C6 alkyl. For example, L can be *-OCH2-**. In some embodiments, when L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR 6 -C1-C6 alkylene-**, L is replaced by R L Substitute, where each R L are independently C1-C6 alkyl or halogen, or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclic group. As a specific example, when L is *-OC(R L )2-**, two R LTogether with the one or more carbon atoms to which they are attached, they may form a C3-C6 cycloalkyl or a 3- to 6-membered heterocyclyl. In some embodiments, L is *-O-C1-C6 alkylene-**. In some embodiments, L is *-O-C1-C3 alkylene-**. In some embodiments, L is *-OCH2-**.
[0137] In some embodiments of compounds of formula (0) or (1) (including compounds of formula (0)-(10) and subformulae thereof, if applicable), Ring B is an optionally substituted C3-C 10 Cycloalkyl. Exemplary C3-C 10 Cycloalkyl groups include but are not limited to Each of them is independently optionally substituted. In some of the aforementioned embodiments, ring B is optionally substituted by one to three substituents, and the substituents are independently selected from the group consisting of: halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, OC1-C6 alkyl optionally substituted by halo or CN, –COCH3, –CONH2, –S(O)2CH3, and phenyl optionally substituted by halo or CN. In some such embodiments, ring B is optionally substituted by one to three substituents, and the substituents are independently selected from the group consisting of halo and CN. In some embodiments, ring B is substituted by two substituents, and the substituents are independently selected from F, Cl and CN.
[0138] In some embodiments of compounds of formula (0) or formula (1) (including compounds of formula (0)-(10) and subformulae thereof, if applicable), Ring B is an optionally substituted C6-C 14 For example, the C6-C 14 The aryl group can be It is each independently optionally substituted. In some embodiments, ring B is phenyl, which is optionally substituted. In some embodiments of any of the foregoing, ring B is optionally substituted by one to three substituents, each of which is independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, –COCH3, –CONH2, –S(O)2CH3 and phenyl. In some such embodiments, ring B is optionally substituted by one to three substituents, each of which is independently selected from the group consisting of halo and CN. In some embodiments, ring B is substituted by two substituents, each of which is independently selected from F, Cl and CN.
[0139] In some embodiments of compounds of formula (0) or formula (1) (including compounds of formula (0)-(10) and subformulae thereof, if applicable), Ring B is an optionally substituted 4- to 12-membered heterocyclyl. Exemplary 4- to 12-membered heterocyclyls include, but are not limited to
[0140] Each of them is independently optionally substituted. In some embodiments of any of the foregoing, ring B is optionally substituted with one to three substituents, each of which is independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, –COCH3, –CONH2, –S(O)2CH3 and phenyl. In some such embodiments, ring B is optionally substituted with one to three substituents, each of which is independently selected from the group consisting of halo and CN. In some embodiments, ring B is substituted with two substituents, each of which is independently selected from F, Cl and CN.
[0141] In some embodiments, Ring B is an optionally substituted 5- to 12-membered heteroaryl. Exemplary 5- to 12-membered heteroaryl groups include, but are not limited to
[0142] Each of them is independently optionally substituted. In some embodiments of any of the foregoing, Ring B is optionally substituted with one to three substituents, each of which is independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, –COCH3, –CONH2, –S(O)2CH3 and phenyl. In some such embodiments, Ring B is optionally substituted with one to three substituents, each of which is independently selected from the group consisting of halo and CN.
[0143] In some embodiments of formulae (2)-(10) or subformulae thereof (if applicable), p is 0, 1 or 2, and each R 10 (when present) is halo. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 2 and each R 10 For example, in some embodiments, part for
[0144] In some embodiments of formula (3), (4), (6), (7), (9), and (10), or subformulae thereof (if applicable), q is 0, 1, 2, or 3. In some embodiments, q is 2 or 3. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 2, and each R 11 Independently selected from halo or CN.
[0145] In the description herein, it should be understood that each description, variation, embodiment or aspect of a part / variable can be combined with each description, variation, embodiment or aspect of any other part / variable, just as if each and every combination of the descriptions were specifically and individually listed, for example, as shown in the sub-formula below.
[0146]
[0147]
[0148]
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157] In formulas (1A), (1A-i), (1A-ii), (1A-iii), (1B), (1C), (1D), (2A), (2A-i), (2A-ii), (2A-iii), (2B), (2C), (2D), (3A), (3A-i), (3A-ii), (3A- iii), (3B), (3C), (3D), (4A), (4A-i), (4A-ii), (4A-iii), (4B), (4C), (4D), (5A), (5A-i), (5A-ii), (5A-iii), (5B), (5C), (5D), (6A), (6 In some embodiments of the invention, R 5 is triazolyl or thiazolyl, each of which is optionally substituted. 5 is an unsubstituted triazolyl. 5 is an optionally substituted thiazolyl. In some embodiments of any of the foregoing, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, and -OC1-C6 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br, oxo, CN, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br, C1-C3 alkyl, and -OC1-C3 alkyl. In some such embodiments, R 5 is optionally substituted with one to three substituents independently selected from the group consisting of Cl, F, Br and C1-C3 alkyl, such as methyl, ethyl, propyl or isopropyl. 5 is unsubstituted.
[0158] In formulas (1A), (1A-i), (1A-ii), (1A-iii), (1B), (1C), (1D), (2A), (2A-i), (2A-ii), (2A-iii), (2B), (2C), (2D), (3A), (3A-i), (3A-ii), (3A- iii), (3B), (3C), (3D), (4A), (4A-i), (4A-ii), (4A-iii), (4B), (4C), (4D), (5A), (5A-i), (5A-ii), (5A-iii), (5B), (5C), (5D), (6A), (6 In some embodiments of the invention, R 5 for Where R 12 is C1-C6 alkyl. In some such embodiments, R 12 In other such embodiments, R 12 In other such embodiments, R 12 In other such embodiments, R 12 It is isobutyl.
[0159] The present disclosure also includes any or all stereochemical forms, including any enantiomeric or diastereomeric forms of the compounds described. Any compound of any formula given herein may have an asymmetric center and therefore exist in different enantiomeric or diastereomeric forms. All optical isomers and stereoisomers of the general formula compound and mixtures of any ratio thereof are considered to be within the scope of the formula. Therefore, unless otherwise specified specific stereochemistry, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomer forms and mixtures of any ratio thereof. When the formula or compound of Table 1 is depicted as having a specific stereochemical configuration, any alternative stereochemical configuration of the compound is also provided herein, as well as a mixture of the stereoisomers of the compound in any ratio. For example, when the formula or compound of Table 1 has a stereocenter in an "S" stereochemical configuration, the enantiomer of the compound in which the stereocenter is in an "R" stereochemical configuration is also provided herein. Likewise, when the formula or compound of Table 1 has a stereocenter in the "R" configuration, the enantiomer of the compound in the "S" stereochemical configuration is also provided herein. Also provided are mixtures of compounds having both "S" and "R" stereochemical configurations. As another example, in formulas (0)-(7) and subformulae thereof, part Including Chinese Also provided are Similarly, part Including Chinese Also provided are In some embodiments, one diastereomeric form may be preferred, for example, correspondingly, relative to the configurations shown in formula (2.2), formula (2.2a) and formula (2.2b), the compound of formula (2) or its subformula may preferably have the configurations shown in formula (2.1), formula (2.1a) and formula (2.1b).
[0160]
[0161]
[0162] As is well known to the skilled artisan, the compounds depicted herein may exist as salts even if no salts are depicted, and it is understood that the disclosure encompasses all salts and solvates of the compounds depicted herein, as well as non-salt forms and non-solvate forms of the compounds. In some embodiments, the salts of the compounds provided herein are pharmaceutically acceptable salts.
[0163] The present invention is also intended to be isotopically labeled and / or isotopically enriched forms of the compounds described herein. The compounds herein may contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds. In some embodiments, the compounds are isotopically labeled, such as isotopically labeled compounds of formula (0), formula (1) (including compounds of formula (2)-(10) or subformulas of any of the foregoing) or variants thereof described herein, wherein a portion of one or more atoms is replaced by an isotope of the same element. Exemplary isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 O. 17 O. 32 P. 35 S. 18 F. 36 Cl. Certain isotopically labeled compounds (e.g. 3 H and 14 C) can be used for compound or matrix tissue distribution studies. Incorporation of heavier isotopes (such as deuterium ( 2 H)) may offer certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in some circumstances.
[0164] Isotopically labeled compounds of the present invention can be prepared by standard methods and techniques known to those skilled in the art or by following procedures analogous to those described in the accompanying examples by substituting an appropriate isotopically labeled reagent for the corresponding non-labeled reagent.
[0165] The present invention also includes any or all metabolites of any of the compounds described. Metabolites may include any chemical species generated by the biotransformation of any of the compounds described, such as intermediates and products of compound metabolism, such as generated in vivo following administration to humans.
[0166] Representative compounds are listed in Table 1 below. In some embodiments, a compound or a pharmaceutically acceptable salt thereof is provided, which is selected from Compound Nos. 1 to 46 in Table 1. In some embodiments, a compound or a pharmaceutically acceptable salt thereof is provided, which is Compound 1 of Table 1.
[0167] Table 1
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179] Pharmaceutically acceptable compositions and formulations
[0180] The present invention encompasses pharmaceutically acceptable compositions of any of the compounds described in detail herein, or simply "pharmaceutical compositions". Thus, the present invention includes pharmaceutical compositions comprising a compound of formula (0), formula (1) (including compounds of formula (2)-(10) or subformulas of any of the foregoing) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
[0181] In some embodiments, pharmaceutically acceptable salts are acid addition salts, such as salts formed with inorganic or organic acids.The pharmaceutical compositions according to the invention may be in a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or in a form suitable for administration by inhalation.
[0182] In one aspect, the compounds detailed herein can be in purified form, and compositions containing compounds in purified form are detailed herein. Compositions containing compounds or salts thereof detailed herein are provided, such as compositions of substantially pure compounds. In some embodiments, compositions containing compounds or salts thereof detailed herein are in substantially pure form. In one variant, "substantially pure" is intended to contain compositions containing no more than 35% impurities, wherein impurities represent compounds other than the compounds or salts that constitute the majority of the composition. For example, compositions of substantially pure compounds are intended to contain compositions containing no more than 35% impurities, wherein impurities represent compounds other than the compounds or salts thereof. In one variant, compositions of substantially pure compounds or salts thereof are provided, wherein the compositions contain no more than 25% impurities. In one variant, compositions of substantially pure compounds or salts thereof are provided, wherein the compositions contain no more than 20% impurities. In yet another variant, compositions of substantially pure compounds or salts thereof are provided, wherein the compositions contain no more than 10% impurities. In a further variant, compositions of substantially pure compounds or salts thereof are provided, wherein the compositions contain no more than 5% impurities. In one variation, a composition of a substantially pure compound or its salt is provided, wherein the composition contains no more than 3% impurities. In yet another variation, a composition of a substantially pure compound or its salt is provided, wherein the composition contains no more than 1% impurities. In a further variation, a composition of a substantially pure compound or its salt is provided, wherein the composition contains no more than 0.5% impurities. In yet other variations, a composition of a substantially pure compound means that the composition contains no more than 15% impurities, or preferably no more than 10% impurities, or more preferably no more than 5% impurities, or even more preferably no more than 3% impurities, and most preferably no more than 1% impurities, which may be compounds of different stereochemical forms.
[0183] In one variation, the compounds herein are synthetic compounds prepared for administration to individuals (such as humans). In another variation, compositions containing substantially pure forms of the compounds are provided. In another variation, the invention encompasses pharmaceutical compositions comprising the compounds detailed herein and a pharmaceutically acceptable carrier or excipient. In another variation, methods of administering the compounds are provided. The purified forms, pharmaceutical compositions, and methods of administering the compounds are suitable for any compound or form thereof detailed herein.
[0184] The compounds can be formulated for any available delivery route, including oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery forms. The compounds can be formulated with suitable carriers to provide delivery forms, including but not limited to tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, lozenges, lozenges, gums, dispersions, suppositories, ointments, cataplasms (pastes), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
[0185] The compounds described herein can be used to prepare preparations, such as pharmaceutical preparations, by combining the compound as an active ingredient with a pharmaceutically acceptable carrier (such as those described above). Depending on the treatment form of the system (e.g., transdermal patch and oral tablet), the carrier can be in various forms. In addition, the pharmaceutical preparation may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts, buffers, coating agents, or antioxidants for regulating osmotic pressure. The preparation containing the compound may also contain other substances with valuable therapeutic properties. Pharmaceutical preparations can be prepared by known pharmaceutical methods. Suitable preparations can be found in, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st edition. (2005), which is incorporated herein by reference.
[0186] The compounds as described herein can be administered to individuals (e.g., humans) in the form of generally accepted oral compositions such as tablets, coated tablets, and hard or soft shell gel capsules, emulsions, or suspensions. Examples of carriers that can be used to prepare such compositions are lactose, corn starch or its derivatives, talc, stearic acid or its salts, and the like. Acceptable carriers for soft shell gel capsules are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols, and the like. In addition, the pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts, buffers, coating agents, or antioxidants for regulating osmotic pressure.
[0187] Compositions comprising two compounds utilized herein are described. Any compound described herein may be formulated as a tablet in any dosage form described herein. In some embodiments, the composition comprises a compound of formula (0), formula (1) as described herein (including a compound of formula (2)-(10) or a subformula of any of the foregoing) or a pharmaceutically acceptable salt thereof. In some embodiments, dosage forms are provided herein comprising a therapeutically effective amount of a compound of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing) or a pharmaceutically acceptable salt thereof. In some embodiments, the compound or its pharmaceutically acceptable salt is selected from compound numbers 1-46 in Table 1.
[0188] Usage and Purpose
[0189] In some aspects, the compounds and compositions described herein can be used to treat the diseases and / or disorders described herein, such as diseases and / or disorders mediated by GLP-1R. In some embodiments, the method of treating a disease or disorder in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing) or a pharmaceutically acceptable salt thereof. In some embodiments, the method of treating a disease or disorder in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound selected from compound numbers 1-46 in Table 1 or a pharmaceutically acceptable salt thereof.
[0190] According to the present application, the disease or condition to be treated and / or prevented is selected from the group consisting of: cardiovascular metabolic diseases and related diseases, including diabetes (T1D and / or T2DM, including prediabetes), idiopathic T1D (type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), atypical diabetes in the young (YOAD), maturity-onset diabetes in the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disease, tubular dysfunction, proinflammatory changes in the proximal tubules), diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep apnea, obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urinary incontinence), eating disorders (including binge eating syndrome, bulimia nervosa and syndromic obesity, such as Prader-Willi syndrome (Prader-Willi syndrome) syndrome and Bardet-Biedl syndrome), weight gain with other agents (e.g., from use of steroids and antipsychotics), excessive sugar cravings, dyslipidemia (including hyperlipidemia, hypertriglyceridemia, elevated total cholesterol, high LDL cholesterol, and low HDL cholesterol), hyperinsulinemia, liver disease such as NAFLD, steatosis, NASH, fibrosis, cirrhosis, and hepatocellular carcinoma, cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction (e.g., necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's disease Disease), left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataracts, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina, thrombosis, atherosclerosis, transient ischemic attack, vascular restenosis, impaired glucose metabolism, impaired fasting glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcers, ulcerative colitis, hyperlipoprotein B blood, Alzheimer's Disease, schizophrenia, cognitive impairment, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome and addiction (e.g., alcohol and / or drug abuse), prevention or treatment of polycystic ovary syndrome, and treatment of addiction (e.g., alcohol and / or drug abuse).
[0191] In some embodiments, provided herein is a method of treating a cardiometabolic disease in a subject (eg, a human patient) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.
[0192] In some embodiments, provided herein is a method for treating diabetes in a subject (e.g., a human patient) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. Exemplary diabetes includes, but is not limited to, T1D, T2DM, prediabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, and gestational diabetes.
[0193] In some embodiments, provided herein is a method for treating a liver disorder in a subject (e.g., a human patient) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof. Exemplary liver disorders include, but are not limited to, liver inflammation, fibrosis, and steatohepatitis. In some embodiments, the liver disorder is selected from the list consisting of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), drug-induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition-associated cholestasis (PNAC), bacterial overgrowth or sepsis-associated cholestasis, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), graft-versus-host disease, transplant liver regeneration, congenital hepatic fibrosis, common bile duct stones, granulomatous liver disease, intrahepatic or extrahepatic malignancy, Sjogren's syndrome, sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, or oti-antitrypsin deficiency. In some embodiments, the liver disorder is selected from the list consisting of: liver inflammation, liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In some embodiments, the liver disorder is selected from the group consisting of liver fibrosis, alcoholic fibrosis, steatosis, alcoholic steatosis, NAFLD and NASH. In one embodiment, the liver disorder is NASH. In another embodiment, the liver disorder is liver inflammation. In another embodiment, the liver disorder is liver fibrosis. In another embodiment, the liver disorder is alcoholic fibrosis. In another embodiment, the liver disorder is steatosis. In another embodiment, the liver disorder is alcoholic steatosis. In another embodiment, the liver disorder is NAFLD. In one embodiment, the treatment methods provided herein hinder or slow the progress of NAFLD to NASH. In one embodiment, the treatment methods provided herein hinder or slow the progress of NASH. NASH can progress to one or more of, for example, cirrhosis, liver cancer, etc. In some embodiments, the liver disorder is NASH. In some embodiments, the patient has undergone a liver biopsy. In some embodiments, the method further comprises obtaining the results of the liver biopsy.
[0194] According to the present application, the compounds described herein or their pharmaceutically acceptable salts can be administered by any suitable route, in the form of a pharmaceutical composition suitable for such route, and at a dose that is expected to be effective for treatment. In some embodiments, it is a compound of any embodiment of formula (0), formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the compounds of Table 1 or its pharmaceutically acceptable salt. The compounds and / or compositions described herein can be administered orally, rectally, vaginally, parenterally or topically.
[0195] In some embodiments, the compounds and / or compositions can be administered orally. Oral administration can involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration can be employed, whereby the compound enters the bloodstream directly from the mouth.
[0196] In some embodiments, the compound and / or composition can be directly administered into the bloodstream, muscle or internal organs. Suitable modes for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) syringes, needle-free syringes and infusion techniques.
[0197] In some embodiments, the compound and / or composition can be topically applied to the skin or mucous membrane, i.e., transdermally or transdermally. In some embodiments, the compound and / or composition can be administered intranasally or by inhalation. In some embodiments, the compound and / or composition can be administered rectally or vaginally. In some embodiments, the compound and / or composition can be directly applied to the eyes or ears.
[0198] The dosage regimen of the compounds and / or compositions described herein is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the illness; the route of administration; and the activity of the specific compound used. Therefore, the dosage regimen may vary greatly. In some embodiments, for the treatment of the specified illness discussed herein, the total daily dose of the compound of the present application is generally about 0.001 to about 100 mg / kg (i.e., mg compound / kg body weight). In one embodiment, the total daily dose of the compound of the present application is about 0.01 to about 30 mg / kg, and in another embodiment, about 0.03 to about 10 mg / kg, and in yet another embodiment, about 0.1 to about 3 mg / kg. It is not uncommon for the administration of the compound of the present application to be repeated multiple times (usually no more than 4 times) in one day. If desired, multiple doses per day can usually be used to increase the total daily dose.
[0199] For oral administration, the compounds and / or compositions described herein can be provided in the form of tablets containing 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 30.0, 50.0, 75.0, 100, 125, 150, 175, 200, 250 and 500 mg of active ingredients to adjust the dosage according to the patient's symptoms. The drug typically contains about 0.01 mg to about 500 mg of active ingredient, or in another embodiment, about 1 mg to about 100 mg of active ingredient. Intravenously, during a constant rate infusion, the dose can be in the range of about 0.01 to about 10 mg / kg / minute.
[0200] The compounds and / or compositions described herein can be used alone or in combination with other therapeutic agents. The "combination" administration of two or more agents means that the administration time of all agents is close enough so that each agent can generate a biological effect within the same time frame. The presence of an agent may change the biological effect of other agents. Two or more agents can be administered simultaneously, in parallel or in sequence. In addition, simultaneous administration can be performed by mixing the agents before administration, or by administering the compounds in separate dosage forms at the same time point but at the same or different administration sites.
[0201] The present application provides any use, method or composition as defined herein, wherein a compound of formula (0), any embodiment of formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the compounds of Table 1 as described herein, or a pharmaceutically acceptable salt thereof, is used in combination with one or more other therapeutic agents. This would include a pharmaceutical composition comprising a mixture of a compound of formula (0), any embodiment of formula (1) (including a compound of formula (2)-(10) or a subformula of any of the foregoing), or a compound selected from the compounds of Table 1, or a pharmaceutically acceptable salt thereof, as defined in any embodiment described herein, and at least one pharmaceutically acceptable excipient and one or more other therapeutic agents.
[0202] In some embodiments, the one or more additional therapeutic agents are antidiabetic agents, including but not limited to biguanides (e.g., metformin), sulfonylureas (e.g., tolbutamide, glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, or glipizide), thiazolidinediones (e.g., pioglitazone, rosiglitazone, or lobeglitazone), glitazars (e.g., saroglitazar, aleglitazar, muraglitazar, or tesaglitazar), meglitinides (e.g., nateglinide), nateglinide, repaglinide), dipeptidyl peptidase 4 (DPP-4) inhibitors (e.g., sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, dutogliptin, or omarigliptin), glitazones (e.g., pioglitazone, rosiglitazone, balaglitazone, rivoglitazone, or lobeglitazone), sodium glucose transporter 2 (SGLT2) inhibitors (e.g.,empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, ipragliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate or ertugliflozin), SGLT1 inhibitors, GPR40 agonists (FFAR1 / FFA1 agonists, such as fasiglifam), glucose-dependent insulinotropic peptide (GIP) and its analogs, alpha glucosidase inhibitors (e.g., voglibose, acarbose or miglitol), or insulin or insulin analogs, including pharmaceutically acceptable salts of the specifically specified agents and pharmaceutically acceptable solvates of the agents and salts.
[0203] In some embodiments, the one or more additional therapeutic agents are anti-obesity agents, including but not limited to peptide YY or an analog thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, an NPYR1 or NPYR5 antagonist, a cannabinoid receptor type 1 (CB1R) antagonist, a lipase inhibitor (e.g., orlistat), human proinsulin peptide (HIP), a melanocortin receptor 4 agonist (e.g., setmelanotide), a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist (e.g., obeticholic acid), or a combination thereof. acid), zonisamide, phentermine (alone or in combination with topiramate), norepinephrine / dopamine reuptake inhibitors (e.g., buproprion), opioid receptor antagonists (e.g., naltrexone), combinations of norepinephrine / dopamine reuptake inhibitors and opioid receptor antagonists (e.g., a combination of buproprion and naltrexone), GDF-15 analogs, sibutramine, cholecystokinin agonists, amylin and its analogs (e.g., pramlintide), leptin and its analogs (e.g., metroleptin), serotonergic agents (e.g., lorcaserin), methionine aminopeptidase 2 (MetAP2) inhibitors (e.g., , beloranib or ZGN-1061), phendimetrazine, diethylaminophenone, benzphetamine, SGLT2 inhibitors (e.g., empagliflozin, canagliflozin, dapagliflozin, isagliflozin, isagliflozin, togliflozin, sergliflozin etabonate, remogliflozin etabonate or eregflozin), SGLTL1 inhibitors, SGLT2 / SGLT1 dual inhibitors, fibroblast growth factor receptor (FGFR) modulators, AMP-activated protein kinase (AMPK) activators, biotin, MAS receptor modulators or glucagon receptor agonists (alone or in combination with another GLP-1R agonist (e.g., liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide or semaglutide)), including pharmaceutically acceptable salts of specifically specified agents and pharmaceutically acceptable solvates of the agents and salts.
[0204] In some embodiments, the one or more additional therapeutic agents are agents that treat NASH, including but not limited to PF-05221304, FXR agonists (e.g., obeticholic acid), PPAR a / d agonists (e.g., alafinol), synthetic fatty acid-bile acid conjugates (e.g., aramchol), caspase inhibitors (e.g., emricasan), anti-lysyl oxidase homolog 2 (LOXL2) monoclonal antibodies (e.g., simtuzumab), galectin 3 inhibitors (e.g., GR-MD-02), MAPK5 inhibitors (e.g., GS-4997), dual antagonists of chemokine receptor 2 (CCR2) and CCR5 (e.g., cenicriviroc), fibroblast growth factor 21 (FGF21) agonists (e.g., BMS-986036), leukotriene D4 (LTD4) receptor antagonists (e.g., tipelukast), niacin analogs (e.g., ARI 3037MO), ASBT inhibitors (e.g., volixibat), acetyl-CoA carboxylase (ACC) inhibitors (e.g., NDI 010976), ketohexokinase (KHK) inhibitors, diacylglycerol acyltransferase 2 (DGAT2) inhibitors, CB1 receptor antagonists, anti-CB1R antibodies or apoptosis signal regulating kinase 1 (ASK1) inhibitors, including pharmaceutically acceptable salts of specifically specified agents and pharmaceutically acceptable solvates of the agents and salts.
[0205] Products and kits
[0206] The present disclosure also provides articles, which are contained in suitable packaging according to the compounds of the present application or their pharmaceutically acceptable salts, compositions described herein, or one or more unit doses described herein. In certain embodiments, the articles are used in any of the methods described herein. Suitable packaging (e.g., containers) are known in the art and include, for example, vials, vessels, ampoules, bottles, jars, flexible packaging, etc. The articles may be further sterilized and / or sealed.
[0207] The kit can be a unit dosage form, bulk packaging (e.g., multi-dose packaging) or subunit dosage. For example, a kit containing a sufficient dose of a compound according to the present application or a pharmaceutically acceptable salt thereof, a composition as described herein, and / or one or more other therapeutic agents for the disease described in detail herein can be provided, thereby providing effective treatment for an individual over an extended period of time, such as 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months or any one of the longer periods of time. The kit may also include multiple unit doses and instructions for use of the compound / composition as described herein, and is packaged in an amount sufficient for storage and use in a pharmacy (e.g., a hospital pharmacy and a compounding pharmacy).
[0208] The kit may optionally include a set of instructions related to the use of the components of the methods of the present disclosure, generally written instructions, but electronic storage media (e.g., magnetic or optical disks) containing instructions are also acceptable. The instructions included in the kit typically include information about the components and their administration to an individual.
[0209] General synthetic scheme
[0210] Scheme A. Preparation of 5-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane intermediate A7.
[0211]
[0212] The pyridine-substituted 2-azabicyclo[4.1.0]heptane intermediate A7 can be synthesized by reacting 2,6-dichloropyridine with the S-type enolate A2. N Ar reaction, the enolate A2 is prepared from commercially available 5-methyl 2-azabicyclo [4.1.0] heptane-2,5-dicarboxylic acid 2- (tert-butyl) ester and a base (such as potassium or other basic bis (trimethylsilyl) amide). The intermediate ester A3 is saponified with an alkaline hydroxide and thermally decarboxylated. The chloropyridine A5 is reacted with a suitably substituted 2- (hydroxymethyl) aryl under Buchwald-Hartwig etherification conditions, and the resulting Boc-protected intermediate A6 is deprotected with a strong acid (such as trifluoroacetic acid) to give A7 in salt form.
[0213] Scheme B. Preparation of 5-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-substituted-1H-benzo[d]imidazole-6-carboxylic acids B1, B2, B3 and B4.
[0214]
[0215] The 5-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane intermediate A7 is reacted with an appropriately R1-substituted benzimidazole-6-carboxylate B1 (prepared according to various known synthetic methods, such as those described in WO2019239371) in the presence of an acid scavenger (such as an alkaline carbonate) to give a mixture of 4 diastereomers having (1R, 5R, 6R), (1R, 5S, 6R), (1S, 5R, 6S) and (1S, 5S, 6S) configurations. The diastereomeric intermediate mixture is separated by supercritical fluid chromatography (SFC), and each discrete compound is then saponified with an alkaline hydroxide to give the final products B2, B3, B4 and B5. Alternatively, intermediate A7 can be prepared by stereoselective synthesis, or purified to obtain only the desired isomer for subsequent steps.
[0216] Scheme C. Preparation of 2-(6-(aryloxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]-heptane intermediate C4.
[0217]
[0218] Pyridine substituted 2,5-diazabicyclo[4.1.0]heptane intermediate C3 can be prepared by nucleophilic substitution of 2,6-dihalopyridine C1 with an appropriately substituted 2-(hydroxymethyl)aryl anion formed from C1A and a strong base such as sodium hydride. 2-(Aryloxy)-6-halopyridine C2 is reacted with commercially available tert-butyl 2,5-diazabicyclo[4.1.0]heptane-2-carboxylate C2A under Buchwald-Hartwig amination conditions, and the resulting Boc protected intermediate C3 is deprotected with a strong acid such as hydrochloric acid to afford intermediate C4 in salt form.
[0219] Scheme D. Preparation of 2-((5-(6-(aryloxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]-hept-2-yl)methyl)-1-substituted-1H-benzo[d]imidazole-6-carboxylic acids D1 and D2.
[0220]
[0221] The 2-(6-(aryloxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]-heptane intermediate C4 is reacted with an appropriately R1-substituted benzimidazole-6-carboxylate B1 (prepared according to various known synthetic methods, such as the method described in WO2019239371) in the presence of an acid scavenger (such as an alkaline carbonate) to obtain a mixture of 2 diastereomers having (1R, 6S) and (1S, 6R) configurations. The diastereomeric intermediate mixture is separated by supercritical fluid chromatography (SFC), and each discrete compound is then saponified with an alkaline hydroxide to obtain the final products D1 and D2. Alternatively, the intermediate C4 can be prepared by stereoselective synthesis, or purified to obtain only the desired isomer for subsequent steps.
[0222] Scheme E. Preparation of (S)-4,4,5,5-tetramethyl-2-(2-methyl-2-(substituted aryl)benzo[d][1,3]dioxol-4-yl)-1,3,2-dioxaborolane intermediate E6.
[0223]
[0224] Seyferth-Gilbert homologation from appropriately substituted aryl aldehyde E1 and dimethyl(diazomethyl)phosphonate afforded the alkyne intermediate E2. Addition of 3-bromocatechol to the alkyne E2 in the presence of triruthenium dodecacarbonyl afforded 4-bromo-2-methyl-2-arylbenzo[d][1,3]dioxole as a mixture of enantiomers E4 and E5, which could be separated by supercritical fluid chromatography (SFC) to afford the desired (S)-isomer.
[0225] Scheme F. Preparation of 5-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-2-azabicyclo[4.1.0]heptane intermediate F7.
[0226]
[0227] Metal-free cross-coupling of sulfonyl hydrazide F2 with (S)-4,4,5,5-tetramethyl-2-(2-methyl-2-(substituted-aryl)benzo[d][1,3]dioxol-4-yl)-1,3,2-dioxaborolane intermediate E6 in the presence of a base such as cesium carbonate affords tert-butyl-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-3,4-dihydropyridine-1(2H)-carboxylate F3. Reaction of F3 with dibromocarbene generated under phase transfer conditions affords gem-dibromocyclopropane adduct F5, which is then reductively dehalogenated with tri-n-butyltin hydride. Deprotection of F6 with a strong acid such as HCl or TFA affords F7.
[0228] Scheme G. Alternative preparation of tert-butyl-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-3,4-dihydropyridine-1(2H)-carboxylate Intermediate F3.
[0229]
[0230] Alternatively, intermediate F3 can be prepared by Suzuki coupling of commercially available tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate with intermediate E4. The resulting dihydropyridine G1 is reduced and oxidized with catalytic ruthenium(III) chloride and sodium periodate to afford lactam G3. Lactam G3 can be converted to dihydropyridine F3 by organosilanes such as tetramethyldisiloxane and catalytic Vaska reagents.
[0231] Scheme H. Alternative preparation of tert-butyl-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-3,4-dihydropyridine-1(2H)-carboxylate Intermediate F3.
[0232]
[0233] Alternatively, intermediate F3 can be prepared by rhodium-catalyzed cross-coupling of commercially available tert-butyl 6-oxo-3,6-dihydropyridine-1(2H)-carboxylate with intermediate E6. Reduction of lactam G3 affords hydroxypiperidine H1, which is treated with aqueous acid to afford intermediate F3.
[0234] Scheme I. Alternative preparation of 5-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-2-azabicyclo[4.1.0]heptane intermediate F7.
[0235]
[0236] Under traditional Simmons-Smith reaction conditions, intermediate F7 can be obtained from G4 in very low yield.
[0237] Scheme J. Preparation of 1-substituted-2-((5-((S)-2-methyl-2-substituted-phenylbenzo[d][1,3]dioxol-4-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acids J1, J2, J3 and J4.
[0238]
[0239] The 5-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-2-azabicyclo[4.1.0]heptane intermediate F7 is reacted with an appropriately R1-substituted benzimidazole-6-carboxylate B1 (prepared according to various known synthetic methods, such as those described in WO2019239371) in the presence of an acid scavenger such as an alkaline carbonate to give a mixture of 4 diastereomers having (1R,5R,6R), (1R,5S,6R), (1S,5R,6S) and (1S,5S,6S) configurations. The diastereomeric intermediate mixture is separated by supercritical fluid chromatography (SFC), and each discrete compound is then saponified with an alkaline hydroxide to give the final products J1, J2, J3 and J4. Alternatively, intermediate F7 can be prepared by stereoselective synthesis or purified to obtain only the desired isomer for subsequent steps.
[0240] Scheme K. Preparation of 2-((S))-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]heptane intermediate K2.
[0241]
[0242] Commercially available tert-butyl 2,5-diazabicyclo[4.1.0]heptane-2-carboxylate was reacted with E4 under Buchwald amination conditions, and the resulting intermediate was deprotected with strong acid to give K2.
[0243] Scheme L. 1-Substituted-2-((5-((S)-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acids L1 and L2.
[0244]
[0245] The 2-((S))-2-methyl-2-substituted-arylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]heptane intermediate K2 is reacted with an appropriately R1-substituted benzimidazole-6-carboxylate B1 (prepared according to various known synthetic methods, such as the method described in WO2019239371) in the presence of an acid scavenger (such as an alkaline carbonate) to obtain a mixture of 2 diastereomers having (1R,6S) and (1S,6R) configurations. The diastereomeric intermediate mixture is separated by supercritical fluid chromatography (SFC), and each discrete compound is then saponified with an alkaline hydroxide to obtain the final products L1 and L2. Alternatively, intermediate K2 can be prepared by stereoselective synthesis or purified to obtain only the desired isomer for subsequent steps.
[0246] Scheme M. Preparation of 2-((2-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]-hept-5-yl)methyl)-1-substituted-1H-benzo[d]imidazole-6-carboxylic acids M7.
[0247]
[0248] Commercially available tert-butyl 5-oxo-2-azabicyclo[4.1.0]heptane-2-carboxylate and phosphonate M2A were subjected to Horner-Wadsworth-Emmons olefination to afford methyl 2-((2-(tert-butyloxycarbonyl)-2-azabicyclo[4.1.0]heptane-5-methylene)methyl)-1-substituted-1H-benzo[d]imidazole-6-carboxylate M3, which was reduced and deprotected with strong acid. Amination of 2-(aryloxy)-6-bromopyridine C2 under Buchwald conditions afforded M6, which was then saponified with alkaline hydroxide to afford M7 as a mixture of 4 diastereomers. Alternatively, M6 can be separated by supercritical fluid chromatography (SFC) to give (1S, 5R, 6S), (1S, 5S, 6S), (1R, 5R, 6R) and (1R, 5S, 6R) discrete isomers, which can be saponified with alkaline hydroxide to give the final product. Alternatively, intermediate M6 can be prepared by stereoselective synthesis or purified to obtain only the desired isomer for subsequent steps.
[0249] Scheme N. Preparation of 2-((5-(6-substituted-aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-substituted-6-(1H-tetrazol-5-yl)-1H-benzo[d]imidazole N6.
[0250]
[0251] Commercially available 3-fluoro-4-nitrobenzonitrile is nucleophilically substituted with the desired amine R1NH2, followed by reduction and condensation with 2-chloro-1,1,1-trimethoxyethane to give 2-(chloromethyl)-1-substituted-1H-benzo[d]imidazole-6-carbonitrile N4. N4 reacts with 5-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane intermediate A7 in the presence of an acid scavenger such as an alkaline carbonate to give N5. N5 is cycloadded with trimethylsilyl azide in the presence of a catalyst such as tri-n-butyltin oxide to give N6 as a mixture of 4 diastereomers. If desired, the mixture of diastereomers can be separated by supercritical fluid chromatography (SFC).
[0252] Scheme O. Preparation of 3-(2-((5-(6-(substituted-aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-substituted-1H-benzo[d]imidazol-6-yl)-1,2,4-oxadiazol-5(4H)-one O2.
[0253]
[0254] Reaction of hydroxylamine with N5 yields 2-((5-(6-(substituted aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-N'-hydroxy-1-substituted-1H-benzo[d]imidazole-6-carboximidamide O1, which is further cyclized with 1,1'-carbonyldiimidazole or phosgene in the presence of a base to give O2. The reaction can be carried out with discrete diastereomers N5 or a mixture of four diastereomers separated by supercritical fluid chromatography (SFC).
[0255] Scheme P. Preparation of 5-(2-((5-(6-(substituted-aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)-1-substituted-1H-benzo[d]imidazol-6-yl)isoxazol-3(2H)-one P10.
[0256]
[0257] 2-(Chloromethyl)-6-iodo-1-substituted-1H-benzo[d]imidazole P4 was prepared by similar methods used to synthesize N4. Conversion to TBS ether and Sonogashira coupling with ethyl propiolate gave alkyne P6, which was cyclized with hydroxylamine to give isoxazol-3-one P7. Deprotection, mesylation and reaction with 5-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane intermediate A7 in the presence of an acid scavenger such as an alkaline carbonate gave P10. The reaction can be carried out with discrete diastereomers A7 or with a mixture of 4 diastereomers separated by supercritical fluid chromatography (SFC).
[0258] Scheme Q. Alternative preparation of 2-((5-(6-Substituted-aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-substituted-6-(1H-tetrazol-5-yl)-1H-benzo[d]imidazole N6.
[0259]
[0260] When Y = CN, it is advantageous to install the tetrazolyl heterocycle at an early stage of the synthesis. Azide cycloaddition of N2 affords N-substituted-2-nitro-5-(1H-tetrazol-5-yl)anilines Q1, which are reduced and condensed with 2-chloro-1,1,1-trimethoxyethane to afford 2-(chloromethyl)-1-substituted-6-(1H-tetrazol-5-yl)-1H-benzo[d]imidazole Q3. Reaction of Q3 with 5-(6-(aryloxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane intermediate A7 in the presence of an acid scavenger such as an alkali metal carbonate affords N6.
[0261] GLP-1R Cellular Assay
[0262] Stable cell lines expressing high GLP-1R surface expression and low GLP-1R surface expression were generated in CHO-K1 cells (Fugene 6) transfected with a puromycin-selective DNA plasmid encoding the human GLP-1R receptor under the control of the EF1A promoter (Accession No.: NM_002062.5). Transfected cells were seeded into 24-well plates (9,000 cells / well) containing complete medium and incubated in a humidified incubator at 37°C and 5% carbon dioxide. After incubation overnight, the medium was replaced with complete medium supplemented with puromycin (6 μg / mL) and refreshed every 2-3 days to select stably transfected cells. Individual pools of selected cells were amplified and then analyzed for reactivity to a GLP-1 control peptide using a TR-FRET assay to detect cAMP (LANCEUltra cAMP assay, Perkin Elmer). Briefly, cells were collected in Versene solution, plated in 384-well plates (1,000 cells / well), and combined with serially diluted GLP-1R control peptide (10 nL) using an acoustic dispenser (ECHO). The plates were incubated at 25°C for 30 minutes, and then EU-cAMP tracer (5 μL) and Ulight anti-cAMP (5 μL) reagents were added to each well, followed by incubation at 25°C for 15 minutes. TR-FRET signals were detected using an EnVision multimode plate reader (excitation = 320 nm; emission = 615 and 655 nm). EC was generated using dose-response curves. 50 Values were obtained as a measure of reactivity to the GLP-1R control peptide. The reactivity of the selected cell lines was monitored for multiple passages to ensure stability. CHO-K1_hGLP-1Rhigh_clone16 and CHO-K1_hGLP-1Rlow_clone10 showed consistent high and low reactivity to the GLP-1R control peptide, respectively, and were selected for further analysis to determine the relative level of GLP-1R surface expression. In brief, GLP-1R expression was analyzed by flow cytometry using a fluorescein-labeled Exendin-4 peptide fluorescent probe (FLEX). Cells were harvested in Versene solution and washed three times with PBS + 0.5% BSA and then incubated with FLEX reagent (10 μM) for 2 hours at room temperature. After incubation, the cells were washed three times in PBS + 0.5% BSA and then finally resuspended in PBS and analyzed by flow cytometry to measure the FLEX mean fluorescence intensity (MFI) as a measure of GLP-1R expression on the cell surface.
[0263] For compound testing in the CHO-K1_hGLP-1Rlow_clone10 cell line, cells were seeded into 384-well plates (1,000 cells / well). Test compounds were serially diluted in DMSO (10 points, 3-fold dilutions), added to the wells using an ECHO dispenser (10 nL / well), and the plates were centrifuged for 1 minute and stirred for 2 minutes at room temperature, then incubated at 25°C for 30 minutes. After incubation, Eu-cAMP (5 μL) and Ulight anti-cAMP (5 μL) reagents were added to each well, followed by centrifugation for 1 minute, stirring for 2 minutes at room temperature, and finally the plates were incubated at 25°C for 15 minutes. The plates were read using an EnVision microplate reader (excitation = 320 nm; emission = 615 and 655 nm). Dose response curves were generated from duplicate wells based on the percentage of activation calculated relative to a control GLP-1 peptide agonist run in parallel. EC 50 Values were determined by fitting the percent activation as a function of compound concentration using the Hill equation (XLfit).
[0264] The EC50 values of exemplary compounds 1 and 2 in the low expression assay are shown in the table below. The EC50 values were compared to reference compound A and reference compound B. The compounds tested were compound samples prepared according to the general procedures described in the Examples section.
[0265] Metabolic stability in hepatocytes
[0266] The test compound was incubated in human hepatocytes and stability was assessed by substrate depilation. The test compound was dissolved in dimethyl sulfoxide (DMSO) to make a 10mM stock solution, and then further diluted with DMSO in a 96-well plate to make a 1000× working stock solution of 1mM of the test compound and the positive control (midazolam). The vial containing the frozen hepatocytes was taken out from the liquid nitrogen tank and immediately immersed in a 37°C water bath. The vial was gently shaken until the contents were thawed, and then immediately poured into the 48mL preheated HT culture medium in a 50mL conical tube. The remaining cells in the vial were resuspended with 1.0mL preheated HT culture medium and added to the conical tube. The tube was capped and then gently flipped several times to resuspend the hepatocytes. The cell suspension was centrifuged at room temperature at 50x g for 5 minutes and the supernatant was discarded. The cell pellet was loosened by gently rotating the centrifuge tube and resuspended in 4mL warm Dulbecco's modified Eagle culture medium (DMEM). The cell density was determined by a Nexcelom cell counter and DMEM medium was added to obtain a target density of 1 x 106 cells / mL. The assay was performed in 96-well microtiter plates. Test compounds were co-cultured at 1 μM in DMEM with 1 x 10 6Cells / mL hepatocytes were incubated for 0, 30, 60, 120 and 240 minutes. Incubation was performed with gentle shaking at 37°C in a humid atmosphere of 95% air / 5% CO2. The volume of the incubation mixture was 37 μL with a final 0.1% DMSO. At each time point, incubation was stopped by adding 150 μL of quenching solution (100 acetonitrile, 0.1% formic acid, containing bucetin as an internal standard for positive ESI mode). Subsequently, the mixture was vortexed for 20 minutes and centrifuged at 4,000 RPM at 10°C. The supernatant (80 μL) was transferred to a clean 96-well plate and analyzed by LC-MS / MS. 1 μM midazolam with a final 0.1% DMSO was included as a positive control to verify the assay performance. Calculate the remaining parent percentage, intrinsic liver clearance and predicted liver clearance as well as t 1 / 2 All samples were analyzed by LC-MS / MS using an AB Sciex API 4000 instrument coupled to a Shimadzu LC-20AD LC pump system. Separation was achieved using a Waters Atlantis T3dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL / min. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in 100% acetonitrile (solvent B).
[0267] Elution conditions are described in detail below.
[0268] Time (min) Flow rate (μL / min) %A %B 0 500 98 2 0.30 500 98 2 1.40 500 2 98 2.20 500 2 98 2.21 500 98 2 3.00 500 98 2
[0269] The ion optics of each test compound were optimized for its declustering potential (DP), collection energy (CE), collision cell exit potential (CXP) and used in selected ion monitoring experiments in positive ion mode. The stability of the peak area ratio of each test compound to the internal standard was then evaluated. The extent of metabolism was calculated based on the disappearance of the test compound compared to its initial concentration. The initial clearance rate of the test compound was calculated using a linear regression plot of the semi-log % remaining of the compound versus time. The elimination rate constant (k) from the linear regression plot was then used to determine t 1 / 2 and intrinsic clearance (CL int ), using the following formula, where C 肝细胞 (million cells / mL) is the cell density of the incubation:
[0270] k=-slope
[0271] t 1 / 2 =0.693 / k
[0272] CL int = k / C 肝细胞
[0273] This method of determining intrinsic clearance assumes that the test compound concentration is well below the Michaelis-Menten constant for the compound to its metabolizing enzymes.
[0274] Predicted hepatic clearance (CL hep ) is calculated using the following formula using the fully stirred method, where CL int(体内) Normalization was performed based on liver weight:
[0275] CL int(体内) =CL int x Hepatocellularity x liver weight
[0276] CL hep(预测) =(CL int(体内) x Q 肝脏 ) / (CL int(体内) +Q 肝脏 )
[0277] Where Q 肝脏 (ml / min / kg) is the liver blood flow
[0278] The relevant physiological parameters of human liver weight, blood flow and hepatocellularity are listed below:
[0279]
[0280] Passive permeability and outflow rate
[0281] Caco-2 cells (clone C2BBe1) are obtained from, for example, the American Type Culture Collection (Manassas, VA). Cell monolayers are grown to confluence on collagen-coated microporous membranes in 12-well assay plates. The permeability assay buffer is a Hanks balanced salt solution containing 10 mM HEPES and 15 mM glucose, with a pH of 7.4. The buffer in the receiving chamber also contains 1% bovine serum albumin. The dosing solution concentration is 5 μM test article in the assay buffer. Cell monolayers are administered on the apical side (A to B) or the basolateral side (B to A) and incubated in a humidified incubator at 37 ° C and 5% CO2. Samples are collected from the donor chamber and the receiving chamber at 120 minutes. Each determination is performed in duplicate. The fluorescein yellow flux of each monolayer was also measured after the experiment to ensure that no damage to the cell monolayer was caused during the flux. All samples were determined by LC-MS / MS using electrospray ionization. The apparent permeability (P app ) and the recovery percentage are calculated as follows:
[0282] P app = (dC r / dt) × V r / (A × C A ) (1)
[0283] Recovery percentage = 100 × ((V r ×C r 最终 )+(V d ×C d 最终 )) / (V d ×C N )(2),
[0284] Among them, dC r / dt is the slope of the cumulative received concentration versus time, in μM s -1 ; V r is the volume of the receiving chamber in cm 3 ; V d is the volume of the donor chamber in cm 3 ; A is the insertion area (12 holes is 1.13 cm 2 );C A is the average of the nominal dose concentration and the measured 120-min donor concentration, in μM; C N is the nominal concentration of the dosing solution in μM; C r 最终 is the cumulative received concentration at the end of the incubation period, in μM; C d 最终 is the donor concentration at the end of the incubation period, expressed in μM. The efflux rate (ER) is defined as P app (B to A) / P app (A to B).
[0285] Pharmacokinetics in rats
[0286] Intravenous administration: The compound was formulated at 0.5 mg / mL in a solution containing 5% polyethylene glycol 400 and 95% (12% (w / v) sulfobutyl-β-cyclodextrin in water) (v / v). The formulated compound was sterile filtered through a 0.22 micron filter before administration. The compound was administered to 7-11 week old male Sprague-Dawley rats at a dose of 1 mg / kg by infusion into the jugular vein cannula over 30 minutes.
[0287] Oral administration: The compound was formulated at 0.3 mg / mL or 0.6 mg / mL in a solution containing 5% polyethylene glycol 400 and 95% (12% (weight / volume) sulfobutyl-β-cyclodextrin aqueous solution) (volume / volume). The formulated compound was administered by oral gavage at a dose of 10 mL / kg to 7-11 week old male Sprague-Dawley rats.
[0288] Sample Collection: Collect approximately 0.2 mL of blood from the jugular vein or other appropriate site of each animal at each time point into pre-cooled commercial EDTA-K2 tubes and place on wet ice until centrifugation. Blood samples were processed to obtain plasma by centrifugation at approximately 4°C, 3,200 g for 10 minutes. Plasma was collected and transferred to pre-labeled 96-well plates or polypropylene tubes, snap-frozen on dry ice and stored at -60°C or lower until LC-MS / MS analysis.
[0289] Data Analysis: Plasma concentration versus time data were plotted in graphs and analyzed by non-partitioning methods using Phoenix WinNonlin 6.3 software program. Relevant PK parameters were calculated according to the route of administration, e.g., CL, V for intravenous administration, and dss and C0, extravascularly administered C max , T max or %F, and T of all pathways 1 / 2 , AUC (0-t) , AUC (0-inf) , MRT (0-t) , MRT (0-inf) .
[0290] Example
[0291] For illustrative purposes, neutral compounds of formula (0) and formula (1) were synthesized and tested in the examples. It should be understood that the neutral compounds of formula (0) and formula (1) can be converted into pharmaceutically acceptable salts corresponding to the compounds using techniques in the art (e.g., by saponifying esters to carboxylates, or by hydrolyzing amides to form corresponding carboxylic acids, and then converting carboxylates to carboxylates).
[0292] It is to be understood that the values described in the examples are approximate and are subject to experimental and instrumental variations.
[0293] abbreviation:
[0294]
[0295]
[0296] Example 1 (Synthesis of Compound 1)
[0297] Compound 1 was prepared by the synthetic method shown in Scheme 1.
[0298] Solution 1
[0299]
[0300] Preparation procedure of compound S3
[0301]
[0302] A mixture of compound S1 (500 mg, 2.52 mmol, 1.1 eq), compound S2 (704.12 mg, 2.29 mmol, 1 eq), Pd2(dba)3 (104.97 mg, 114.63 umol, 0.05 eq), racemic-BINAP (142.76 mg, 229.27 umol, 0.1 eq) and t-BuONa (661.00 mg, 6.88 mmol, 3 eq) in toluene (1 mL) was degassed and purged 3 times with N2, and then the mixture was purged at 100° C. under N2 atmosphere for 2 hours. LC-MS showed that compound S1 was completely consumed. The reaction mixture was cooled to 20° C., filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 10 / 1). Compound S3 (440 mg, 1.04 mmol, 45% yield) was obtained as a white solid.
[0303] LCMS: RT = 2.142 min, MS calculated value: 424.2, [M+H] + =325.2
[0304] 1 H NMR (400MHz, chloroform-d) δ = 0.39 (br s,1H)1.02-1.21(m,1H)1.50(s,10H)2.75-2.91(m,1H)3.05-3.60(m,4H)3.83-4.08(m,1H)5.41-5.51(m,2H)6.18(d,J=7.82Hz,1H)6.34(br s,1H)7.37(dd,J=9.29,1.22Hz,1H)7.43-7.51(m,2H)7.59-7.66(m,1H).
[0305] General procedure for the preparation of compound S4
[0306]
[0307] A mixture of compound S3 (400 mg, 942.36 umol, 1 eq), TFA (1 mL) in DCM (3 mL) was degassed and purged with N2 three times, then the mixture was stirred at 20°C under N2 atmosphere for 1 hour, at which time the reaction mixture was concentrated under reduced pressure. Compound S4 was a yellow oil and was used directly.
[0308] General procedure for the preparation of compounds S6A and S6B
[0309]
[0310] The mixture of compound S4, compound S5 (300mg, 924.92umol, 1eq), KCO (383.49mg, 2.77mmol, 3eq) in CHCN (5mL) is degassed, and purged 3 times with N, then the mixture is stirred for 3 hours at 50 ℃ under N atmosphere.The reaction mixture is filtered and distributed with 5mL HO.The mixture is extracted with EtOAc (10mL x3).The organic layers are merged, and washed with 10mL salt water, concentrated under reduced pressure. The residue was purified by preparative HPLC (neutral condition column: Waters XbridgePrep OBD C18150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 45%-80%, 8min) to obtain the desired compound (400mg, yield 90%, purity 90%) as a white solid, which was further separated by SFC (conditions: column: DAICEL CHIRALCEL OD (250mm*30mm, 10um); mobile phase: [0.1% NH3H2O MEOH]; B%: 50%-50%, 15min). Compound S6A (120mg, 196.83umol, 21.28% yield) was obtained as a white solid.
[0311] LCMS: RT = 2.532 min, MS calculated value: 617.2, [M+H] + =618.2
[0312] 1 H NMR (400 MHz, chloroform-d) δ = 0.46-0.61 (m, 1H) 0.79 (q, J = 6.30 Hz, 1H) 1.22 (d, J = 6.00 Hz, 1H) 1.25-1.31 (m, 1H) 2.37-2.45 (m, 1H) 2.58-2.66 (m, 1H) 2.72-2.83 (m, 2H) 3.00-3.09 (m, 1H) 3.96 (s, 3H) 4.01-4.08 (m, 1H) 4.10-4.21 (m, 3H) 5. 37-5.52(m,2H)5.86(s,2H)6.16(d,J=7.88Hz,1H)6.31(d,J=8.00Hz,1H)7.34(d,J=9.26Hz,1H)7.41-7.51(m,2H )7.61(t,J=7.50Hz,1H)7.79(d,J=8.38Hz,1H)7.90(s,1H)8.02(d,J=8.50Hz,1H)8.15(s,1H)8.74-8.77(m,1H).
[0313] Compound S6B (80 mg, 131.22 umol, 14.19% yield) was obtained as a white solid.
[0314] LCMS: RT = 2.534 min, MS calculated value: 617.2, [M+H] + =618.2
[0315] 1 H NMR (400MHz, chloroform-d) δ = 0.50-0.60 (m, 1H) 0.79 (q, J = 6.34Hz, 1H) 1.20-1.29 (m, 1H) 2.39-2.47 (m, 1H) 2.59-2. 67(m,1H)2.72-2.84(m,3H)3.05(ddd,J=12.38,9.76,2.25Hz,1H)3.96(s,4H)4.03-4.21(m,4H)5.37-5.50( m,2H)5.86(s,2H)6.16(d,J=7.88Hz,1H)6.31(d,J=8.13Hz,1H)7.34(d,J=9.38Hz,1H)7.41-7.50(m,3H)7.6 1(t,J=7.44Hz,1H)7.79(d,J=8.50Hz,1H)7.90(s,1H)8.02(d,J=8.50Hz,1H)8.15(s,1H)8.74-8.77(m,1H).
[0316] General procedure for the preparation of compound 1
[0317]
[0318] A mixture of compound S6A (90 mg, 147.62 umol, 1 eq), LiOH.H2O (12.39 mg, 295.24 umol, 2 eq) in THF (0.7 mL) and H2O (0.3 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 25 ° C under N2 atmosphere for 16 hours. The reaction mixture was purified by preparative HPLC (neutral condition column: Waters Xbridge PrepOBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-50%, 8min). Compound 1 (29.88 mg, 50.16 umol, 33.98% yield) was obtained as a white solid.
[0319] LCMS: RT = 2.508 min, MS calculated value: 595.2, [M+H] + =596.1
[0320] 1 H NMR (400 MHz, methanol-d4) δ ppm 0.49-0.55 (m, 1H) 0.75 (q, J = 6.00 Hz, 1H) 2.37-2.45 (m, 1H) 2.67 (td, J = 7.42, 5.42 Hz, 1H) 2.76-2.85 (m, 2H) 3.00 (ddd, J = 12.84, 9.80, 2.62 Hz, 1H) 4.08-4.24 (m, 3H) 5.46 (s, 2H) 6.00 (s, 2H) 6.13 (d, J = 7.7 5Hz,1H)6.36(d,J=8.11Hz,1H)7.48(t,J=7.93Hz,1H)7.53-7.57(m,2H)7.62-7.68(m,1H)7.71(d,J= 8.46Hz,1H)8.01(dd,J=8.46,1.43Hz,1H)8.06(s,1H)8.27(d,J=0.83Hz,1H)8.94(d,J=0.72Hz,1H),
[0321] LCMS: RT = 2.508 min, MS calculated value: 595.2, [M+H] + =596.1
[0322] HPLC: RT = 11.351 min
[0323] Example 2 (Synthesis of Compound 2)
[0324] Compound 2 was prepared from compound S6B. The preparation of compound S6B is described in Example 1.
[0325]
[0326] To a solution of compound S6B (70 mg, 114.82 umol, 1 eq) in THF (0.7 mL) was added a solution of LiOH.H2O (9.64 mg, 229.63 umol, 2 eq) in H2O (0.3 mL). The mixture was stirred at 25 ° C for 12 hours. The mixture was directly purified. The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge BEH C18 100*30mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-60%, 8min). Compound 2 (35 mg, 58.76 umol, 51.18% yield) was obtained as a white solid.
[0327] LCMS: Rt = 2.474 min, MS calculated value: 595.65, [M+H] + =596.6
[0328] HPLC: Rt=11.346min
[0329] 1 H NMR (400 MHz, methanol-d4) δ = 0.47-0.54 (m, 1H) 0.68-0.78 (m, 1H) 2.35-2.45 (m, 1H) 2.65 (td, J = 7.43, 5.56 Hz, 1H) 2.73-2.85 (m, 2H) 2.93-3.02 (m, 1H) 4.06-4.25 (m, 3H) 5.44 (s, 2H) 5.98 (s, 2H) 6.11 (d, J = 7.7 0Hz,1H)6.34(d,J=8.07Hz,1H)7.46(t,J=7.95Hz,1H)7.51-7.58(m,2H)7.60-7.66(m,1H)7.71(d,J =8.44Hz,1H)7.99(dd,J=8.56,1.47Hz,1H)8.05(s,1H)8.27(d,J=0.86Hz,1H)8.92(d,J=0.73Hz,1H)
[0330] Example 3 (Synthesis of Compound 16)
[0331] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 diastereomers
[0332]
[0333] Preparation of 2-(tert-butyl) 5-methyl-2-azabicyclo[4.1.0]heptane-2,5-dicarboxylate (2)
[0334]
[0335] A mixture of 2-(tert-butyloxycarbonyl)-2-azabicyclo[4.1.0]heptane-5-carboxylic acid (2.5 g, 10.4 mmol, 1 eq), CH3I (2.94 g, 20.7 mmol, 1.29 mL, 2 eq), K2CO3 (2.15 g, 15.5 mmol, 1.5 eq) in DMF (30 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 25° C. under N2 atmosphere for 1 hour. TLC (petroleum ether / ethyl acetate=5 / 1 R f=0.46) indicated that the starting material was completely consumed. The combined reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (50 mL*2). The combined organic phase was concentrated in vacuo to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product, which was an oil (2.4 g, 9.40 mmol, 90.7% yield); 1 H NMR (400MHz, DMSO-d6) δ3.67 (d, J = 10.8Hz, 3H), 3.45-3.38 (m, 0.5H), 3.04-2.90 (m, 0.5H), 2.89-2.61 (m, 2H), 1.86 -1.71(m,1H),1.70-1.55(m,1H),1.45-1.40(m,9.5H),1.33-1.19(m,0.5H),0.88-0.73(m,1H),0.34-0.26(m,1H).
[0336] Preparation of 5-methyl 5-(6-chloropyridin-2-yl)-2-azabicyclo[4.1.0]heptane-2,5-dicarboxylic acid 2-(tert-butyl) ester (3)
[0337]
[0338] To 5-methyl 2-azabicyclo [4.1.0] heptane-2,5-dicarboxylic acid 2- (tert-butyl) ester (1.5g, 5.88mmol, 1eq) and 2,6-dichloropyridine (869mg, 5.88mmol, 1eq) in THF (15mL) solution, KHMDS solution (1M, 6.46mL, 1.1eq) was slowly added to control the internal temperature within -10 to -3°C. The reaction mixture was then kept stirring at -10 to -5°C for 1.5 to 2 hours. TLC showed that the starting material was completely consumed. The reaction mixture was poured into water (50mL) and extracted with ethyl acetate (50mL*2). The combined organic phases were concentrated in vacuo to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product as a white solid (1.5g, 4.09mmol, 69.6% yield).
[0339] Preparation of 2-(tert-butyloxycarbonyl)-5-(6-chloropyridin-2-yl)-2-azabicyclo[4.1.0]heptane-5-carboxylic acid (4)
[0340]
[0341] A mixture of 5-methyl 5-(6-chloropyridin-2-yl)-2-azabicyclo[4.1.0]heptane-2,5-dicarboxylic acid 2-(tert-butyl) ester (1.4 g, 3.82 mmol, 1 eq), NaOH (2M, 5.72 mL, 3 eq) in MeOH (15 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 45 ° C under N2 atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The solution was concentrated in vacuo at about 40 ° C to remove about 1 / 2 of the solvent. The water layer was neutralized with HCl aqueous solution (2N, about 7 mL, 3.5 eq) at -5 ° C to 5 ° C to a pH of about 3 to 5. A white suspension was formed during neutralization. The reaction mixture was filtered and the filter cake was washed with H2O (10 mL*3). The filter cake was dissolved in DCM (30 mL), washed with brine (30 mL), and concentrated under reduced pressure to give the product as a white solid (1.3 g, 3.68 mmol, 96.6% yield); LCMS: RT = 1.262 min, MS calculated: 352.82, [M-55] + =297.1.
[0342] Preparation of tert-butyl 5-(6-chloropyridin-2-yl)-2-azabicyclo[4.1.0]heptane-2-carboxylate (5)
[0343]
[0344] A mixture of 2-(tert-butyloxycarbonyl)-5-(6-chloropyridin-2-yl)-2-azabicyclo[4.1.0]heptane-5-carboxylic acid (1.3 g, 3.68 mmol, 1 eq) in dioxane (13 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 100 ° C under N2 atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The reaction mixture was concentrated to give a crude product as a white solid (1.2 g, crude); LCMS: RT = 2.127 min, MS calculated value: 308.81, [M-55] + =253.1.
[0345] Preparation of tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane-2-carboxylate (6)
[0346]
[0347] A mixture of 5-(6-chloropyridin-2-yl)-2-azabicyclo[4.1.0]heptane-2-carboxylic acid tert-butyl ester (0.8 g, 2.59 mmol, 1 eq), 3-fluoro-4-(hydroxymethyl)benzonitrile (392 mg, 2.59 mmol, 1 eq), Cs2CO3 (1.77 g, 5.44 mmol, 2.1 eq), Pd2(dba)3 (237 mg, 259 μmol, 0.1 eq) and BINAP (323 mg, 518 μmol, 0.2 eq) in dioxane (12 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 100 ° C under N2 atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The combined reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (50 mL*2). The combined organic phase was concentrated in vacuo to obtain a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to give the product as a white solid (0.8 g, 1.89 mmol, 72.9% yield); 1 H NMR (400MHz, DMSO-d6) δ = 7.94-7.83 (m, 1H), 7.75-7.63 (m, 3H), 7.09-6.9 9(m,1H),6.82-6.72(m,1H),5.53-5.43(m,2H),3.87-3.66(m,1H),3.27-3 .15(m,1H),2.93-2.81(m,1H),2.66-2.57(m,1H),1.84-1.74(m,1H),1.4 6-1.41(m,10H),0.91-0.79(m,1H),0.72-0.60(m,1H),0.44-0.31(m,1H).
[0348] Preparation of 4-(((6-(2-azabicyclo[4.1.0]hept-5-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (7)
[0349]
[0350] A mixture of 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]heptane-2-carboxylic acid tert-butyl ester (0.7 g, 1.65 mmol, 1 eq), TFA (3.08 g, 27.0 mmol, 2 mL, 16.3 eq) in DCM (5 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 25 ° C under N2 atmosphere for 1 hour. LCMS showed that the starting material was completely consumed. The reaction mixture was concentrated to give a crude product as a white solid (0.73 g, crude, TFA); LCMS: RT = 0.899 min, MS calculated: 323.37, [M + H] + =324.2.
[0351] Preparation of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (8)
[0352]
[0353] A mixture of 4-(((6-(2-azabicyclo[4.1.0]hept-5-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (483 mg, 1.50 mmol, 0.9 eq), methyl 2-(chloromethyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (0.73 g, 1.67 mmol, 1 eq, TFA), K2CO3 (1.38 g, 10.0 mmol, 6 eq) in ACN (5 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 60 ° C under N2 atmosphere for 2 hours. LCMS showed that the starting material was completely consumed. TLC (petroleum ether / ethyl acetate=0 / 1R f =0.45) indicated that the starting material was completely consumed. The combined reaction mixture was poured into water (50mL) and extracted with ethyl acetate (50mL*2). The combined organic phase was concentrated in vacuo to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product as a white solid (0.6 g, 986 μmol, 59.1% yield); LCMS: RT=1.029 min, MS calculated value: 608.89, [M+H] + =609.3.
[0354] Preparation of 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 16)
[0355]
[0356] By 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (50mg, 82.1μmol, 1eq), LiOH.HO (5.17mg, 123μmol, 1.5eq) in THF (0.7mL) and HO (0.3mL) mixture degassed, and purged 3 times with N, then the mixture was stirred at 30°C under N atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Phenomenex C18 75*30mm*3um; mobile phase: [water (NH4HCO3)-ACN]; B%: 25%-60%, 8min) to give the product as a white solid (24.8mg, 39.2umol, 47.7% yield, 94% purity); LCMS: RT = 1.654min, MS calculated value: 594.67, [M+H] + =595.2; HPLC: RT = 9.205min, purity: 95.41%; 1 H NMR (400 MHz, methanol-d4) δ8.92 (s, 1H), 8.23 (s, 1H), 8.04 (s, 1H), 8.01-7.94 (m, 1H), 7.72-7.49 (m, 5H), 7.00 (d, J = 8.0 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 6.03 (s, 2H), 5.5 7(s,2H),4.23-4.08(m,2H),3.28-3.20(m,1H),2.74-2.60(m,2H),2.55-2.45(m, 1H),1.75-1.62(m,2H),1.49-1.38(m,1H),0.67-0.60(m,1H),0.44-0.32(m,1H).
[0357] Intermediates of Examples 4-6
[0358]
[0359] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (0.58 g) was purified by SFC (column: DAICELCHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [0.1% NH3H2O IPA]; B%: 40%-40%, 12 min) to give intermediate 9A as a white solid (50 mg, 82.1 μmol, 8.62% yield), intermediate 9B as a white solid (50 mg, 82.1 μmol, 8.62% yield), intermediate 9C as a white solid (50 mg, 82.14 μmol, 8.62% yield) and intermediate 9D as a white solid (50 mg, 82.14 μmol, 8.62% yield).
[0360] Example 4 (Synthesis of Compound 4)
[0361] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, diastereomer 1
[0362]
[0363] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate 9A, 50 mg, 82.1 μmol, 1 eq), LiOH.H2O (5.17 mg, 123 umol, 1.5 eq) in THF (0.7 mL), H2O (0.3 mL) was degassed and purged with N2 3 times, then the mixture was stirred at 30 °C under N2 atmosphere for 12 hours. LCMS showed complete consumption of starting material and one major peak with the expected mass was detected. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-50%, 8min). The crude product was purified by reverse phase HPLC (column: C18-1150*30mm*5μm; mobile phase: [water (FA)-ACN]; B%: 15%-40%, 20min) to obtain the product as a white solid (6.37mg, 10.5umol, 12.7% yield, 97.71% purity); LCMS: RT=2.274min, MS calculated value: 594.67, [M+H] + =595.2; HPLC: RT = 9.259 min, purity: 97.71%; SFC: RT = 10.562 min, purity: 99.34%; 1 H NMR (400 MHz, methanol-d4) δ = 8.93 (s, 1H), 8.25 (s, 1H), 8.05 (s, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.71-7.67 (m, 2H), 7.62 (m, 1H), 7.56-7.50 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 6.02 (s, 2H) ,5.58-5.47(m,2H),4.22-4.15(d,J=13.6Hz,1H),4.09-4.03(d,J=13.6Hz,1H),2.84-2.79(m,1H ),2.71-2.66(m,1H),2.42-2.33(m,2H),1.78-1.66(m,2H),1.30-1.24(m,1H),0.56-0.49(m,2H).
[0364] Example 5 (Synthesis of Compound 5).
[0365] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, diastereomer 2
[0366]
[0367] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate 9B, 100 mg, 164 μmol, 1 eq), LiOH.HO (10.34 mg, 246 μmol, 1.5 eq) in THF (0.7 mL), HO (0.3 mL) was degassed and purged with N2 3 times, then the mixture was stirred at 30 °C under N2 atmosphere for 12 hours. LCMS showed complete consumption of starting material and one major peak with the expected mass was detected. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-50%, 8min) to give the product as a white solid (51.4mg, 83.3μmol, 50.7% yield, 96.4% purity); LCMS: RT = 2.258min, MS calculated value: 594.67, [M+H] + =595.2; HPLC: RT = 9.326 min, purity: 96.40%; SFC: RT = 9.504 min, purity: 98.74%; 1 H NMR (400MHz, DMSO-d6) δ = 9.03 (s, 1H), 8.21 (s, 1H), 8.09 (s, 1H), 7.92 (d, J = 10.1Hz, 1H),7.81(d,J=8.4Hz,1H),7.74-7.65(m,4H),7.03(d,J=8.0Hz,1H),6.76(d,J=8.0 Hz,1H),5.97(s,2H),5.56-5.46(m,2H),4.14-4.01(m,2H),3.27-3.17(m,1H),2.70 -2.54(m,3H),1.69-1.54(m,2H),1.41-1.33(m,1H),0.53(m,1H),0.32-0.25(m,1H).
[0368] Example 6 (Synthesis of Compound 14).
[0369] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, diastereomer 3
[0370]
[0371] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate 9C, 100 mg, 164 μmol, 1 eq), LiOH.HO (10.3 mg, 246 μmol, 1.5 eq) in THF (0.7 mL), HO (0.3 mL) was degassed and purged 3 times with N, then the mixture was stirred at 30 °C under N atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10μm; mobile phase: [water(NH4HCO3)-ACN]; B%: 30%-60%, 8min) to give the product as a white solid (39.1mg, 65.8umol, 40.0% yield); LCMS: RT=1.646min, MS calculated value: 594.67, [M+H] + =595.3; HPLC: RT = 9.197 min, purity: 96.20%; SFC: RT = 17.233 min, purity: 98.01%; 1 H NMR (400MHz, DMSO-d6) δ = 9.02 (s, 1H), 8.27-8.15 (m, 1H), 8.08 (m, 1H), 7.93-7.87 (m, 1 H),7.85-7.75(m,1H),7.69(m,4H),7.02(d,J=8.0Hz,1H),6.76-6.72(d,J=8.0Hz,1H), 6.00-5.88(s,2H),5.55-5.44(m,2H),4.18-3.95(s,2H),3.22(m,2H),2.59-2.54(m,2 H),2.49-2.40(m,1H),1.60(m,2H),1.35(m,1H),0.62-0.47(m,1H),0.35-0.23(m,1H).
[0372] Example 7 (Synthesis of Compound 15).
[0373] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, diastereomer 4
[0374]
[0375] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate 9D, 30 mg, 49.3 μmol, 1 eq), LiOH.HO (3.10 mg, 73.9 μmol, 1.5 eq) in THF (0.7 mL), HO (0.3 mL) was degassed and purged with N2 3 times, then the mixture was stirred at 30 °C under N2 atmosphere for 12 h. LCMS showed complete consumption of the starting material. The mixture was used directly without post-treatment. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBDC18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-50%, 8min) to give the product as a white solid (12.7mg, 21.4μmol, 43.3% yield); LCMS: RT = 1.628min, MS calculated value: 594.67, [M+H] + =595.2; HPLC: RT = 9.290 min, purity: 97.42%; SFC: RT = 8.630 min, purity: 99.60%; 1HNMR(400MHz, DMSO-d6)δ=8.98(s,1H),8.19(s,1H),8.08(s,1H),7.89-7.84(m,1H),7.83-7.79(m,1H), 7.75-7.63(m,4H),6.96-6.92(d,J=8.0Hz,1H),6.76-6.71(d,J=8.0Hz,1H),5.97(s,2H),5.52-5.43(m,2 H),4.16-4.08(d,J=13.6Hz,1H),3.98(d,J=13.6Hz,1H),2.81-2.74(m,1H),2.66-2.57(m,1H),2.44-2.3 6(m,1H),2.31-2.21(m,1H),1.67-1.58(m,2H),1.22-1.13(m,1H),0.55-0.46(m,1H),0.44-0.35(m,1H).
[0376] Example 8 (Synthesis of Compound 21).
[0377] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 enantiomers
[0378]
[0379] Preparation of methyl (R)-3-((2-methoxypropyl)amino)-4-nitrobenzoate (2)
[0380]
[0381] A mixture of methyl 3-fluoro-4-nitrobenzoate (2 g, 10.0 mmol, 1 eq), (R)-2-methoxypropan-1-amine (1.26 g, 10.0 mmol, 1 eq), TEA (3.35 g, 33.1 mmol, 4.61 mL, 3.3 eq) in THF (20 mL) was degassed and purged 3 times with N at 20 ° C, and then the mixture was stirred at 60 ° C for 16 hours under N atmosphere. LC-MS showed that the starting material was completely consumed, and a major peak with the expected mass was detected. The residue was diluted with H2O 100 mL and extracted with EtOAc 150 mL (50 mL*3). The combined organic layer was washed with H2O 15 mL (5 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to give the product as a yellow solid (2.6 g, 9.69 mmol, 96.50% yield); LCMS: RT = 0.746 min, MS calculated: 268.2, [M+H] + =269.0.
[0382] Preparation of methyl (R)-4-amino-3-((2-methoxypropyl)amino)benzoate (3)
[0383]
[0384] Pd / C (1 g, 10% purity) was added to a solution of (R)-3-((2-methoxypropyl)amino)-4-nitrobenzoic acid methyl ester (2.5 g, 9.32 mmol, 1 eq) in THF (30 mL) at 25°C under N2 atmosphere. The suspension was degassed and purged with H2 three times. The mixture was stirred at 25°C under H2 (15 psi) for 2 hours. LC-MS showed complete consumption of the starting material and a major peak with the expected mass was detected. The reactants were filtered, the filter cake was washed with ethyl acetate and concentrated under reduced pressure to give the product as a white solid (2.2 g, 9.23 mmol, 99.1% yield); LCMS: RT = 0.494 min, MS calculated: 238.2, [M+H] + =239.0; 1 H NMR (400 MHz, CHLOROFORM-d) δ = 7.46 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 6.69 (d, J = 8.0 Hz, 1H), 3.91-3.85 (s, 3H), 3.80 (br s, 2H), 3.71-3.63 (m, 1H), 3.40 (s, 3H), 3.25 (m, 1H), 3.08 (m, 1H), 1.27 (d, J = 6.0 Hz, 3H).
[0385] Preparation of (R)-2-(chloromethyl)-1-(2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (4)
[0386]
[0387] A mixture of (R)-4-amino-3-((2-methoxypropyl)amino)benzoic acid methyl ester (1 g, 4.20 mmol, 1 eq), 2-chloro-1,1,1-trimethoxyethane (1.95 g, 12.6 mmol, 1.69 mL, 3 eq), TosOH (72.3 mg, 420 umol, 0.1 eq) in CH3CN (10 mL) was degassed and purged 3 times with N2 at 20°C, and then the mixture was stirred at 60°C under N2 atmosphere for 1 hour. LC-MS showed that the starting material was completely consumed, and a main peak with the desired mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to give the product as a white solid (1 g, 3.37 mmol, 80.3% yield); LCMS: RT = 1.651 min, MS calculated: 296.7, [M+H] + =297.0.
[0388] Preparation of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (5)
[0389]
[0390] A mixture of (R)-2-(chloromethyl)-1-(2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (91.8 mg, 309 μmol, 1 eq), 4-(((6-(2-azabicyclo[4.1.0]hept-5-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (100 mg, 309 μmol, 1 eq), K2CO3 (128 mg, 928 μmol, 3 eq) in CH3CN (1 mL) was degassed and purged with N2 at 20°C for 3 times, and then the mixture was stirred at 60°C under N2 atmosphere for 2 hours. LC-MS showed complete consumption of the starting material and one major peak with the expected mass was detected. The residue was diluted with H2O 1 mL, washed with EA (3 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to give the product as a white solid (100 mg, 171 μmol, 55.4% yield); LCMS: RT = 2.420 min, MS calculated: 583.6, [M+H] + =584.2.
[0391] Preparation of 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 enantiomers (Compound 21)
[0392]
[0393] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (120 mg, 206 μmol, 1 eq), LiOH.HO (12.9 mg, 308 μmol, 1.5 eq) in THF (1.4 mL) / HO (0.6 mL) was degassed and purged with N at 20° C. for 3 times, then the mixture was stirred at 20° C. under N atmosphere for 12 hours. LC-MS showed complete consumption of the starting material, and one major peak with the expected mass was detected. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters Xbridge BEH C18 100*25mm*5μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 30% 65%, 8min) to give the product as a white solid (36.8mg, 61.3μmol, 29.8% yield, 94.88% purity); LCMS: RT = 2.660min, MS calculated value: 569.6, [M+H] + =570.3; 1 H NMR (400 MHz, chloroform-d) δ=8.24 (s, 1H) 8.06 (d, J=8.4 Hz, 1H) 7.82 (d, J=8.4 Hz, 1H) 7.67-7.52 (m, 2H) 7.48-7.34 (m, 2H) 6.99-6.85 (d, J=8.4 Hz, 1H) 6.68 (d, J=8.4 Hz, 1H) 5.51 (s, 2H) 4.61 (m, 1 H)4.45-4.05(m,3H)3.89-3.75(m,1H)3.32-3.14(m,4H)2.74-2.60(m,2H)2.43-2.57(m,1H )1.84-1.57(m,2H)1.47-1.38(m,1H)1.34-1.26(m,3H)0.66-0.57(m,1H)0.53-0.39(m,1H).
[0394] Example 9 (Synthesis of Compound 46).
[0395] 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 diastereomers
[0396]
[0397] Preparation of methyl 2-((diethoxyphosphoryl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (4c)
[0398]
[0399] At 20 ° C, triethyl phosphite (3.87 g, 23.3 mmol, 4.00 mL, 1.5 eq) was added to a mixture of 2- (chloromethyl) -1- (thiazol-5-ylmethyl) -1H- benzo [d] imidazole -6- carboxylic acid methyl ester (5 g, 15.5 mmol, 1 eq) in toluene (50 mL) at once. The mixture was stirred at 100 ° C for 12 hours. LC-MS showed that about 58% of the starting material remained. LC-MS showed several new peaks, and about 31% of the desired compound was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to obtain the product, which was a yellow oil (1.9 g, 4.49 mmol, 28.9% yield); LCMS: RT = 0.564 min, MS calculated value: 423.10, [M + H] + =424.1; LCMS: RT = 1.395 min, MS calculated value: 423.10, [M+H] + =424.1; 1H NMR (400MHz, chloroform-d) δ = 8.75 (s, 1H), 8.12 (s, 1H), 8.03-7.97 (m, 1H), 7.81-7.70 (m, 2H), 5.89 (s, 2H), 4.13 (q, J = 7.2 Hz, 4H), 3.94 (s, 3H), 3.59-3.51 (d, J = 21.6 Hz, 2H), 1.30 (t, J = 7.2 Hz, 6H)
[0400] Preparation of tert-butyl 4-hydroxy-3,4-dihydropyridine-1(2H)-carboxylate (2)
[0401]
[0402] Et2O (1000mL) was charged into a 2L three-necked round-bottom flask, and then 7-oxa-3-azabicyclo [4.1.0] heptane-3-carboxylic acid tert-butyl ester (25g, 125mmol, 1eq) was added at 20°C. At -78°C, n-BuLi (2.5M, 151mL, 3eq) was added dropwise to the reaction mixture at -78°C within 1 hour. After addition, the mixture was stirred at -78°C for 1 hour. The resulting mixture was stirred at 25°C for 1 hour. TLC showed that the starting material was completely consumed and many new spots were formed. According to TLC, the reaction was very chaotic. The reaction mixture was quenched with saturated NaHCO3 aqueous solution (350mL) at 0°C within 30 minutes. The mixture was extracted with EtOAc (200mL*3). The organic phase was then washed with NaCl aqueous solution (300mL). The organic matter was dried over Na2SO4, filtered, and concentrated under reduced pressure at 30°C to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 15 / 1 to 6 / 1) to give the product as a yellow oil (17 g, 85.3 mmol, 34% yield); LCMS: Rt = 1.368 min, MS calculated: 199.12, [M-tBu-OH] + =126.1; 1H NMR (400 MHz, chloroform-d) δ=7.06-6.77 (m, 1H), 5.12-4.89 (m, 1H), 4.19 (m, 1H), 3.85 (m, 1H), 3.33 (m, 1H), 1.89-1.80 (m, 2H), 1.48 (s, 9H).
[0403] Preparation of tert-butyl 5-hydroxy-2-azabicyclo[4.1.0]heptane-2-carboxylate (3)
[0404]
[0405] Et2O (80 mL) was charged into a 500 mL three-necked round bottom flask, and then the material 4-hydroxy-3,4-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (8 g, 40.2 mmol, 1 eq) was added at 20°C. ZnEt2 (1 M, 100 mL, 2.5 eq) was added dropwise to the reaction mixture at 0°C over 1 hour at 0°C. CH2I2 (43 g, 161 mmol, 13 mL, 4 eq) was added dropwise to the reaction mixture at 0°C over 0.5 hours. After the addition, the mixture was stirred at 20°C for 12 hours. TLC indicated that the starting material was completely consumed and many new spots were formed. The reaction mixture was added to H2O (100 ml) at 0°C over 0.5 hours. The mixture was extracted with EtOAc (50 mL*3). The organic phase was then washed with NaCl (50 mL*1). The organic matter was dried (Na2SO4), filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give the product as a yellow oil (3.5 g, 16.4 mmol, 20.4% yield); LCMS: RT = 1.307 min, MS calculated: 213.14, [M+H] + =158.1.
[0406] Preparation of tert-butyl 5-oxo-2-azabicyclo[4.1.0]heptane-2-carboxylate (4)
[0407]
[0408] NMO (2.47g, 21.1mmol, 2.23mL, 3eq) is added to a DCM (25mL) solution of 5-hydroxy-2-azabicyclo [4.1.0] heptane-2-carboxylic acid tert-butyl ester (1.5g, 7.03mmol, 1eq), molecular sieve 3A (2.5g) and TPAP (247mg, 703μmol, 0.1eq) at 0°C. The reaction mixture is warmed to 20°C and stirred for 2 hours. TLC shows that the starting material is completely consumed and a new spot is formed. According to TLC, the reaction is complete. The reaction mixture is diluted with DCM (5mL) and filtered through silica gel. The organic layer is washed with saturated Na2S2O3 (5mL), water (2mL), brine (2mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=15 / 1 to 8 / 1) to give the product as a yellow solid (1.05 g, 4.97 mmol, 70.7% yield); 1H NMR (400 MHz, CHLOROFORM-d) δ = 4.21-3.89 (m, 1H), 3.58-3.21 (m, 2H), 2.46-2.21 (m, 2H), 1.87 (m, 1H), 1.49 (m, 10H), 1.23-1.06 (m, 1H).
[0409] Preparation of (Z)-2-((2-(tert-butyloxycarbonyl)-2-azabicyclo[4.1.0]hept-5-ylidene)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (5)
[0410]
[0411] THF (10mL) was loaded into a 25mL three-necked round-bottom flask, and 2-((diethoxyphosphoryl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (1.82g, 4.30mmol, 1eq) was added. At 0°C, NaH (275mg, 6.89mmol, 60% purity, 1.6eq) was added to the reaction mixture in batches. After 30 minutes, 5-oxo-2-azabicyclo[4.1.0]heptane-2-carboxylic acid tert-butyl ester (1g, 4.73mmol, 1.1eq) was added to the reaction mixture at 0°C. The mixture was stirred at 20°C for 2 hours. TLC showed that the starting material was completely consumed. The reaction mixture was added to NaHCO at 0°C. The mixture was extracted with EtOAc (10mL*2). The organic phase was then washed with brine 10mL. The organics were dried over Na2SO4, filtered, and concentrated under reduced pressure at 30°C to give a residue. The residue was purified by column chromatography (SiO2, DCM:MeOH=100 / 1 to 50 / 1) to give the product as an oil (1.3 g, 2.71 mmol, 62.9% yield); LCMS: RT=0.633 min, MS calculated: 480.10, [M+H] +=481.1; 1H NMR (400MHz, chloroform-d) δ = 8.75 (s, 1H), 8.09 (s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.83-7.73 (m, 2H), 6.56-6.34 (m, 1H), 5.63 (s, 2H), 4.16-3.97 (m, 0.5H), 3.95 (s, 3H), 3.93-3.81 (m, 1H), 3.5 3-3.44(m,0.5H),3.35-3.18(m,1H),3.01-2.74(m,1H),2.48-2.36(m,1H),2.34-2.18(m, 0.5H),2.10-1.96(m,0.5H),1.71-1.57(m,0.5H),1.53-1.48(m,9.5H),0.96-0.82(m,1H).
[0412] Preparation of methyl 2-((2-(tert-butyloxycarbonyl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (6)
[0413]
[0414] Under N2 atmosphere, Pd / C (1 g, 10% purity) was added to a solution of (Z)-2-((2-(tert-butyloxycarbonyl)-2-azabicyclo[4.1.0]hept-5-ylidene)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (1 g, 2.08 mmol, 1 eq) in MeOH (100 mL). The suspension was degassed and purged 3 times with H2. The mixture was stirred for 4 hours under H2 (50 psi) at 25 °C. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give the product as a white solid (1 g, 2.07 mmol, 99.6% yield); LCMS: RT = 1.306 min, MS calculated: 482.2, [M+H] + =483.3.
[0415] Preparation of methyl 2-((2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (7)
[0416]
[0417] To a solution of methyl 2-((2-(tert-butyloxycarbonyl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (0.3 g, 622 μmol, 1 eq) in DCM (3 mL) was added TFA (924 mg, 8.10 mmol, 600.00 μL, 13.04 eq). The mixture was stirred at 20° C. for 1 hour. TLC indicated that the starting material was completely consumed and a new spot was formed. The reaction mixture was diluted with Na CO to pH=8-9 and extracted with DCM 30 mL (15 mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give the product as a yellow solid (200 mg, 523 μmol, 84.1% yield); LCMS: RT = 0.740 min, MS calculated: 382.15, [M+H] + =383.1.
[0418] Preparation of methyl 2-((2-(6-fluoropyridin-2-yl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (8)
[0419]
[0420] A mixture of 2-((2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (143 mg, 375 μmol, 1.1 eq), 2-bromo-6-fluoropyridine (60 mg, 341 μmol, 1 eq), KCO (141 mg, 1.02 mmol, 3 eq) in DMF (2 mL) was degassed and purged 3 times with N, then the mixture was stirred at 80 ° C under N atmosphere for 12 hours. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The residue was diluted with H2O 20 mL and extracted with EtOAc 20 mL (10 mL*2). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give the product as a white solid (100 mg, 186 umol, 54.5% yield); LCMS: RT = 0.947 min, MS calculated value: 477.17, [M+H] + =478.2.
[0421] Preparation of methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (9)
[0422]
[0423] A mixture of 2-((2-(6-fluoropyridin-2-yl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (100 mg, 186 μmol, 1 eq), 3-fluoro-4-(hydroxymethyl)benzonitrile (28.07 mg, 186 μmol, 1 eq), Xphos Pd G4 (16 mg, 18.6 μmol, 0.1 eq), t-BuONa (44.6 mg, 464 μmol, 2.5 eq) in toluene (2 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 100 ° C under N2 atmosphere for 2 hours. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The residue was diluted with H2O20 mL and extracted with EtOAc 20 mL (20 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give the product (70 mg, 115 μmol, 61.9% yield); LCMS: Rt = 2.689 min, MS calculated value: 608.2, [M+H] + =609.2
[0424] Preparation of 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 diastereomers (Compound 46)
[0425]
[0426] To a solution of methyl 2-((2-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2-azabicyclo[4.1.0]hept-5-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (65 mg, 107 μmol, 1 eq) in THF (0.7 mL) was added a solution of LiOH.HO (5.38 mg, 128 μmol, 1.2 eq) in HO (0.3 mL). The mixture was stirred at 20 °C for 12 hours. LC-MS showed complete consumption of the starting material and the desired mass was detected. The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water(NH4HCO3)-ACN]; B%: 30%-70%, 8min) to give the product as a white solid (28 mg, 47.1 μmol, 44.1% yield); LCMS: RT=1.986 min, MS calculated: 594.18, [M+H] + =595.2; HPLC:RT=3.096min; 1 H NMR(400MHz,DMSO-d6)δ9.00(s,1H)8.27(s,1H)7.99(s,1H)7.90-7.85(m,1H)7.81(m,1H)7.72 -7.62(m,3H)7.51-7.42(m,1H)6.35-6.28(m,1H)6.10-6.03(m,1H)5.96-5.88(m,2H)5.44-5.3 6(m,2H)4.40-4.31(m,1H)3.12-3.02(m,1H)3.00–2.90(m,1H)2.84-2.68(m,2H)2.61-2.55(m, 1H)1.76-1.68(m,1H)1.54-1.43(m,1H)1.00–0.82(m,1H)0.79-0.69(m,1H),0.25-0.21(m,1H).
[0427] Intermediates of Examples 10-11
[0428]
[0429] Preparation of tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (2)
[0430]
[0431] A mixture of tert-butyl 2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (500 mg, 2.52 mmol, 1.1 eq), 4-(((6-bromopyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (704 mg, 2.29 mmol, 1 eq), Pd2(dba)3 (105 mg, 115 μmol, 0.05 eq), BINAP (143 mg, 229 μmol, 0.1 eq) and t-BuONa (661 mg, 6.88 mmol, 3 eq) in toluene (5 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 100 °C under N2 atmosphere for 1 hour. LC-MS showed that the starting material was completely consumed, and a major peak with the expected mass was detected. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (50 mL). The organic layer was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 10 / 1) to give the product as a white solid (440 mg, 1.04 mmol, 45% yield); RT = 2.142 min; MS calculated value: 424.2, [M+H] + =325.2; 1 H NMR (400MHz, chloroform-d) δ7.66-7.59(m,1H),7.51-7.43(m,2H),7.37(d,J=9.2Hz,1H),6.34(m,1H),6.18(d,J=7.6Hz,1H),5. 51-5.41(m,2H),4.08-3.83(m,1H),3.60-3.05(m,4H),2.91-2.75(m,1H),1.50(s,9H),1.21-1.02(m,1H),0.39(m,1H).
[0432] Preparation of 4-(((6-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (3)
[0433]
[0434] A mixture of tert-butyl 5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (400 mg, 942 μmol, 1 eq), TFA (107 mg, 942 μmol, 69.8 μL, 1 eq) in DCM (4 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 20°C under N2 atmosphere for 1 hour. TLC showed that the starting material was completely consumed and a new spot was formed. According to TLC, the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (neutral condition column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water(NH4HCO3)-ACN]; gradient: 45%-80% B in 8 minutes) to give the desired compound as a white solid (300 mg, yield 45%, purity 95%).
[0435] Preparation of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (4A) and (4B)
[0436]
[0437] A mixture of 4-(((6-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (298 mg, 925 μmol, 1 eq), methyl 2-(chloromethyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (300 mg, 925 μmol, 1 eq), KCO (383 mg, 2.77 mmol, 3 eq) in CHCN (5 mL) was degassed and purged with N3 three times, then the mixture was stirred at 60 °C under N2 atmosphere for 3 hours. LC-MS showed complete consumption of the starting material and a major peak with the desired mass was detected. The resulting product was dissolved in EtOAc (20 ml) and filtered to remove insoluble material. The filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (neutral conditions: column: Waters Xbridge PrepOBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 45%-80%, 8min) to give a mixture of intermediates 4A & 4B (400mg, 90% yield, 90% purity) as a white solid, which was further separated by SFC (conditions: column: DAICEL CHIRALCEL OD nv (250mm*30mm, 10μm); mobile phase: [0.1% NH3H2O MEOH]; B%: 50%-50%, 15min). Intermediate 4A isomer 1 was obtained as a white solid (120mg, 197μmol, 21.3% yield); RT = 2.532min, MS calculated value: 617.2, [M+H] + =618.2; 1H NMR (400 MHz, chloroform-d) δ8.77 (s, 1H), 8.15 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.90 (s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.51-7.41 (m, 2H), 7.34 (d, J = 9.2 Hz, 1H), 6.31 (d, J = 8.0 Hz, 1H), 6.16 (d, J = 8.0 Hz, 1H), 5.86 (s, 2H), 5.52-5.37 (m, 2H), 4.21-4.10 (m, 3H), 4.08-4.01 (m, 1H), 3.96 (s, 3H), 3.09-3.00 (m, 1H), 2.83-2.72 (m, 2H), 2.66-2.58 (m, 1H), 2.45-2.37 (m, 1H), 0.81-0.79 (m, 1H), 0.61-0.46 (m, 1H). Intermediate 4B isomer 2 was obtained as a white solid (80 mg, 131 μmol, 14.2% yield); RT = 2.534 min, MS calculated value: 617.2, [M+H] + =618.2; 1 H NMR (400 MHz, chloroform-d) δ = 8.77 (s, 1H), 8.15 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.90 (s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.50-7.41 (m, 2H), 7.34 (d, J = 9.4 Hz, 1H), 6.31 (d, J = 8.0 Hz, 1H), 6 .16(d,J=8.0Hz,1H),5.86(s,2H),5.50-5.37(m,2H),4.21-4.03(m,4H),3.96(s,3H),3.05(m,1H ),2.84-2.72(m,2H),2.67-2.59(m,1H),2.47-2.39(m,1H),0.81-0.79(m,1H),0.60-0.50(m,1H).
[0438] Example 10 (Synthesis of Compound 2).
[0439] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, diastereomer 1
[0440]
[0441] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (90 mg, 148 μmol, 1 eq) and LiOH.H2O (12.4 mg, 295 μmol, 2 eq) in THF (0.7 mL) and H2O (0.3 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 25°C under N2 atmosphere for 12 hours. LC-MS showed complete consumption of the starting material, and one major peak with the expected mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (neutral condition column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-50%, 8min) to give the product as a white solid (29.9mg, 50.2μmol, 34% yield); RT = 2.508min, MS calculated value: 595.2, [M+H] + =596.1; 1 H NMR (400 MHz, methanol-d4) δ = 8.94 (s, 1H), 8.27 (s, 1H), 8.06 (s, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.68-7.62 (m, 1H), 7.57-7.53 (m, 2H), 7.48 (t, J = 8.0 Hz, 1H), 6.36 (d, J =8.0Hz,1H),6.13(d,J=8.0Hz,1H),6.00(s,2H),5.46(s,2H),4.24-4.08(m,3H),3.00(m ,1H),2.85-2.76(m,2H),2.67(m,1H),2.45-2.37(m,1H),0.75(m,1H),0.55-0.49(m,1H).
[0442] Example 11 (Synthesis of Compound 1).
[0443] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid, diastereomer 2
[0444]
[0445] To a solution of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (70 mg, 115 μmol, 1 eq) in THF (0.7 mL) was added a solution of LiOH.HO (9.64 mg, 230 μmol, 2 eq) in HO (0.3 mL). The mixture was stirred at 25 °C for 12 h. LC-MS showed complete consumption of the starting material and the expected mass was detected. The residue was purified by preparative HPLC (neutral conditions: column: Waters Xbridge BEH C18100*30mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-60%, 8min) to give the product as a white solid (35 mg, 58.76 μmol, 51.2% yield); RT = 1.843 min, MS calculated value: 595.65, [M+H] + =596; 1 H NMR (400 MHz, methanol-d4) δ8.93 (s, 1H), 8.26 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.67-7.62 (m, 1H), 7.55-7.51 (m, 2H), 7.45 (t, J = 8.0 Hz, 1H), 6.34 (d, J =8.0Hz,1H),6.11(d,J=8.0Hz,1H),6.07(s,2H),5.43(s,2H),4.24-4.06(m,3H),2.97(m ,1H),2.79-2.76(m,2H),2.65(m,1H),2.45-2.38(m,1H),0.75(m,1H),0.51-0.48(m,1H).
[0446] Intermediates of Examples 12-13
[0447]
[0448] Preparation of 4-(((2-chloropyrimidin-4-yl)oxy)methyl)-3-fluorobenzonitrile (2)
[0449]
[0450] t-BuOK (4.14 g, 36.9 mmol, 1.1 eq) was added in batches to a THF (40 mL) solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (5.33 g, 35.2 mmol, 1.05 eq) at 20 ° C, and then stirred until completely dissolved. At a temperature of less than 65 ° C, under an N2 atmosphere, the solution was added dropwise to a DMF (60 mL) solution of 2,4-dichloropyrimidine (5 g, 33.6 mmol, 1 eq) over 1.5 hours. The reaction mixture was slowly warmed to 10 ° C over 1.5 hours and stirred for 0.5 hours. LCMS showed 0.3% of the starting material and 85.9% of the product. The reaction mixture was slowly poured into H2O (300 mL) at 0 ° C, and a solid was formed. The mixture was stirred for 15 minutes and filtered. Solid is collected, dissolved in DCM (100mL), and washed with salt solution (20mL), through NaSODry, filtered and concentrated under reduced pressure, to obtain crude product (5g). Crude product is stirred in MTBE (10mL), and stirred for 5 minutes, normal hexane (50mL) is added to the mixture, stirred for 10 minutes, and filter cake is collected. Filter cake is added to MTBE (5mL), and stirred for 5 minutes, normal hexane (25mL) is added to the mixture, stirred for 5 minutes, filter and collect filter cake, vacuum dried for 20 minutes, to obtain product, it is yellow solid (4g, 15.2mmol, 45.2% yield);RT=2.056min, MS calculated value: 263.0, [M+H] + =264.0; 1 H NMR (400 MHz, chloroform-d) δ = 8.40 (d, J = 5.6 Hz, 1H) 7.64 (t, J = 7.2 Hz, 1H) 7.55-7.39 (m, 2H) 6.80-6.71 (d, J = 5.6 Hz, 1H, 1H) 5.55 (s, 2H).
[0451] Preparation of tert-butyl 5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (3)
[0452]
[0453] A mixture of 4-(((2-chloropyrimidin-4-yl)oxy)methyl)-3-fluorobenzonitrile (500 mg, 1.90 mmol, 1 eq), tert-butyl 2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (490 mg, 2.09 mmol, 1.1 eq, HCl), KCO (786 mg, 5.69 mmol, 3 eq) in DMF (5 mL) was degassed and purged 3 times with N, and then the mixture was stirred at 100 ° C under N atmosphere for 1 hour. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The residue was diluted with H O (30 mL) and extracted with EtOAc (30 mL*3). The combined organic layer was dried over Na SO, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 0 / 1) to give the product as a white solid (500 mg, 1.18 mmol, 61.9% yield); RT = 2.522 min, MS calculated: 425.19, [M+H] + =426.2; 1 H NMR (400MHz, chloroform-d) δ = 8.24 (s, 1H) 7.66-7.59 (m, 1H) 7.53 (d, J = 9.6Hz, 1H) 7.42 (d, J = 9.6Hz, 1H) 6.19 (d, J = 5 .6Hz,1H)5.60(s,2H)3.94-3.72(m,1H)3.71-3.31(m,3H)3.29-3.05(m,2H)1.59-1.70(m,1H)1.53(s,9H).
[0454] Preparation of 4-(((2-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyrimidin-4-yl)oxy)methyl)-3-fluorobenzonitrile (4)
[0455]
[0456] TFA (1.54 g, 13.5 mmol, 1.00 mL, 19.2 eq) was added to a solution of tert-butyl 5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (0.3 g, 705 μmol, 1 eq) in DCM (3 mL). The mixture was stirred at 25 ° C for 1 hour. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was concentrated under reduced pressure to give the product as a yellow oil (220 mg, 676 umol, 95.9% yield); RT = 0.777 min, MS calculated value: 325.13, [M + H] + =326.3.
[0457] Preparation of methyl 2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (6A and 6B)
[0458]
[0459] To a solution of 4-(((2-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyrimidin-4-yl)oxy)methyl)-3-fluorobenzonitrile (210 mg, 645 μmol, 1 eq) in CHCN (1 mL) was added KCO (268 mg, 1.94 mmol, 3 eq) and methyl 2-(chloromethyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (208 mg, 645 μmol, 1 eq). The mixture was stirred at 60 °C for 1 hour. LC-MS showed complete consumption of the starting material and the expected mass was detected. The residue was diluted with H0 (30 mL) and extracted with EtOAc (30 mL*3). The combined organic layers were dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 0 / 1 to dichloromethane / methanol = 10 / 1). The residue was further separated by SFC (conditions: column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [0.1% NH3H2O MEOH]; B%: 60%-60%, 5min) to give intermediate 6A as a white solid (120mg, 197μmol, 30.4% yield); LCMS: RT = 2.229min, MS calculated value: 610.19, [M+H] + =611.2; SFC: RT = 1.174 min, ee%: 100.0%, and intermediate 6B as a white solid (120 mg, 197 μmol, 30.4% yield); LCMS: RT = 2.229 min, MS calculated value: 610.19, [M+H] + =611.1; SFC:RT=1.685min, ee%:97.9%.
[0460] Example 12 (Synthesis of Compound 20).
[0461] 2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0462]
[0463] To a solution of methyl 2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 164 μmol, 1 eq) in THF (1.4 mL) was added a solution of LiOH.HO (13.7 mg, 328 μmol, 2 eq) in HO (0.6 mL). The mixture was stirred at 20 °C for 12 h. LC-MS showed complete consumption of the starting material and the expected mass was detected. The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge Prep OBD C18150*40mm*10μm; mobile phase: [water(NH4HCO3)-ACN]; B%: 20%-60%, 8min) to give the product as a white solid (29 mg, 48.6umol, 29.7% yield); LCMS: RT=1.626min, MS calculated value: 596.18, [M+H] + =597.2; SFC:RT=1.312min,ee%:99.64%; 1 H NMR (400 MHz, methanol-d4) δ = 8.94 (s, 1H) 8.27 (s, 1H) 8.16-8.04 (m, 2H) 8.00 (d, J = 8.4 Hz, 1H) 7.71 (d, J = 8.4 Hz, 1H) 7.69-7.63 (m, 1H) 7.60-7.53 (m, 2H) 6.19 (d, J = 5.6 Hz,1H)6.01(s,2H)5.67(s,2H)4.26-4.15(m,2H)4.13-4.08(m,1H)3.13-2.98( m,2H)2.87-2.78(m,1H)2.45-2.61(m,1H)2.55-2.42(m,1H)0.83-0.53(m,2H).
[0464] Example 13 (Synthesis of Compound 19).
[0465] 2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0466]
[0467] A mixture of methyl 2-((5-(4-((4-cyano-2-fluorobenzyl)oxy)pyrimidin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (110 mg, 180 μmol, 1 eq), LiOH.H2O (15.1 mg, 360 μmol, 2 eq) in THF (3 mL) and H2O (1.2 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 25°C under N2 atmosphere for 12 hours. LC-MS showed complete consumption of the starting material and one major peak with the desired m / z. The reaction solution was adjusted to pH = 7 with citric acid. The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 10%-45%, 8min) to give the product as a white solid (26.2mg, 43.8μmol, 24.3% yield); LCMS: RT = 1.631min, MS calculated value: 596.18, [M+H] + =597.2; SFC:RT=1.381min,ee%:99.70%; 1 H NMR (400MHz, methanol-d4)δ=ppm 8.94(s,1H)8.27(s,1H)8.12-8.07(m,1H)8.05(s,1H)7.99(d,J=8.6Hz,1H)7.73-7.63(m,2H)7.60-7.54(m,2H)6.19(d,J=5.6Hz,1H)5. 99(s,2H)5.52(s,2H)4.27-4.15(m,2H)4.14-4.08(m,1H)3.14-3.00(m,2H)2.82(m,1H)2.66(m,1H)2.52-2.43(m,1H)0.84-0.52(m,2H).
[0468] Intermediates of Examples 14-15
[0469]
[0470] Preparation of methyl 4-amino-3-(((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)amino)benzoate (2)
[0471]
[0472] A mixture of intermediate 1 (1 g, 3.28 mmol, 1 eq), Fe (915 mg, 16.4 mmol, 5 eq), NH4Cl (876 mg, 16.4 mmol, 5 eq) in MeOH (10 mL) and H2O (5 mL) was stirred at 70 ° C under N2 atmosphere for 2 hours. TLC showed that the starting material was completely consumed and a new spot was formed. The reaction mixture was filtered and the filtrate was concentrated. The residue was diluted with H2O (100 mL) and extracted with DCM (40 mL*3). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure to obtain the product as a white solid (800 mg, 2.91 mmol, 88.7% yield), which was directly used in the next step reaction.
[0473] Preparation of methyl 2-(chloromethyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (3)
[0474]
[0475] A mixture of 4-amino-3-(((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)amino)benzoic acid methyl ester (300mg, 1.09mmol, 1eq), 2-chloroacetyl chloride (110.77mg, 980.73μmol, 78.00μL, 0.9eq) and TosOH (37.53mg, 217.94μmol, 0.2eq) in CH3CN (5mL) was stirred at 60°C under N2 atmosphere for 1 hour. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was concentrated under reduced pressure to give the product as a brown oil (360mg, 1.08mmol, 99% yield), which was used directly in the next step; LCMS: RT = 0.697min, MS calculated value: 333.8, [M+H] + =334.2
[0476] Preparation of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (4A and 4B)
[0477]
[0478] To a CH3CN (5mL) solution of 2-(chloromethyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (320mg, 958.74μmol, 1eq) and 4-(((6-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (311mg, 959μmol, 1eq) was added K2CO3 (398mg, 2.88mmol, 3eq). The mixture was stirred at 50°C for 4 hours. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was diluted with H2O (20mL) and extracted with EtOAc (20mL*3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO2, dichloromethane:methanol=100 / 1 to 10 / 1) to give the product as a yellow solid (405 mg, 651 μmol, 68% yield); LCMS: RT=2.439 min, MS calculated: 621.7, [M+H] + =622.3.
[0479] The product (400 mg) was further separated by SFC (conditions, column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 um); mobile phase: [0.1% NH3H2O MEOH]; B%: 60%-60%, 20 min) to give intermediate 4A isomer 1 as a yellow oil (150 mg, 241 μmol, 35% yield); LCMS: RT = 2.448 min, MS calculated value: 621.7, [M+H] + =622.3; SFC:RT=1.678min,ee%:100%; 1H NMR (400MHz, chloroform-d)δ=8.04(d,J=8.0Hz,1H),8.03(s,1H),7.82(d,J=9.2Hz,1H),7.60(t,J=7.6Hz,1H),7.49-7.41(m,2H),7.34(d,J=9.2 Hz,1H),7.23(s,1H),6.28(d,J=8.0Hz,1H),6.15(d,J=8.0Hz,1H),5.74(s,2H),5.47(d,J=14Hz,1H),5.42(d,J=14Hz,1H),4.40(q,J=7.2 Hz, 2H), 4.09-3.97 (m, 3H), 3.95 (s, 3H), 2.92-2.83 (m, 1H), 2.75-2.61 (m, 2H), 2.57-2.49 (m, 1H), 2.38-2.29 (m, 1H), 1.56-1.43 (t, J = 7.2 Hz,, 3H), 0.76-0.73 (m, 1H), 0.53-0.47 (m, 1H) and Intermediate 4B Isomer 2 as a yellow oil (154 mg, 248 μmol, 36% yield); LCMS: RT = 2.454 min, MS calculated: 621.7, [M+H] + =622.3; SFC:RT=2.220min,ee%:100%; 1 H NMR (400 MHz, chloroform-d) δ = 8.07-8.02 (m, 2H), 7.83 (d, J = 9.2 Hz, 1H), 7.61 (t, J = 7.2 Hz, 1H), 7.49-7.41 (m, 2H), 7.34 (d, J = 9.2 Hz, 1H), 7.24 (s, 1H), 6.28 (d, J = 8.0 Hz, 1H), 6.16 (d, J = 8.0 Hz, 1H), 5.74 (s, 2H), 5.46 (d, J = 14 Hz ,1H),5.38(d,J=14Hz,1H),4.40(q,J=7.2Hz,2H),4.11-4.01(m,2H),4.00-3.95(m,1H),3.95(s,3H),2.93- 2.83(m,1H),2.76-2.61(m,2H),2.53(m,1H),2.35(m,1H),1.50(t,J=7.2Hz,3H),0.76(m,1H),0.51(m,1H).
[0480] Example 14 (Synthesis of Compound 45).
[0481] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0482]
[0483] To a solution of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 129 μmol, 1 eq) in THF (0.7 mL) was added a solution of LiOH.HO (10.8 mg, 257 μmol, 2 eq) in HO (0.3 mL). The mixture was stirred at 25 °C for 12 hours. LCMS showed complete consumption of the starting material and a major peak with the desired mass was detected. The reaction solution was adjusted to pH 6-7 with citric acid. After the reagents were concentrated, the residue was purified by preparative HPLC (neutral conditions, column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-60%, 8min) to give the product as a white solid (43.93mg, 72.30umol, 56.18% yield); LCMS: RT = 2.491min, MS calculated value: 607.7, [M+H] + =608.1; SFC: RT = 1.476min, ee%: 100%; HPLC: RT = 11.507min, purity: 98.57%; 1H NMR (400 MHz, methanol-d4) δ = 8.17 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.62 (t, J = 7.2 Hz, 1H), 7.56-7.50 (m, 2H), 7.44 (t, J = 8 Hz, 1H), 7.20 (s, 1H), 6.30 (d, J = 8.0 Hz, 1H), 6.09 (d, J = 8.0Hz,1H),5.94(s,2H),5.41(s,2H),4.52(q,J=7.2Hz,2H),4.20(d,J=14.0Hz,1H),4.01(m,2H ),2.71-2.54(m,4H),2.29-2.22(m,1H),1.50(t,J=7.2Hz,3H),0.69(m,1H),0.46-0.41(m,1H).
[0484] Example 15 (Synthesis of Compound 44).
[0485] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0486]
[0487] A mixture of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-ethyl-1H-1,2,3-triazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 129 μmol, 1 eq) and LiOH.H2O (10.8 mg, 257 μmol, 2 eq) in THF (0.7 mL) and H2O (0.3 mL) was stirred at 25°C under N2 atmosphere for 12 hours. LCMS showed complete consumption of the starting material and one major peak with the expected mass was detected. The reaction solution was adjusted to pH 6-7 with citric acid. After the reagents were concentrated, the residue was purified by preparative HPLC (neutral condition column: Waters Xbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 25%-55%, 8min) to give the product as a white solid (26.9mg, 44.3μmol, 34% yield); LCMS: RT = 2.491min, MS calculated value: 607.7, [M+H] +=608.1; SFC: RT = 1.530min, ee%: 100%; HPLC: RT = 11.539min, purity: 98.67%; 1 H NMR (400 MHz, methanol-d4) δ = 8.15 (s, 1H) 8.03 (d, J = 8.4 Hz, 1H) 7.76 (d, J = 8.4 Hz, 1H) 7.59-7.65 (m, 1H) 7.51-7.55 (m, 2H) 7.44 (t, J = 8.0 Hz, 1H) 7.20 (s, 1H) 6.30 (d, J = 8.0 Hz, 1H) 6.10 (d, J = 8.0 Hz, 1H) z,1H)5.93(s,2H)5.41(s,2H)4.52(q,J=7.2Hz,2H)4.20(d,J=14Hz,1H)3.95-4.05(m,2H)2. 66-2.73(m,1H)2.54-2.65(m,3H)2.26(m,1H)1.50(t,J=7.2Hz,3H)0.69(m,1H)0.44(m,1H).
[0488] Intermediates of Examples 16-17
[0489]
[0490] Preparation of methyl (S)-4-amino-3-((oxetane-2-ylmethyl)amino)benzoate (2)
[0491]
[0492] Under N2 atmosphere, Pd / C (0.1g, 751umol, 10% purity) was added to a THF (10mL) solution of (S)-4-nitro-3-((oxetanes-2-ylmethyl)amino)benzoic acid methyl ester (0.5g, 1.88mmol, 1eq). The suspension was degassed and purged 3 times with H2. At 20 ℃, the mixture was stirred for 4 hours under H2 (15Psi). TLC showed that the starting material was completely consumed and formed a new spot. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the product, which was a colorless oil (400mg, 1.69mmol, 90.2% yield).
[0493] Preparation of (S)-2-(chloromethyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (3)
[0494]
[0495] To (S) -4-amino -3- ((oxetane -2- ylmethyl) amino) benzoic acid methyl ester (0.3g, 1.27mmol, 1eq) CH3CN (3mL) solution was added TosOH (21.9mg, 127μmol, 0.1eq) and 2-chloro-1,1,1-trimethoxyethane (206mg, 1.33mmol, 179μL, 1.05eq). The mixture was stirred at 60 ° C for 2 hours. TLC showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to give the product as a white solid (370mg, 1.26mmol, 99% yield); LCMS: RT = 0.555min, MS calculated value: 294.74, [M + H] + =295.9; 1 H NMR (400 MHz, chloroform-d) δ = 8.15 (s, 1H) 8.03 (d, J = 8.4 Hz, 1H) 7.81-7.85 (d, J = 8.4 Hz, 1H) 5.22 (m, 1H) 5.08 (s, 2H) 4.68-4.51 (m, 3H) 4.35 (m, Hz, 1H) 3.97 (s, 3H) 2.83-2.72 (m, 1H) 2.50-2.39 (m, 1H).
[0496] Preparation of methyl 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (4A and 4B)
[0497]
[0498] To a solution of (S)-2-(chloromethyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (0.37 g, 1.26 mmol, 1 eq) in ACN (10 mL) was added KCO (522 mg, 3.78 mmol, 3 eq) and 4-(((6-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (409 mg, 1.26 mmol, 1 eq). The mixture was stirred at 60 °C for 2 hours. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The residue was diluted with H0 30 mL and extracted with EtOAc 30 mL (30 mL*3). The combined organic layers were dried over NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=10 / 1 to 0 / 1) and then by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [0.1% NH3H2OMEOH]; B%: 50%-50%, 40min) to give the product 4A isomer 1 as a white solid (180mg, 309μmol, 36% yield), and 4B isomer 2 as a white solid (180mg, 309μmol, 36% yield); LCMS: RT=2.587min, MS calculated value: 582.64, [M+H] + =583.2
[0499] Example 16 (Synthesis of Compound 43).
[0500] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0501]
[0502] To a solution of 4A isomer 1 (100 mg, 172 umol, 1 eq) in THF (0.6 mL) was added a solution of LiOH.H2O (14.4 mg, 343 umol, 2 eq) in H2O (0.2 mL). The mixture was stirred at 20°C for 12 hours. TLC showed that the starting material was completely consumed and a new spot was formed. The mixture was purified by preparative HPLC (neutral conditions; column: Waters Xbridge Prep OBDC18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-60%, 8min) to give the product as a white solid (53 mg, 93.2 μmol, 54.3% yield); LCMS: RT = 2.368 min, MS calculated value: 568.61, [M+H] + =569.2; HPLC: RT = 10.178min, purity: 99.30%; SFC: RT = 1.443min, ee%: 100%; 1 H NMR (400MHz, methanol-d4) δ = 8.32 (s, 1H) 7.97 (d, J = 8.4Hz, 1H) 7.67 (d, J = 8.4Hz, 1H) 7.65-7.55 (m, 3H) 7.4 5(t,J=8.0Hz,1H)6.34(d,J=8.0Hz,1H)6.10(d,J=8.0Hz,1H)5.43(s,2H)5.24(m,1H)4.71(m,1H)4. 66-4.59(m,1H)4.46(m,1H)4.29(d,J=13.6Hz,1H)4.15-4.09(m,1H)4.06(d,J=13.6Hz,1H)3.07–2. 97(m,1H)2.84-2.64(m,4H)2.56-2.46(m,1H)2.42-2.33(m,1H)0.74-0.65(m,1H)0.48-0.40(m,1H).
[0503] Example 17 (Synthesis of Compound 42).
[0504] 2-((5-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0505]
[0506] To a solution of 4B isomer 2 (100 mg, 172 μmol, 1 eq) in THF (1.5 mL) was added a solution of LiOH.H2O (14.41 mg, 343 μmol, 2 eq) in H2O (0.3 mL). The mixture was stirred at 25 ° C for 12 hours. TLC showed that the starting material was completely consumed. The solution was adjusted to neutrality with citric acid and the solution was concentrated. The residue was purified by preparative HPLC (neutral conditions; column: WatersXbridge Prep OBD C18 150*40mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 15%-45%, 8min) to give the product as a white solid (31.9 mg, 56.0 μmol, 32.6% yield); LCMS: RT = 1.824min, MS calculated value: 568.61, [M+H] + =569.2; HPLC: RT = 10.196 min, purity: 97.65%; SFC: RT = 1.916 min, ee%: 99.14%; 1 H NMR (400 MHz, methanol-d4) δ = 8.33 (s, 1H) 8.00 (d, J = 8.4 Hz, 1H) 7.71 (d, J = 8.4 Hz, 1H) 7.69-7.63 (m, 1H) 7.60-7.53 (m, 2H) 7.48-7.45 (m, 1H) 6.33 (d, J = 7.2 Hz, 1H) 6.11 (d, J = 7.2 Hz, 1H) 5.43 (s, 2H) 5.27-5.25 (m, 1H) 4.90-4.88 (m, 1H) 4.7 5-4.73(m,1H)4.64-4.61(m,1H)4.50-4.48(m,1H),4.18(s,1H)4.17-4.15(m,1H)3.10-4.25(m,1H)2.73-2.77(m ,3H)2.65-2.62(m,1H)4.50-4.48(m,1H)2.55-2.52(m,1H)2.45-2.49(m,1H)0.74-0.69(m,1H)0.47-0.44(m,1H).
[0507] Example 18 (Synthesis of Compound 34).
[0508] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0509]
[0510] Preparation of 4-ethynyl-3-fluorobenzonitrile (2)
[0511]
[0512] A mixture of 3-fluoro-4-formylbenzonitrile (20 g, 134 mmol, 1 eq), dimethyl (1-diazo-2-oxopropyl)phosphonate (38.6 g, 201 mmol, 1.5 eq), K2CO3 (27.8 g, 201 mmol, 1.5 eq) in MeOH (200 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 0°C under N2 atmosphere for 2 hours. TLC (petroleum ether / ethyl acetate=5 / 1R f =0.55) shows that starting material is completely consumed. The combined reaction mixture is poured into water (50mL) and extracted with ethyl acetate (50mL*2). The combined organic phase is concentrated in vacuo to obtain residue. The residue is purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product, which is a white solid (12g, 82.7mmol, 61.7% yield).
[0513] Preparation of 4-(4-bromo-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (3)
[0514]
[0515] 4-ethynyl-3-fluorobenzonitrile (15.6 g, 82.7 mmol, 1 eq), 3-bromobenzene-1,2-diol (12 g, 82.7 mmol, 1 eq), PPh3 (2.17 g, 8.27 mmol, 0.1 eq), Ru3(CO) 12 (2.64g, 4.13mmol, 0.05eq) in toluene (120mL) was degassed and purged 3 times with N2, then the mixture was stirred at 100°C under N2 atmosphere for 24 hours. HPLC showed that the starting material was completely consumed. The combined reaction mixture was poured into water (100mL) and extracted with ethyl acetate (50mL*2). The combined organic phases were concentrated in vacuo to obtain a residue. The crude product was purified by reverse phase HPLC (column: WelchXtimate C18 250*100mm#10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 50%-85%, 20min) to obtain the product as a black oil (13g, 38.9mmol, 47% yield).
[0516] Preparation of tert-butyl 5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (4)
[0517]
[0518] A mixture of tert-butyl 2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (11.1 g, 56.1 mmol, 1.5 eq), 4-(4-bromo-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (12.5 g, 37.4 mmol, 1 eq), Cs2CO3 (18.3 g, 56.1 mmol, 1.5 eq), BINAP (2.33 g, 3.74 mmol, 0.1 eq), Pd2(dba)3 (1.71 g, 1.87 mmol, 0.05 eq) in toluene (120 mL) was degassed and purged 3 times with N2, and then the mixture was stirred at 100° C. under N2 atmosphere for 1 hour. LCMS showed that the starting material was completely consumed. TLC (petroleum ether / ethyl acetate=3:1R f =0.4) showed that the starting material was completely consumed. The combined reaction mixture was poured into water (100mL) and extracted with ethyl acetate (50mL*2). The combined organic phase was concentrated in vacuo to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product as a yellow solid (5.6g, 12.4mmol, 33.2% yield); LCMS: RT=2.670min, MS calculated value: 451.5, [M-55] + =396.1.
[0519] Preparation of 4-(4-(2,5-diazabicyclo[4.1.0]hept-2-yl)-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (5)
[0520]
[0521] A mixture of 5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylic acid tert-butyl ester (334 mg, 740 μmol, 1 eq) and HCl / EtOAc (4M, 1.67 mL, 9.03 eq) in DCM (2 mL) was degassed and purged with N2 3 times, and the mixture was then stirred at 25 °C under N2 atmosphere for 1 hour. LCMS showed that the starting material was completely consumed. The reaction mixture was concentrated to give the crude product as a white solid (260 mg, crude); LCMS: RT=0.579 min, MS calculated: 351.3, [M+H] + =352.1.
[0522] Preparation of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (6)
[0523]
[0524] A mixture of 4-(4-(2,5-diazabicyclo[4.1.0]hept-2-yl)-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (238 mg, 740 μmol, 1 eq), 2-(chloromethyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (260 mg, 740 μmol, 1 eq), K2CO3 (307 mg, 2.22 mmol, 3 eq) in ACN (5 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 60 ° C under N2 atmosphere for 2 hours. LCMS showed that the starting material was completely consumed. The combined reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (50 mL*2). The combined organic phases were concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 0 / 1) to give the product as a white solid (330 mg, 518 μmol, 70% yield); LCMS: RT = 0.754 min, MS calculated value: 636.70, [M+H] + =637.1; 1H NMR (400 MHz, chloroform-d) δ=8.76 (s, 1H) 8.15 (s, 1H) 8.15-8.05 (d, J=8.4 Hz, 1H) 7.91 (s, 1H) 7.81-7.66 (m, 2H) 7.47-7.42 (m, 1H) 7.41-7.34 (m, 1H) 6.77 (m, 1H) 6.49 (m, 1H) 6.40 (m, 1H)5.95(m,2H)4.19-4.08(m,1H)4.06-4.00(m,1H)3.99-3.92(m,3H)3.86-3.66(m,1H )3.44-3.30(m,1H)2.96-2.83(m,2H)2.65-2.42(m,2H)2.01(s,3H)0.59-0.78(m,2H).
[0525] Preparation of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 34)
[0526]
[0527] A mixture of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (330 mg, 518 μmol, 1 eq), LiOH.HO (30.5 mg, 726 μmol, 1.4 eq) in THF (2.8 mL), HO (1.2 mL) was degassed and purged 3 times with N, and the mixture was then stirred at 25 °C under N atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 25%-55%, 8min) to give the product as a white solid (25.3mg, 37.3μmol, 7.2% yield, 92% purity); LCMS: RT = 1.882min, MS calculated value: 622.8, [M+H] + =623.2; HPLC: RT = 11.63min, purity: 91.76%; 1H NMR (400 MHz, methanol-d4) δ = 8.94 (d, J = 9.6 Hz, 1H) 8.26 (s, 1H) 8.06 (s, 1H) 8.01-7.97 (m, 1H) 7.80-7.67 (m, 2H) 7.64-7.53 (m, 2H) 6.69-6.77 (m, 1H) 6.50 (m, 1H) 6.31-6. 36(m,1H)5.99(s,2H)4.24-4.14(m,1H)4.13-4.03(m,1H)3.80-3.71(m,1H)3.29 -3.23(m,1H)2.95-2.74(m,2H)2.67-2.43(m,2H)2.05(s,3H)0.74-0.50(m,2H).
[0528] Intermediates of Examples 19-22
[0529]
[0530] Example 19 (Synthesis of Compound 37).
[0531] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0532]
[0533] A mixture of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (90 mg, 141 μmol, 1 eq), LiOH.HO (8.90 mg, 212 μmol, 1.5 eq) in THF (0.7 mL), HO (0.3 mL) was degassed and purged 3 times with N, and the mixture was then stirred at 30 °C under N atmosphere for 12 hours. LCMS showed that the starting material was completely consumed. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters XbridgePrep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-60%, 8min) to give the product as a white solid (21.2 mg, 34.1 μmol, 24.1% yield); LCMS: RT = 1.733 min, MS calculated value: 622.68, [M+H]+ =623.2; HPLC: RT = 11.744 min, purity: 94.48%; SFC: RT = 5.660 min, purity: 100.00%; 1 H NMR (400MHz, methanol-d4) δ = 8.97 (s, 1H) 8.27 (s Hz,1H)8.06(s,1H)7.99(d,J=8.4Hz,1H)7.78(t,J=7.6Hz,1H)7.70(d,J=8.4H z,1H)7.66-7.54(m,2H)6.69-6.78(m,1H)6.52-6.48(m,1H)6.36-6.33(m,1H) 5.99(s,2H)4.22-4.16(m,1H)4.12-4.07(m,1H)3.80-3.73(m,1H)3.29-3.24( m,1H)2.91(m,1H)2.80(m,1H)2.64-2.50(m,2H)2.03(s,3H)0.63-0.55(m,2H).
[0534] Example 20 (Synthesis of Compound 38).
[0535] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0536]
[0537] A mixture of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (50 mg, 78.5 μmol, 1 eq), LiOH.HO (4.94 mg, 118 μmol, 1.5 eq) in HO (0.1 mL), THF (0.4 mL) was degassed and purged 3 times with N, and then the mixture was stirred at 30 °C under N atmosphere for 12 hours. 71% of the desired compound was detected by LC-MS. The solution was adjusted to neutral with citric acid and the solution was concentrated. The residue was purified by preparative HPLC (neutral conditions: column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-60%, 8min) to give the product as a white solid (17.5mg, 28.1umol, 35.7% yield); LCMS: RT = 1.722min, MS calculated value: 622.68, [M+H] + =623.2; HPLC: RT = 11.691 min, purity: 91.87%; 1 H NMR (400MHz, methanol-d4) δ=8.93(s,1H),8.27(s,1H),8.06(s,1H),7.99(d,J=8.4Hz,1H),7.78-7.68(m,2H),7.63-7.54(m,2H),6.77-6.71(m,1H),6.52(m,1H),6.37-6.32(m,1H), 5.99(s,2H),4.24-4.16(d,J=13.6Hz,1H),4.11-4.04(d,J=13.6Hz,1H),3.79-3.71(m, 1H),2.87-2.75(m,2H),2.67-2.60(m,1H),2.48(m,1H),2.02(s,3H),0.72-0.60(m,2H).
[0538] Example 21 (Synthesis of Compound 36).
[0539] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0540]
[0541] A mixture of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (110 mg, 173 μmol, 1 eq), LiOH.HO (10.9 mg, 259 μmol, 1.5 eq) in THF (0.7 mL), HO (0.3 mL) was degassed and purged 3 times with N, and then the mixture was stirred at 30 °C under N atmosphere for 12 hours. TLC showed that the starting material was completely consumed. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 35%-65%, 8min) to give the product as a white solid (15.2mg, 24.4μmol, 14.1% yield); LCMS: RT = 1.733min, MS calculated value: 622.68, [M+H] + =623.2; HPLC: RT = 11.770 min, purity: 93.95%; SFC: RT = 5.825 min, purity: 100.00%; 1 H NMR (400 MHz, methanol-d4) δ=8.92 (s, 1H) 8.26 (s, 1H) 8.06 (s, 1H) 7.99 (d, J=8.4 Hz, 1H) 7.77-7.68 (m, 2H) 7.61-7.454 (m, 2H) 6.76-6.71 (m, 1H) 6.51 (m, 1H) 6.34 (m, 1H) 5.98 (s,2H)4.22-4.16(m,1H)4.10-4.04(m,1H)3.79-3.71(m,1H)3.29-3.23(m,1H)2. 85-2.76(m,2H)2.66-2.60(m,1H)2.50-2.44(m,1H)2.02(s,3H)0.71-0.60(m,2H).
[0542] Example 22 (Synthesis of Compound 35).
[0543] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0544]
[0545] To a solution of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 157 μmol, 1 eq) in THF (0.7 mL) was added a solution of LiOH.HO (9.89 mg, 236 μmol, 1.5 eq) in HO (0.3 mL). The mixture was stirred at 20 °C for 12 h. LC-MS showed complete consumption of the starting material and the expected mass was detected. The residue was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; gradient: 30%-60% B in 8 minutes) to give the product as a white solid (34.6 mg, 55.5 μmol, 35.3% yield); LCMS: RT = 2.118 min, MS calculated value: 622.68, [M+H] + =623.2; HPLC: RT = 11.544 min, purity: 93.04%; SFC: RT = 1.914 min, purity: 100.00%; 1 H NMR (400 MHz, methanol-d4) δ = 8.96 (s, 1H) 8.27 (s, 1H) 8.14 (, 1H) 8.00 (dd, J = 8.4 Hz, 1H) 7.78 (t, J = 7.6 Hz, 1H) 7.70 (d, J = 8.4 Hz, 1H) 7.66-7.53 (m, 2H) 6.78-6.67 (m, 1H) 6.50 (m, 1H) )6.41-6.30(m,1H)6.00(s,2H)4.30-4.04(m,2H)3.81-3.70(m,1H)3.29-3.24(m,1H) 2.98-2.88(m,1H)2.85-2.73(m,1H)2.65-2.43(m,2H)2.04(s,3H)0.67-0.53(m,2H).
[0546] Example 23 (Synthesis of Compound 41). 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 diastereomers
[0547]
[0548] Preparation of methyl (S)-4-amino-3-((oxetane-2-ylmethyl)amino)benzoate (2)
[0549]
[0550] Under N2 atmosphere, Pd / C (10%, 200 mg) was added to a MeOH (5 mL) solution of (S)-4-nitro-3-((oxetanes-2-ylmethyl)amino)benzoic acid methyl ester (500 mg, 1.88 mmol, 1 eq). The suspension was degassed and purged 3 times with H2. At 25 ℃, the mixture was stirred for 1 hour under H2 (15 Psi.). TLC showed that the starting material was completely consumed and a new spot was formed. According to TLC, the reaction was complete. The reaction solution was filtered and the filtrate was concentrated to obtain the product (400 mg, 1.69 mmol, 90.2% yield) as a white solid.
[0551] Preparation of (S)-2-(chloromethyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (3)
[0552]
[0553] A mixture of (S)-4-amino-3-((oxetane-2-ylmethyl)amino)benzoic acid methyl ester (300 mg, 1.27 mmol, 1 eq), 2-chloro-1,1,1-trimethoxyethane (393 mg, 2.54 mmol, 341 μL, 2 eq), TosOH (43.7 mg, 254 μmol, 0.2 eq) in CH3CN (3 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 60 °C under N2 atmosphere for 1 hour. TLC showed that the starting material was completely consumed and a new spot was formed. According to TLC, the reaction was complete. The reaction mixture was concentrated under reduced pressure to give the product as a white solid (350 mg, 1.19 mmol, 93.5% yield); LCMS: RT = 1.590 min, MS calculated value: 294.74, [M+H] + =295.0.
[0554] Preparation of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (4)
[0555]
[0556] A mixture of (S)-methyl 2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (247 mg, 840 μmol, 1 eq), 4-(4-(2,5-diazabicyclo[4.1.0]hept-2-yl)-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (295 mg, 840 μmol, 1 eq), K2CO3 (232 mg, 1.68 mmol, 2 eq) in ACN (5 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 60° C. under N2 atmosphere for 2 hours. LC-MS showed complete consumption of the starting material, and one major peak with the expected mass was detected. The reaction mixture was diluted with H2O50mL and extracted with EtOAc150mL (50mL*3), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product as a white solid (250mg, 410μmol, 49% yield); LCMS: RT=2.624min, MS calculated: 609.66, [M+H] + =610.2.
[0557] Preparation of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of four diastereomers (Compound 41)
[0558]
[0559] A mixture of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 246 μmol, 1 eq), LiOH.HO (17.6 mg, 418 μmol, 1.7 eq) in THF (1.2 mL) and HO (0.3 mL) was degassed and purged with N2 three times, then the mixture was stirred at 20 °C under N2 atmosphere for 16 hours. LC-MS showed 22% of the starting material remaining. LC-MS showed several new peaks, and 62% of the desired compound was detected. The solution was adjusted to neutral with citric acid and concentrated. The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 20%-60%, 8min) to give the product as a white solid (30 mg, 50.4 μmol, 20.5% yield); LCMS: RT = 1.865 min, MS calculated value: 595.63, [M+H] + =596.3; HPLC: RT = 10.534min, purity: 96.05%; 1 H NMR (400MHz, methanol-d4) δ = 8.33 (s, 1H) 7.97 (d, J = 8.4Hz, 1H) 7.77-7.70 (m, 1H) 7.68 (d, J = 8.4Hz, 1H) 7.66-7.60 (m, 1H) 7.55(d,J=8.0Hz,1H)6.73-6.72(m,1H)6.53-6.49(m,1H)6.35-6.32(m,1H)5.26-5.24(m,1H)4.90-4.89(m,1H)4.7 4-4.70(m,1H)4.64-4.62(m,1H)4.47-4.46(m,1H)4.28-4.26(m,0.5H)4.17-4.18(m,1H)4.10-4.05(m,0.5H)3.70 6-3.7(m,1H)3.33-3.31(m,1H)2.80-2.78(m,4H)2.55-2.51(m,2H)2.03-2.01(d,J=4.8Hz,,3H)0.69-0.52(m,2H).
[0560] Example 24 (Synthesis of Compound 40).
[0561] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-cyanocyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of 4 diastereomers
[0562]
[0563] Preparation of methyl 3-(((1-cyanocyclopropyl)methyl)amino)-4-nitrobenzoate (2)
[0564]
[0565] A mixture of methyl 3-fluoro-4-nitrobenzoate (1.90 g, 9.55 mmol, 1 eq), 1-(aminomethyl)cyclopropane-1-carbonitrile (1.9 g, 14.3 mmol, 1.5 eq), TEA (3.87 g, 38.2 mmol, 5.32 mL, 4 eq) in THF (10 mL) and MeOH (10 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 60° C. under N2 atmosphere for 12 hours. TLC (petroleum ether / ethyl acetate=3 / 1 R f =0.46) indicated that the starting material was completely consumed and a new spot was formed. According to TLC, the reaction was complete. The residue was diluted with H2O (100ml) and extracted with ethyl acetate (100mL*3). The combined organic phase was washed with brine (100mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product as a yellow solid (2.5g, 9.08mmol, 95.07% yield); LCMS: RT=1.948min, MS calculated: 275.26, [M+H] + =276.2; 1 H NMR (400 MHz, CHLOROFORM-d) δ = 8.25 (d, J = 8.8 Hz, 1H), 8.15 (br s, 1H), 7.58 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 4.01 (s, 3H), 3.57 (d, J = 5.6 Hz, 2H), 1.48-1.42 (m, 2H), 1.14-1.08 (m, 2H).
[0566] Preparation of methyl 4-amino-3-(((1-cyanocyclopropyl)methyl)amino)benzoate (3)
[0567]
[0568] A mixture of methyl 3-(((1-cyanocyclopropyl)methyl)amino)-4-nitrobenzoate (2.5 g, 9.08 mmol, 1 eq), Fe (5.07 g, 90.8 mmol, 10 eq), NH4Cl (4.86 g, 90.8 mmol, 10 eq) in H2O (8 mL) and MeOH (24 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 70°C under N2 atmosphere for 2 hours. TLC (petroleum ether / ethyl acetate=3 / 1 R f =0.35) indicated that the starting material was completely consumed and a new spot was formed. The resulting product was dissolved in MeOH and filtered to remove insoluble matter. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to give the product as a yellow solid (1.94 g, 7.91 mmol, 87% yield); LCMS: RT=1.529 min, MS calculated: 245.28, [M+H] + =246.1; 1 H NMR (400MHz, DMSO-d6) δ = 7.22 (d, J = 8.0Hz, 1H), 7.04 (s, 1H), 6.56 (d, J = 8.0Hz, 1H), 5.55 (br s, 2H), 4.94 (br t,J=5.6Hz,1H),3.72(s,3H),3.23(d,J=5.6Hz,2H),1.30-1.21(m,2H),1.10-1.01(m,2H).
[0569] Preparation of methyl 2-(chloromethyl)-1-((1-cyanocyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (4)
[0570]
[0571] A mixture of 4-amino-3-(((1-cyanocyclopropyl)methyl)amino)benzoic acid methyl ester (300 mg, 1.22 mmol, 1 eq), 2-chloro-1,1,1-trimethoxyethane (567 mg, 3.67 mmol, 493 μL, 3 eq), TosOH (105 mg, 612 μmol, 0.5 eq) in ACN (5 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 60 ° C under N2 atmosphere for 2 hours. LC-MS showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to give the product as a white solid (372 g, crude); LCMS: RT = 1.588 min, MS calculated value: 303.72, [M + H] + =304.1.
[0572] Preparation of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-cyanocyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (5)
[0573]
[0574] A mixture of 2-(chloromethyl)-1-((1-cyanocyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (216 mg, 711 μmol, 1 eq), 4-(4-(2,5-diazabicyclo[4.1.0]hept-2-yl)-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (250 mg, 711 μmol, 1 eq), K2CO3 (295 mg, 2.13 mmol, 3 eq) in ACN (5 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 50 °C under N2 atmosphere for 6 hours. LC-MS showed that the starting material was completely consumed. TLC (petroleum ether / ethyl acetate=0 / 1 R f =0.47) indicated that the starting material was completely consumed. The residue was diluted with H2O (30ml) and extracted with ethyl acetate (30mL*3). The combined organic phase was washed with brine (20mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to obtain the product as a yellow solid (240mg, 388μmol, 54.5% yield); LCMS: RT=2.630min, MS calculated: 618.66, [M+H] + =619.3.
[0575] Preparation of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-cyanocyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 40)
[0576]
[0577] A mixture of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((1-cyanocyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 162 μmol, 1 eq), LiOH.H2O (10.17 mg, 242.46 μmol, 1.5 eq) in THF (1.5 mL) and H2O (0.6 mL) was degassed and purged with N2 three times, then the mixture was stirred at 20° C. under N2 atmosphere for 16 h. LCMS showed complete consumption of the starting material. The crude product was purified by reverse phase HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 20% 50%, 8min) to give the product as a white solid (18 mg, 29.8umol, 18.4% yield); LCMS: RT = 2.510min, MS calculated value: 604.63, [M+H] + =605.3; HPLC: purity = 93.9%; 1 H NMR (400MHz, methanol-d4) δ = 8.35 (s, 1H), 8.02 (d, J = 8.4Hz, 1H), 7.80-7.74 (m, 1H), 7.73-7.69 (m, 1H), 7 .65-7.59(m,1H),7.58-7.54(m,1H),6.73(m,1H),6.51(m,1H),6.37-6.31(m,1H),4.81-4.77(m,2H ),4.36-4.26(m,1H),4.20-4.13(m,1H),3.83-3.71(m,1H),3.40-3.33(m,1H),2.90-2.84(m,2H), 2.68-2.60(m,1H),2.58-2.45(m,1H),2.02(d,J=4.6Hz,3H),1.52-1.43(m,4H),0.72-0.49(m,2H).
[0578] Example 25 (Synthesis of Compound 13)
[0579] 3-Fluoro-4-(2-methyl-4-(5-((1-(thiazol-5-ylmethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-2-yl)methyl)-2,5-diazabicyclo[4.1.0]hept-2-yl)benzo[d][1,3]dioxol-2-yl)benzonitrile, mixture of 4 diastereomers
[0580]
[0581] Preparation of 4-nitro-3-((thiazol-5-ylmethyl)amino)benzonitrile (2)
[0582]
[0583] TEA (4.02 g, 39.7 mmol, 5.53 mL, 3.3 eq) was added to a solution of 3-fluoro-4-nitrobenzonitrile (2 g, 12.0 mmol, 1 eq) and thiazol-5-ylmethylamine (2.25 g, 12.0 mmol, 1 eq, 2 HCl) in THF (10 mL) and MeOH (10 mL). The mixture was stirred at 60 ° C for 5 hours. TLC showed that the starting material was completely consumed and a new spot was formed. The reaction mixture was slowly poured into H2O (60 mL) at 0 ° C, and a solid was formed. The mixture was stirred for 15 minutes and filtered. The solid was collected under reduced pressure to give the product as a yellow solid (3 g, 11.5 mmol, 95.7% yield); LCMS: RT = 0.774 min, MS calculated value: 260.3, [M + H] + =261.1; 1 H NMR (400MHz, DMSO-d6) δ 8.99 (s, 1H) 8.72 (br t, J = 6.0Hz, 1H) 8.19 (d, J = 8.8Hz, 1H) 7.96 (s, 1H) 7.67 (s, 1H) 7.06 (d, J = 8.8Hz, 1H) 4.93 (d, J = 6.0Hz, 2H).
[0584] Preparation of N'-hydroxy-4-nitro-3-((thiazol-5-ylmethyl)amino)benzamidine (3)
[0585]
[0586] Hydroxylamine (429 mg, 6.49 mmol, 50% purity, 1.3 eq) was added to a solution of 4-nitro-3-((thiazol-5-ylmethyl)amino)benzonitrile (1.3 g, 4.99 mmol, 1 eq) in EtOH (15 mL). The mixture was stirred at 90 ° C for 1 hour. LC-MS showed that the starting material was completely consumed and the expected mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent. The crude product was obtained as a yellow solid (1.46 g); LCMS: RT = 1.290 min, MS calculated value: 293.3, [M + H] + = 294.0; 1HNMR(400MHz,DMSO-d6)δ=10.10(br s,1H)8.98(s,1H)8.71(br t,J=6.0Hz,1H)8.03(d,J=9.2Hz,1H)7.90(s,1H)7.34(s,1H)7.05(d,J=9.2Hz,1H)6.02(br s,2H)4.96(d,J=6.0Hz,2H).
[0587] Preparation of 2-nitro-N-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)aniline (4)
[0588]
[0589] TFAA (1.40 g, 6.65 mmol, 924.76 μL, 1.5 eq) was added to a solution of N'-hydroxy-4-nitro-3-((thiazol-5-ylmethyl)amino)benzamidine (1.3 g, 4.43 mmol, 1 eq) in THF (8 mL). The mixture was stirred at 20 ° C for 2 hours. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The residue was diluted with NaHCO (30 mL) and extracted with EtOAc (30 mL * 2). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 30 / 1 to 1 / 1) to obtain the product as a yellow solid (1.5 g, 4.04 mmol, 91% yield); LCMS: RT = 2.324 min, MS calculated value: 371.3, [M + H] + =372.0; 1 H NMR (400 MHz, CHLOROFORM-d) δ = 8.81 (s, 1H) 8.45 (br s, 1H) 8.40 (d, J = 8.8 Hz, 1H) 7.95 (s, 1H) 7.72 (s, 1H) 7.48 (d, J = 8.8 Hz, 1H) 4.90 (d, J = 5.6 Hz, 2H).
[0590] Preparation of 2-nitro-N-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)aniline (5)
[0591]
[0592] NH2NH2.H2O (539 mg, 10.8 mmol, 524 μL, 5 eq) was added dropwise to a solution of 2-nitro-N-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-1,2,4-oxadiazole-3-yl)aniline (0.8 g, 2.15 mmol, 1 eq) in EtOH (10 mL) at 0-5 ° C. The mixture was stirred at 60 ° C for 2 hours. LC-MS showed that the starting material was completely consumed and the expected mass was detected. The reaction mixture was concentrated under reduced pressure at 30 ° C to obtain a residue. The residue was diluted with H2O (20 mL) and extracted with EtOAc / i-PrOH=2 / 1 (20 mL*3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (neutral conditions; column: Phenomenex luna C18 250*50mm*10um; mobile phase: [water (TFA)-ACN]; B%: 25%-55%, 10 min) to give the product as a yellow solid (500 mg, 1.35 mmol, 62.7% yield); LCMS: RT = 1.815 min, MS calculated value: 370.3, [M+H] + = 371.1; 1 H NMR (400 MHz, methanol-d4) δ = 9.03 (s, 1H) 8.36 (d, J = 8.8 Hz, 1H) 8.01 (s, 1H) 7.78 (s, 1H) 7.35 (d, J = 8.8 Hz, 1H) 5.02 (s, 2H).
[0593] Preparation of N1-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)benzene-1,2-diamine (6)
[0594]
[0595] Pd / C was added to a solution of 2-nitro-N-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)aniline (130 mg, 351 μmol, 1 eq) in MeOH (5 mL) under N2 atmosphere. The suspension was degassed and purged with H2 3 times. The mixture was stirred at 20 °C under H2 (15 psi) for 1 hour. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give the product as a yellow solid (119 mg, 350 umol, 99.6% yield); LCMS: Rt = 1.327 min, MS calculated value: 340.3, [M+H]+ = 341.0.
[0596] Preparation of 5-((2-(chloromethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)methyl)thiazole (7)
[0597]
[0598] To a solution of N1-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)benzene-1,2-diamine (0.11 g, 323 μmol, 1 eq) in CH3CN (1 mL) was added TosOH (11.1 mg, 64.6 μmol, 0.2 eq) and 2-chloro-1,1,1-trimethoxyethane (75 mg, 485 μmol, 65.2 μL, 1.5 eq). The mixture was stirred at 60 ° C for 1 hour. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was concentrated under reduced pressure to give the product as a yellow solid (120 mg, 301 μmol, 93.1% yield); LCMS: RT = 1.284 min, MS calculated value: 398.8, [M + H] + = 399.0.
[0599] Preparation of 3-fluoro-4-(2-methyl-4-(5-((1-(thiazol-5-ylmethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-2-yl)methyl)-2,5-diazabicyclo[4.1.0]hept-2-yl)benzo[d][1,3]dioxol-2-yl)benzonitrile, mixture of 4 diastereomers (Compound 13)
[0600]
[0601] To a solution of 5-((2-(chloromethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)methyl)thiazole (110 mg, 166 μmol, 60% purity, 1 eq) in CH3CN (2 mL) was added K2CO3 (91.5 mg, 662 μmol, 4 eq) and 4-(4-(2,5-diazabicyclo[4.1.0]hept-2-yl)-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (64 mg, 166 μmol, 1 eq, HCl). The mixture was stirred at 60 °C for 1 hour. LC-MS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (neutral conditions: column: Phenomenex C18 75*30mm*3um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; B%: 40%-65%, 8 min) to give the product as a white solid (8.88 mg, 12.4 μmol, 7.5% yield); LCMS: RT=2.201 min, MS calculated value: 713.7, [M+H] + =714.2; HPLC: RT = 4.071min, purity: 87.6%; 1H NMR (400MHz, methanol-d4) δ = 8.94 (d, J = 11.4Hz, 1H), 8.27 (s, 1H), 8.10 (s, 1H), 7.96-7.91 (m, 1H), 7.83-7.79 (m, 1H), 7.79-7.73 (m, 1H), 7.65-7.54 (m, 2H), 6.74 (dt, J = 2.8, 8.1Hz, 1H), 6.54-6.48 (m, 1H), 6.35 (dd, J=1.3,7.8Hz,1H),6.00(s,2H),4.24-4.17(m,1H),4.13-4.05(m,1H),3.80-3.72(m,1H),3.30-3.25(m, 1H),2.95-2.77(m,2H),2.69-2.59(m,1H),2.59-2.45(m,1H),2.03(d,J=4.8Hz,3H),0.73-0.55(m,2H).
[0602] Example 26 (Synthesis of Compound 12).
[0603] 3-Fluoro-4-(((6-(5-((1-(thiazol-5-ylmethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-2-yl)methyl)-2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)benzonitrile, mixture of 2 diastereomers
[0604]
[0605] Preparation of 5-((2-(chloromethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)methyl)thiazole (2)
[0606]
[0607] A mixture of N1-(thiazol-5-ylmethyl)-5-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)benzene-1,2-diamine (100 mg, 294 μmol, 1 eq), 2-chloro-1,1,1-trimethoxyethane (114 mg, 735 μmol, 98.8 μL, 2.5 eq), TosOH (5.06 mg, 294 μmol, 0.1 eq) in CH3CN (2 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 60 °C under N2 atmosphere for 1 hour. LC-MS showed that the starting material was completely consumed, and a major peak with the expected mass was detected. The reaction solution was concentrated to give the product as a white solid (80 mg, 201 μmol, 68.3% crude material); LCMS: RT = 1.140 min, MS calculated value: 398.1, [M+H] + =399.0.
[0608] Preparation of 3-fluoro-4-(((6-(5-((1-(thiazol-5-ylmethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-2-yl)methyl)-2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)benzonitrile (Compound 12)
[0609]
[0610] A mixture of 5-((2-(chloromethyl)-6-(5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)methyl)thiazole (80 mg, 201 μmol, 1 eq), 4-(((6-(2,5-diazabicyclo[4.1.0]hept-2-yl)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (65.1 mg, 201 μmol, 1 eq), K2CO3 (55 mg, 401 μmol, 2 eq) in ACN (3 mL) was degassed and purged with N2 three times, then the mixture was stirred at 50°C under N2 atmosphere for 2 hours. LCMS showed complete consumption of the starting material and one major peak with the expected mass was detected. The reaction mixture was diluted with H2O (30mL) and extracted with EtOAc 60mL (20mL*3), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-70%, 8min) to obtain the product as a white solid (2.73mg, 3.98umol, 1.98% yield); LCMS: RT = 2.673min, MS calculated: 686.1, [M+H] + =687.2; HPLC: RT = 3.232min, purity: 91.2%; 1 H NMR (400MHz, methanol-d4) δ = 8.91 (s, 1H) 8.27 (s, 1H) 8.08 (s, 1H) 7.94 (d, J = 8.4Hz, 1H) 7.84 -7.79(m,1H)7.64(t,J=7.6Hz,1H)7.56-7.51(m,2H)7.49-7.44(m,1H)6.37(d,J=8.4H z,1H)6.14(d,J=8.4Hz,1H)5.99(s,2H)5.44(s,2H)4.24-4.08(m,3H)2.98(m,1H)2.84 -2.74(m,2H)2.71-2.63(m,1H)2.44-2.36(m,1H)0.75-0.71(m,1H)0.54-0.47(m,1H).
[0611] Example 27 (Synthesis of Compound 39)
[0612] 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0613]
[0614] Preparation of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (2)
[0615]
[0616] A mixture of (R)-2-(chloromethyl)-1-(2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (250 mg, 842 umol, 1.29 eq), 4-(4-(2,5-diazabicyclo[4.1.0]hept-2-yl)-2-methylbenzo[d][1,3]dioxol-2-yl)-3-fluorobenzonitrile (230 mg, 655 umol, 1 eq), K2CO3 (271 mg, 1.96 mmol, 3 eq) in CH3CN (3 mL) was degassed and purged with N2 for 3 times at 25°C, and then the mixture was stirred at 60°C under N2 atmosphere for 1 hour. LC-MS showed complete consumption of the starting material and one major peak with the expected mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with H2O 25mL and extracted with DCM 45mL (15mL*3). The combined organic layer was washed with H2O 35mL, dried over Na2SO4, filtered and concentrated under reduced pressure to give the product as a white solid (200mg, 327umol, 50% yield); LCMS: RT = 2.437min, MS calculated value: 611.6, [M+H] + =612.2.
[0617] Preparation of 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylic acid, mixture of four diastereomers (Compound 39)
[0618]
[0619] A mixture of methyl 2-((5-(2-(4-cyano-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)-2,5-diazabicyclo[4.1.0]hept-2-yl)methyl)-1-((R)-2-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (120 mg, 196 μmol, 1 eq), LiOH.H2O (12.4 mg, 294 μmol, 1.5 eq) in H2O (0.6 mL) / THF (1.4 mL) was degassed and purged with N2 for 3 times at 25°C, and then the mixture was stirred at 25°C under N2 atmosphere for 12 hours. LC-MS showed complete consumption of the starting material and one major peak with the expected mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (column: Phenomenex C18 75*30mm*3um; mobile phase: [water (NH4HCO3)-ACN]; B%: 30%-65%, 8min) to give the product as a white solid (26 mg, 43.5umol, 22.2% yield); LCMS: RT = 2.427min, MS calculated value: 597.6, [M+H] + =598.3; 1 H NMR (400MHz, DMSO-d6) δ = 8.19 (s, 1H) 7.99-7.93 (m, 1H) 7.80 (d, J = 8.4Hz, 1H) 7.76-7.69 ( m,2H)7.64(d,J=8.4Hz,1H)6.74(m,1H)6.45-6.53(m,1H)6.39(m,1H)4.52-4.37(m,2H)4. 23-4.13(m,1H)3.99-3.84(m,1H)3.82-3.74(m,1H)3.58-3.73(m,1H)3.21(m,1H)3.13(s ,3H)2.89-2.60(m,3H)2.47-2.29(m,1H)2.06(s,3H)1.27-1.17(m,3H)0.66-0.41(m,2H).
[0620] Biological assays
[0621] Example B1: GLP-1R Cellular Assay
[0622] Stable cell lines expressing high GLP-1R surface expression and low GLP-1R surface expression were generated in CHO-K1 cells (Fugene 6) transfected with a puromycin-selective DNA plasmid encoding the human GLP-1R receptor under the control of the EF1A promoter (Accession No.: NM_002062.5). Transfected cells were seeded into 24-well plates (9,000 cells / well) containing complete medium and incubated in a humidified incubator at 37°C and 5% carbon dioxide. After overnight incubation, the medium was replaced with complete medium supplemented with puromycin (6 μg / mL) and refreshed every 2-3 days to select for stably transfected cells. Individual pools of selected cells were amplified before cAMP was detected using a TR-FRET assay (LANCE Ultra cAMP assay, Perkin Elmer) to analyze reactivity to a GLP-1 control peptide. Briefly, cells were collected in Versene solution, plated in 384-well plates (1,000 cells / well), and combined with serially diluted GLP-1R control peptide (10 nL) using an acoustic dispenser (ECHO). The plates were incubated at 25°C for 30 minutes, and then EU-cAMP tracer (5 μL) and Ulight anti-cAMP (5 μL) reagents were added to each well, followed by incubation at 25°C for 15 minutes. TR-FRET signals were detected using an EnVision multimode plate reader (excitation = 320 nm; emission = 615 and 655 nm). EC was generated using dose-response curves. 50Values, as a measure of reactivity to the GLP-1R control peptide. The reactivity of the selected cell lines was monitored for multiple passages to ensure stability. CHO-K1_hGLP-1Rhigh_clone16 and CHO-K1_hGLP-1Rlow_clone10 showed consistent high and low reactivity to the GLP-1R control peptide, respectively, and were selected for further analysis to determine the relative level of GLP-1R surface expression. In brief, GLP-1R expression was analyzed by flow cytometry using a fluorescein-labeled Exendin-4 peptide fluorescent probe (FLEX). Cells were harvested in Versene solution and washed three times with PBS + 0.5% BSA and then incubated with FLEX reagent (10 μM) at room temperature for 2 hours. After incubation, the cells were washed three times in PBS + 0.5% BSA and then finally resuspended in PBS and analyzed by flow cytometry to measure the FLEX mean fluorescence intensity (MFI) as a measure of cell surface GLP-1R expression. Both cell lines showed higher MFI values relative to control CHO-K1 cells, confirming GLP-1R surface expression; CHO-K1_hGLP-1Rhigh_clone16 cells showed significantly higher MFI levels relative to CHO-K1-hGLP-1low_clone10 cells.
[0623] For compound testing in the CHO-K1_hGLP-1Rlow_clone10 cell line, cells were seeded into 384-well plates (1,000 cells / well). Test compounds were serially diluted in DMSO (10 points, 3-fold dilutions), added to the wells using an ECHO dispenser (10 nL / well), and the plates were centrifuged for 1 minute and stirred for 2 minutes at room temperature, then incubated at 25°C for 30 minutes. After incubation, Eu-cAMP (5 μL) and Ulight anti-cAMP (5 μL) reagents were added to each well, followed by centrifugation for 1 minute, stirring for 2 minutes at room temperature, and finally the plates were incubated at 25°C for 15 minutes. The plates were read using an EnVision microplate reader (excitation = 320 nm; emission = 615 and 655 nm). Dose response curves were generated from duplicate wells based on the percentage of activation calculated relative to a control GLP-1 peptide agonist run in parallel. EC 50 Values were determined by fitting the percent activation as a function of compound concentration using the Hill equation (XLfit).
[0624] EC50 values for exemplary compounds in the low expression assay are shown in the table below. EC50 values were compared to reference compound A and reference compound B. The compounds tested were compound samples prepared according to the general procedures described in the Examples section.
[0625]
[0626]
[0627] A: >100nM; B: 50-100nM; C: 5.0-50nM; D: <5.0nM
[0628] Example B2: Metabolic stability in hepatocytes
[0629] The test compound was incubated in human hepatocytes and stability was assessed by matrix depilation method. The test compound was dissolved in dimethyl sulfoxide (DMSO) to make a 10mM stock solution, and then further diluted with DMSO in a 96-well plate to make a 1000× working stock solution of 1mM of the test compound and the positive control (midazolam). The vial containing the frozen hepatocytes was taken out from the liquid nitrogen tank and immediately immersed in a 37°C water bath. The vial was gently shaken until the contents were thawed, and then immediately poured into 48mL of preheated HT culture medium in a 50mL conical tube. The remaining cells in the vial were resuspended with 1.0mL of preheated HT culture medium and added to the conical tube. The tube was capped and then gently flipped several times to resuspend the hepatocytes. The cell suspension was centrifuged at room temperature at 50x g for 5 minutes and the supernatant was discarded. The cell pellet was loosened by gently rotating the centrifuge tube and resuspended in 4mL of warm Dulbecco's modified Eagle medium (DMEM). The cell density was determined by a Nexcelom cell counter and DMEM medium was added to obtain a target density of 1 x 106 cells / mL. The assay was performed in 96-well microtiter plates. Test compounds were co-cultured at 1 μM in DMEM with 1 x 10 6 Cells / mL hepatocytes were incubated for 0, 30, 60, 120 and 240 minutes. Incubation was performed with gentle shaking at 37°C in a humid atmosphere of 95% air / 5% CO2. The volume of the incubation mixture was 37 μL with a final 0.1% DMSO. At each time point, incubation was stopped by adding 150 μL quenching solution (100 acetonitrile, 0.1% formic acid, containing bucetin as an internal standard for positive ESI mode). Subsequently, the mixture was vortexed for 20 minutes and centrifuged at 4,000RPM at 10°C. The supernatant (80 μL) was transferred to a clean 96-well plate and analyzed by LC-MS / MS. 1 μM midazolam with a final 0.1% DMSO was included as a positive control to verify the assay performance. Calculation of the remaining parent percentage, intrinsic liver clearance and predicted liver clearance as well as t 1 / 2All samples were analyzed by LC-MS / MS using an AB Sciex API 4000 instrument coupled to a Shimadzu LC-20ADLC pump system. Separation was achieved using a Waters Atlantis T3dC18 reverse phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL / min. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in 100% acetonitrile (solvent B). Elution conditions are detailed below.
[0630]
[0631] The ion optics for each test compound were optimized for its declustering potential (DP), collection energy (CE), collision cell exit potential (CXP) and used in selected ion monitoring experiments in positive ion mode. The stability of the peak area ratio of each test compound to the internal standard was then evaluated. The extent of metabolism calculation was calculated based on the disappearance of the test compound compared to its initial concentration. The initial clearance rate of the test compound was calculated using a linear regression plot of the semi-log % remaining of the compound versus time. The elimination rate constant (k) from the linear regression plot was then used to determine t 1 / 2 and intrinsic clearance (CL int ), using the following formula, where C 肝细胞 (million cells / mL) is the cell density of the incubation:
[0632] k=-slope
[0633] t 1 / 2 =0.693 / k
[0634] CL int = k / C 肝细胞
[0635] This method of determining intrinsic clearance assumes that the test compound concentration is well below the Michaelis-Menten constant for the compound to its metabolizing enzymes.
[0636] Predicted hepatic clearance (CL hep ) is calculated using the following formula using the fully stirred method, where CL int(体内) Normalization was based on liver weight:
[0637] CL int(体内) =CL int x Hepatocellularity x liver weight
[0638] CL hep(预测) =(CL int(体内) x Q 肝脏 ) / (CLint(体内) +Q 肝脏 )
[0639] Where Q 肝脏 (ml / min / kg) is the liver blood flow
[0640] The relevant physiological parameters of human liver weight, blood flow and hepatocellularity are listed below:
[0641]
[0642] The results for intrinsic clearance (mL / min / kg) and half-life (t1 / 2) are presented in the table below.
[0643] Table 2
[0644]
[0645] Example B3. Passive Permeability and Flow Rate
[0646] Caco-2 cells (clone C2BBe1) were obtained from the American Type Culture Collection (Manassas, VA). Cell monolayers were grown to confluence on collagen-coated microporous membranes in 12-well assay plates. Details of the plates and their certification are shown below. The permeability assay buffer was a Hanks balanced salt solution containing 10 mM HEPES and 15 mM glucose, pH 7.4. The buffer in the receiving chamber also contained 1% bovine serum albumin. The dosing solution concentration was 5 μM test article in the assay buffer. Cell monolayers were dosed on the apical side (A to B) or the basolateral side (B to A) and incubated in a humidified incubator at 37°C and 5% CO2. Samples were collected from the donor chamber and the receiving chamber at 120 minutes. Each determination was performed in duplicate. The lucifer yellow flux of each monolayer was also measured after the experiment to ensure that no damage was caused to the cell monolayer during the flux. All samples were determined by LC-MS / MS using electrospray ionization. The apparent permeability (P app ) and the recovery percentage are calculated as follows:
[0647] P app = (dC r / dt) × V r / (A × C A ) (1)
[0648] Recovery percentage = 100 × ((V r ×C r 最终 )+(V d ×C d 最终 )) / (V d×C N )(2),
[0649] Among them, dC r / dt is the slope of the cumulative received concentration versus time, in μM s -1 ; V r is the volume of the receiving chamber in cm 3 ; V d is the volume of the donor chamber in cm 3 ; A is the insertion area (12 holes is 1.13 cm 2 );C A is the average of the nominal dose concentration and the measured 120-min donor concentration, in μM; C N is the nominal concentration of the dosing solution in μM; C r 最终 is the cumulative received concentration at the end of the incubation period, in μM; C d 最终 is the donor concentration at the end of the incubation period, expressed in μM. The efflux rate (ER) is defined as P app (B to A) / P app (A to B).
[0650] Table 3
[0651] Compound No. <![CDATA[P app (A to B)]]> ER 1 15 2.51 5 27.9 1.71 18 16.8 1.31 34 19.9 1.82 40 17.5 2.27
[0652] Example B4: Pharmacokinetics in rats
[0653] Intravenous administration: The compound was formulated at 0.5 mg / mL in a solution containing 5% polyethylene glycol 400 and 95% (12% (w / v) sulfobutyl-β-cyclodextrin in water) (v / v). The formulated compound was sterile filtered through a 0.22 micron filter before administration. The compound was administered to 7-11 week old male Sprague-Dawley rats at a dose of 1 mg / kg over 30 minutes via jugular vein cannula infusion.
[0654] Oral administration: The compound was formulated at 0.3 mg / mL or 0.6 mg / mL in a solution containing 5% polyethylene glycol 400 and 95% (12% (weight / volume) sulfobutyl-β-cyclodextrin aqueous solution) (volume / volume). The formulated compound was administered by oral gavage at a dose of 10 mL / kg to 7-11 week old male Sprague-Dawley rats.
[0655] Sample Collection: Collect approximately 0.2 mL of blood from the jugular vein or other appropriate site of each animal at each time point into pre-cooled commercial EDTA-K2 tubes and place on wet ice until centrifugation. Blood samples were processed to obtain plasma by centrifugation at approximately 4°C, 3,200 g for 10 minutes. Plasma was collected and transferred to pre-labeled 96-well plates or polypropylene tubes, snap-frozen on dry ice and stored at -60°C or lower until LC-MS / MS analysis.
[0656] Data Analysis: Plasma concentration versus time data were plotted in graphs and analyzed by non-partitioning methods using Phoenix WinNonlin 6.3 software program. Relevant PK parameters were calculated according to the route of administration, e.g., CL, V for intravenous administration, and dss and C0, extravascularly administered C max , T max or %F, and T of all pathways 1 / 2 , AUC (0-t) , AUC (0-inf) , MRT (0-t) , MRT (0-inf) .
[0657] Table 4
[0658]
[0659] Exemplary embodiments
[0660] Exemplary embodiment No. 1. A compound of formula (0):
[0661]
[0662] or a pharmaceutically acceptable salt thereof, wherein:
[0663] R 13 -C(O)OH or
[0664] X is N or CR x , where R x is hydrogen, OH or C1-C6 alkyl;
[0665] Y is N or CR y , where R y is hydrogen, OH or C1-C6 alkyl;
[0666] n is 0 or 1;
[0667] Q choose freedom – C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where
[0668] R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl; and
[0669] R 9 is hydrogen or C1-C6 alkyl;
[0670] R 1 is an optionally substituted -C1-C6 alkylene group or -C1-C6 alkylene group-R 5 , where R 5 is C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN;
[0671] R 2 and R 3 Together with the carbon atom to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring; or
[0672] R 2 and R x When present, together with the carbon atom to which they are attached, form an optionally substituted C3-C5 cycloalkyl ring, and R 3 is hydrogen, oxo or C1-C6 alkyl;
[0673] m is 0, 1, 2 or 3;
[0674] R 4 is oxo or C1-C6 alkyl;
[0675] Ring A is C6-C 14 Aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH;
[0676] L is a bond, -O-, C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *–NR 6 -C1-C6 alkylene-**, wherein * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, and wherein:
[0677] When L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR6 -C1-C6 alkylene-**, L is optionally replaced by one to three R L Substituents, where each R L are independently halogen, OH or C1-C6 alkyl; or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclic group;
[0678] R 6 When present, hydrogen or C1-C6 alkyl; and
[0679] Ring B is C3-C 10 Cycloalkyl, C6-C 14 Aryl, 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents, the substituents being independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3 and phenyl optionally substituted by halo or CN.
[0680] Exemplary embodiment No. 2. A compound of formula (1):
[0681]
[0682] or a pharmaceutically acceptable salt thereof, wherein:
[0683] X is N or CR x , where R x is hydrogen, OH or C1-C6 alkyl, and
[0684] Y is N or CR y , where R y is hydrogen, OH or C1-C6 alkyl;
[0685] n is 0 or 1;
[0686] Q choose freedom – C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where
[0687] R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl, and
[0688] R 9 is hydrogen or C1-C6 alkyl;
[0689] R 1is -C1-C6 alkylene-R 5 , where R 5 is a 3- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN;
[0690] R 2 and R 3 Together with the carbon atom to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring; or
[0691] R 2 and R x When present, together with the carbon atom to which they are attached, form an optionally substituted C3-C5 cycloalkyl ring, and R 3 is hydrogen, oxo or C1-C6 alkyl;
[0692] m is 0, 1, 2 or 3;
[0693] R 4 is oxo or C1-C6 alkyl;
[0694] Ring A is C6-C 14 Aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH;
[0695] L is a bond, -O-, C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *–NR 6 -C1-C6 alkylene-**, wherein * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, and wherein:
[0696] When L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR 6 -C1-C6 alkylene-**, L is optionally replaced by one to three R L Substituents, where each R L are independently halogen, OH or C1-C6 alkyl; or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclyl group; and
[0697] R 6When present, hydrogen or C1-C6 alkyl; and
[0698] Ring B is C3-C 10 Cycloalkyl, C6-C 14 Aryl, 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents, the substituents being independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3 and phenyl optionally substituted by halo or CN.
[0699] Exemplary embodiment No. 3. The compound according to Exemplary embodiment No. 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound has formula (0'):
[0700]
[0701] or a pharmaceutically acceptable salt thereof.
[0702] Exemplary embodiment No. 4. The compound according to exemplary embodiment No. 1-3, or a pharmaceutically acceptable salt thereof, wherein R 13 It is -C(O)OH.
[0703] Exemplary embodiment No. 5. The compound according to exemplary embodiment No. 1-3, or a pharmaceutically acceptable salt thereof, wherein R 13 for
[0704] Exemplary embodiment No. 6. The compound according to Exemplary embodiment No. 1-5, or a pharmaceutically acceptable salt thereof, wherein X is N and Y is CR y .
[0705] Exemplary embodiment No. 7. The compound according to exemplary embodiment No. 1-5, or a pharmaceutically acceptable salt thereof, wherein X is CR x And Y is N.
[0706] Exemplary embodiment No. 8. The compound according to exemplary embodiment No. 1-5, or a pharmaceutically acceptable salt thereof, wherein X is N and Y is N.
[0707] Exemplary embodiment No. 9. The compound according to exemplary embodiment No. 1-8, wherein n is 0.
[0708] Exemplary embodiment No. 10. The compound according to Exemplary embodiment No. 1-8, or a pharmaceutically acceptable salt thereof, wherein n is 1.
[0709] Exemplary embodiment No. 11. The compound according to exemplary embodiment No. 1-10, or a pharmaceutically acceptable salt thereof, wherein Q is -C(R 7 )(R 8 )-.
[0710] Exemplary embodiment No. 12. The compound according to exemplary embodiment No. 1-10, or a pharmaceutically acceptable salt thereof, wherein Q is -CH2-.
[0711] Exemplary embodiment No. 13. The compound according to Exemplary embodiment No. 1-10, or a pharmaceutically acceptable salt thereof, wherein Q is -O-.
[0712] Exemplary embodiment No. 14. The compound according to exemplary embodiment No. 1-10, or a pharmaceutically acceptable salt thereof, wherein Q is -N(R 9 )-.
[0713] Exemplary embodiment No. 15. The compound according to exemplary embodiment No. 1-14, or a pharmaceutically acceptable salt thereof, wherein R 1 For –CH2-R 5 .
[0714] Exemplary embodiment No. 16. The compound according to exemplary embodiment No. 1-15, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 C3-C6 cycloalkyl substituted with alkenyl or C1-C6 haloalkyl.
[0715] Exemplary embodiment No. 17. The compound according to exemplary embodiment No. 16, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 Cyclopropyl substituted with alkenyl or C1-C6 haloalkyl.
[0716] Exemplary embodiment No. 18. The compound according to exemplary embodiment No. 1-15, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 A 4- to 5-membered heterocyclic group substituted with an alkenyl group or a C1-C6 haloalkyl group.
[0717] Exemplary embodiment No. 19. The compound according to exemplary embodiment No. 18, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 A 4-membered heterocyclic group substituted with an alkenyl group or a C1-C6 haloalkyl group.
[0718] Exemplary embodiment No. 20. The compound according to exemplary embodiment No. 19, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 The oxetane group is substituted with an alkenyl group or a C1-C6 haloalkyl group.
[0719] Exemplary embodiment No. 21. The compound according to exemplary embodiment No. 1-15, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, -OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 A 5-membered heteroaryl group substituted with an alkenyl group or a C1-C6 haloalkyl group.
[0720] Exemplary embodiment No. 22. The compound according to exemplary embodiment No. 21, or a pharmaceutically acceptable salt thereof, wherein R 5 is oxazolyl, triazolyl, thiazolyl or isothiazolyl, each of which is optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 The group is substituted with alkenyl or C1-C6 haloalkyl.
[0721] Exemplary embodiment No. 23. The compound according to exemplary embodiment No. 22, or a pharmaceutically acceptable salt thereof, wherein R 5 is triazolyl or thiazolyl, each of which is optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 The group is substituted with alkenyl or C1-C6 haloalkyl.
[0722] Exemplary embodiment No. 24. The compound according to exemplary embodiment No. 23, or a pharmaceutically acceptable salt thereof, wherein R 5 is optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 Alkenyl or C1-C6 haloalkyl substituted
[0723] Exemplary embodiment No. 25. The compound according to exemplary embodiment No. 23, or a pharmaceutically acceptable salt thereof, wherein R5 is optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 Alkenyl or C1-C6 haloalkyl substituted
[0724] Exemplary embodiment No. 26. The compound according to exemplary embodiment No. 23, or a pharmaceutically acceptable salt thereof, wherein R 5 for Where R 12 It is a C1-C6 alkyl group.
[0725] Exemplary embodiment No. 27. The compound according to exemplary embodiment No. 26, or a pharmaceutically acceptable salt thereof, wherein R 12 It is methyl.
[0726] Exemplary embodiment No. 28. The compound according to exemplary embodiment No. 26, or a pharmaceutically acceptable salt thereof, wherein R 12 It is ethyl.
[0727] Exemplary embodiment No. 29. The compound according to Exemplary embodiment No. 1-28, or a pharmaceutically acceptable salt thereof, wherein Ring A is a 5- to 6-membered heteroaryl group optionally substituted with halogen, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halogen or OH.
[0728] Exemplary embodiment No. 30. The compound according to Exemplary embodiment No. 29, or a pharmaceutically acceptable salt thereof, wherein Ring A is a 6-membered heteroaryl optionally substituted with halogen, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halogen or OH.
[0729] Exemplary embodiment No. 31. A compound as described in Exemplary embodiment No. 30, or a pharmaceutically acceptable salt thereof, wherein ring A is pyridyl, pyrimidinyl or pyrazinyl, each of which is optionally substituted with halo, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH.
[0730] Exemplary embodiment No. 32. The compound according to exemplary embodiment No. 31, or a pharmaceutically acceptable salt thereof, wherein ring A is
[0731] Exemplary embodiment No. 33. The compound according to exemplary embodiment No. 32, or a pharmaceutically acceptable salt thereof, wherein ring A is
[0732] Exemplary embodiment No. 34. The compound according to exemplary embodiment No. 33, or a pharmaceutically acceptable salt thereof, wherein ring A is
[0733] Exemplary embodiment No. 35. The compound according to Exemplary embodiment No. 1-28, or a pharmaceutically acceptable salt thereof, wherein Ring A is a 10- to 12-membered heterocyclyl or 10- to 12-membered heteroaryl group optionally substituted with halogen, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halogen or OH.
[0734] Exemplary embodiment No. 36. The compound according to Exemplary embodiment No. 35, or a pharmaceutically acceptable salt thereof, wherein Ring A is an optionally substituted benzodioxole.
[0735] Exemplary embodiment No. 37. The compound according to exemplary embodiment No. 36, or a pharmaceutically acceptable salt thereof, wherein ring A is
[0736] Exemplary embodiment No. 38. A compound as described in Exemplary embodiment No. 1-37, or a pharmaceutically acceptable salt thereof, wherein L is optionally replaced by R L Substituted *-O-C1-C6 alkylene-**.
[0737] Exemplary embodiment No. 39. The compound according to Exemplary embodiment No. 38, or a pharmaceutically acceptable salt thereof, wherein L is *-O-CH2-**.
[0738] Exemplary embodiment No. 40. The compound according to Exemplary embodiment No. 1-37, or a pharmaceutically acceptable salt thereof, wherein L is -O-.
[0739] Exemplary embodiment No. 41. The compound according to Exemplary embodiment No. 1-37, or a pharmaceutically acceptable salt thereof, wherein L is a bond.
[0740] Exemplary embodiment No. 42. The compound according to exemplary embodiment No. 1-41, or a pharmaceutically acceptable salt thereof, wherein ring B is C6-C 14 Aryl, optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0741] Exemplary embodiment No. 43. The compound as described in Exemplary embodiment No. 42, or a pharmaceutically acceptable salt thereof, wherein ring B is phenyl optionally substituted with one to three substituents, each of which is independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0742] Exemplary embodiment No. 44. The compound according to exemplary embodiment No. 43, or a pharmaceutically acceptable salt thereof, wherein ring B is
[0743] Exemplary embodiment No. 45. The compound according to exemplary embodiment No. 44, or a pharmaceutically acceptable salt thereof, wherein ring B is
[0744] Exemplary embodiment No. 46. The compound as described in Exemplary embodiment No. 1-41, or a pharmaceutically acceptable salt thereof, wherein ring B is a 4- to 12-membered heterocyclic group, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0745] Exemplary embodiment No. 47. The compound as described in Exemplary embodiment No. 46, or a pharmaceutically acceptable salt thereof, wherein ring B is tetrahydroisoquinolinyl optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0746] Exemplary embodiment No. 48. The compound according to Exemplary embodiment No. 47, or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted with one to three substituents The substituents are independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0747] Exemplary embodiment No. 49. The compound according to exemplary embodiment No. 48, or a pharmaceutically acceptable salt thereof, wherein ring B is
[0748] Exemplary embodiment No. 50. The compound as described in Exemplary embodiment No. 1-41, or a pharmaceutically acceptable salt thereof, wherein ring B is a 5- to 12-membered heteroaryl group, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0749] Exemplary embodiment No. 51. The compound as described in Exemplary embodiment No. 50, or a pharmaceutically acceptable salt thereof, wherein Ring B is a 9-membered heteroaryl group optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
[0750] Exemplary embodiment No. 52. The compound according to exemplary embodiment No. 1, wherein the compound has formula (8):
[0751]
[0752] or a pharmaceutically acceptable salt thereof.
[0753] Exemplary embodiment No. 53. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from any one of the compounds in Table 1.
[0754] Exemplary embodiment No. 54. A pharmaceutical composition comprising the compound according to Exemplary embodiment No. 1-53 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0755] Exemplary embodiment No. 55. A method for treating a disease mediated by glucagon-like peptide-1 receptor (GLP-1R) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound as described in Exemplary Embodiments No. 1-53 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as described in Exemplary Embodiment No. 54.
[0756] Exemplary embodiment No. 56. The method according to Exemplary embodiment No. 55, wherein the disease is liver disease.
[0757] Exemplary embodiment No. 57. A method as described in Exemplary embodiment No. 56, wherein the liver disease is primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), drug-induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition-associated cholestasis (PNAC), bacterial overgrowth or sepsis-associated cholestasis, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), graft-versus-host disease, transplant liver regeneration, congenital hepatic fibrosis, common bile duct stones, granulomatous liver disease, intrahepatic or extrahepatic malignancy, Sjögren's syndrome, sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis or Otti's antitrypsin deficiency.
[0758] Exemplary embodiment No. 58. The method according to Exemplary embodiment No. 55, wherein the disease is diabetes.
[0759] Exemplary embodiment No. 59. The method according to Exemplary embodiment No. 55, wherein the disease is a cardiovascular metabolic disease.
[0760] Exemplary embodiment No. 60. The method according to Exemplary embodiment No. 55, wherein the disease is obesity.
[0761] Exemplary embodiment No. 61. Use of the compound according to Exemplary embodiment No. 1-53 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease mediated by GLP-1R.
[0762] Equivalent solutions
[0763] It should be understood that the present invention can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the above-mentioned embodiments should be regarded as illustrative in all aspects, rather than limiting the present invention described herein. Therefore, the scope of the present invention is indicated by the appended claims, rather than by the foregoing description, and it is intended to cover all changes that fall within the meaning and scope equivalent to the claims.
Claims
1. A compound of formula (0): or a pharmaceutically acceptable salt thereof, wherein: R 13 -C(O)OH or X is N or CR x , where R x is hydrogen, OH or C1-C6 alkyl; Y is N or CR y , where R y is hydrogen, OH or C1-C6 alkyl; n is 0 or 1; Q choose freedom – C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl; and R 9 is hydrogen or C1-C6 alkyl; R 1 is an optionally substituted -C1-C6 alkylene group or -C1-C6 alkylene group-R 5 , where R 5 is C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN; R 2 and R 3 Together with the carbon atom to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring; or R 2 and R x When present, together with the carbon atom to which they are attached, form an optionally substituted C3-C5 cycloalkyl ring, and R 3 is hydrogen, oxo or C1-C6 alkyl; m is 0, 1, 2 or 3; R 4 is oxo or C1-C6 alkyl; Ring A is C6-C 14 Aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH; L is a bond, -O-, C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *–NR 6 -C1-C6 alkylene-**, wherein * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, and wherein: When L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR 6 -C1-C6 alkylene-**, L is optionally replaced by one to three R L Substituents, where each R L are independently halogen, OH or C1-C6 alkyl; or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclic group; R 6 When present, hydrogen or C1-C6 alkyl; and Ring B is C3-C 10 Cycloalkyl, C6-C 14 Aryl, 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents, the substituents being independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3 and phenyl optionally substituted by halo or CN.
2. A compound of formula (1): or a pharmaceutically acceptable salt thereof, wherein: X is N or CR x , where R x is hydrogen, OH or C1-C6 alkyl, and Y is N or CR y , where R y is hydrogen, OH or C1-C6 alkyl; n is 0 or 1; Q choose freedom – C(R 7 )(R 8 )-、-O-、-N(R 9 )- and -S-, where R 7 and R 8 are independently hydrogen, halogen or C1-C6 alkyl, and R 9 is hydrogen or C1-C6 alkyl; R 1 -C1-C6 alkylene-R 5 , where R 5 is a 3- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl, each of which is independently optionally substituted with one to three substituents independently selected from the group consisting of halo, oxo, CN, C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl, wherein each C1-C6 alkyl, C3-C6 cycloalkyl, and -OC1-C6 alkyl substituent is independently optionally substituted with halo or CN; R 2 and R 3 Together with the carbon atom to which they are attached, they form an optionally substituted C3-C4 cycloalkyl ring; or R 2 and R x When present, together with the carbon atom to which they are attached, form an optionally substituted C3-C5 cycloalkyl ring, and R 3 is hydrogen, oxo or C1-C6 alkyl; m is 0, 1, 2 or 3; R 4 is oxo or C1-C6 alkyl; Ring A is C6-C 14 Aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, each of which is independently optionally substituted with halo, OH, CN, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted with halo or OH; L is a bond, -O-, C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-**, or *–NR 6 -C1-C6 alkylene-**, wherein * represents the point of attachment to ring A, and ** represents the point of attachment to ring B, and wherein: When L is C1-C6 alkylene, *-O-C1-C6 alkylene-**, *-C1-C6 alkylene-O-** or *-NR 6 -C1-C6 alkylene-**, L is optionally replaced by one to three R L Substituents, where each R L are independently halogen, OH or C1-C6 alkyl; or two R L Together with the one or more carbon atoms to which they are attached, they form a C3-C6 cycloalkyl group or a 3- to 6-membered heterocyclyl group; and R 6 When present, hydrogen or C1-C6 alkyl; and Ring B is C3-C 10 Cycloalkyl, C6-C 14 Aryl, 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is independently optionally substituted by one to three substituents, the substituents being independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl optionally substituted by halo or CN, -OC1-C6 alkyl optionally substituted by halo or CN, -COCH3, -CONH2, -S(O)2CH3 and phenyl optionally substituted by halo or CN.
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound has the formula (0'): or a pharmaceutically acceptable salt thereof.
4. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 13 -C(O)OH or 5. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein: (i) X is N and Y is CR y ; (ii) X is CR x and Y is N; or (iii) X is N and Y is N.
6. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
7. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Q is -C(R 7 )(R 8 )-, -CH2-, -O- or -N(R 9 )-.
8. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 For –CH2-R 5 .
9. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 for: (i) optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 alkenyl, or C3-C6 cycloalkyl substituted with C1-C6 haloalkyl; (ii) optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 alkenyl, or a 4- to 5-membered heterocyclic group substituted with a C1-C6 haloalkyl group; or (iii) optionally substituted with halogen, -OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 or a 5-membered heteroaryl substituted with a C1-C6 haloalkyl group.
10. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein R 5 for: (i) optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 Cyclopropyl substituted with alkenyl or C1-C6 haloalkyl; (ii) optionally substituted with halogen, oxo, C1-C6 alkyl, C 1-6 an oxetane substituted with an alkenyl or C1-C6 haloalkyl group; or (iii) oxazolyl, triazolyl, thiazolyl or isothiazolyl, each of which is optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 The group is substituted with alkenyl or C1-C6 haloalkyl.
11. The compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein R 5 for: (i) optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 Alkenyl or C1-C6 haloalkyl substituted (ii) optionally substituted with halogen, -OC 1-6 Alkyl, C1-C6 alkyl, C 1-6 Alkenyl or C1-C6 haloalkyl substituted or (iii) Where R 12 It is a C1-C6 alkyl group.
12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof, wherein R 12 It is methyl or ethyl.
13. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Ring A is: (i) 5- to 6-membered heteroaryl optionally substituted by halo, CN, C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by halo or OH; or (ii) 10- to 12-membered heterocyclyl or 10- to 12-membered heteroaryl optionally substituted by halogen, CN, C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by halogen or OH.
14. The compound or pharmaceutically acceptable salt thereof according to claim 13, wherein Ring A is: (i) pyridinyl, pyrimidinyl or pyrazinyl, each of which is optionally substituted by halo, CN, C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by halo or OH; or (ii) Optionally substituted benzodioxole.
15. The compound or pharmaceutically acceptable salt thereof according to claim 14, wherein ring A is 16. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is optionally replaced by R L Substituted *-O-C1-C6 alkylene-**.
17. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, wherein L is *-O-CH2-**.
18. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is: (i)-O-; or (ii) Key.
19. A compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Ring B is: (i) C6-C 14 Aryl, optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3, and phenyl; (ii) a 4- to 12-membered heterocyclyl group, which is optionally substituted by one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl; or (iii) a 5- to 12-membered heteroaryl group, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
20. The compound according to claim 19 or a pharmaceutically acceptable salt thereof, wherein Ring B is: (i) phenyl, optionally substituted with one to three substituents, each of which is independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl; (ii) tetrahydroisoquinolinyl, optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl; and / or (iii) 9-membered heteroaryl, optionally substituted with one to three substituents independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
21. The compound according to claim 20 or a pharmaceutically acceptable salt thereof, wherein Ring B is optionally substituted with one to three substituents The substituents are independently selected from the group consisting of halo, CN, oxo, C1-C6 alkyl, C1-C6 haloalkyl, -COCH3, -CONH2, -S(O)2CH3 and phenyl.
22. The compound according to claim 20 or a pharmaceutically acceptable salt thereof, wherein ring B is 23. The compound of claim 1, wherein the compound has formula (8): or a pharmaceutically acceptable salt thereof.
24. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from any one of the compounds in Table 1.
25. A pharmaceutical composition comprising a compound as claimed in any one of the preceding claims or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
26. A method of treating a disease mediated by glucagon-like peptide-1 receptor (GLP-1R) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 25.
27. The method of claim 26, wherein the disease is liver disease.
28. The method of claim 27, wherein the liver disease is primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), drug-induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition-associated cholestasis (PNAC), bacterial overgrowth or sepsis-associated cholestasis, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), graft-versus-host disease, transplant liver regeneration, congenital hepatic fibrosis, common bile duct stones, granulomatous liver disease, intrahepatic or extrahepatic malignancy, Sjögren's syndrome, sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, or Otti's antitrypsin deficiency.
29. The method of claim 26, wherein the disease is: (i) Diabetes mellitus; (ii) cardiometabolic disease; and / or (iii) Obesity.
30. Use of a compound as claimed in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease mediated by GLP-1R.
Citation Information
Patent Citations
GLP-1 receptor agonists and uses thereof
WO2019239371A1
US2003-2012
